FLICR

!width="50"|Transcript ID !width="50"|Gene ID !width="50"|Symbol !width="50"|Synonyms !width="50"|Functional Mechanism !width="50"|Biological Process !width="50"|Disease |- |HSALNT0289501 |HSALNG0141612 |HPVC1 |PE5L,HPV18E5L |NA |pathogenic process |NA |- |HSALNT0289605 |HSALNG0141720 |Alpha 250/ Alpha 280 |NONHSAT104559,lnc-C9orf53-2:1 |NA |NA |NA |- |HSALNT0199632 |HSALNG0096226 |N4BP2L2-IT2 |CG030 |NA |NA |NA |- |HSALNT0171094 |HSALNG0082161 |LINC01150 |2G7,TCONS_00019134 |NA |pathogenic process |Wilms' tumor |- |HSALNT0289115 |HSALNG0032599 |LINC01587 |C4orf6,aC1 |NA |pathogenic process |neuroblastoma |- |HSALNT0290105 |HSALNG0142220 |NTT |NONHSAT115106 |NA |NA |NA |- |HSALNT0289234 |HSALNG0053252 |RNF217-AS1 |STL |NA |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0280481 |HSALNG0136795 |INE2 |NCRNA00011 |NA |NA |NA |- |HSALNT0289485 |HSALNG0137683 |INE1 |NCRNA00010 |NA |NA |NA |- |HSALNT0289511 |HSALNG0141622 |LINC01565 |C3orf27,GR6 |NA |pathogenic process |leukemia |- |HSALNT0289068 |HSALNG0006924 |LINC00869 |KIAA0493 |NA |NA |NA |- |HSALNT0289430 |HSALNG0026312 |ERC2-IT1 |C1orf1,C3orf51,Po42 |NA |pathogenic process |NA |- |HSALNT0290394 |HSALNG0142509 |Y RNAs |lnc-PDIA4-1:1 |NA |NA |NA |- |HSALNT0289195 |HSALNG0032409 |NOP14-AS1 |C4orf10,RES4-24 |NA |NA |NA |- |HSALNT0290309 |HSALNG0142424 |TncRNA |NONHSAT022116,AF080092,TSU |NA |developmental process |NA |- |HSALNT0289243 |HSALNG0045080 |SMAD5-AS1 |SMAD5O,DAMS |NA |pathogenic process |malignant hematopoietic |- |HSALNT0289025 |HSALNG0062672 |LINC00244 |C7orf4,NCRNA00244 |NA |pathogenic process |preaxial polydactyly |- |HSALNT0289017 |HSALNG0055219 |KIF25-AS1 |C6orf54,NCRNA00300,HGC6.1.1 |NA |pathogenic process |ovarian cancer |- |HSALNT0289332 |HSALNG0055207 |LINC01558 |C6orf123,LINC01557,HGC6.2,dJ431P23.4 |NA |pathogenic process |ovarian cancer |- |HSALNT0289438 |HSALNG0055209 |AFDN-AS1 |C6orf124,MLLT4-AS1,HGC6.4,dJ431P23.3 |NA |pathogenic process |NA |- |HSALNT0289232 |HSALNG0135027 |RFPL3S |RFPL3-AS1,RFPL3-A, NCRNA00005 |NA |pathogenic process |opitz syndrome |- |HSALNT0289393 |HSALNG0134830 |RFPL1S |RFPL1-AS1,RFPL1-A, NCRNA00006 |NA |pathogenic process |NA |- |HSALNT0289500 |HSALNG0141611 |HCG4B |HCG4P6,HCGIV-6,HCGIV.5,HCGIV-06,bCX67J3.3,Em:AB023056.16,bPG309N1.1,bQB90C11.3 |NA |NA |NA |- |HSALNT0289894 |HSALNG0142009 |LINC00294 |NA |NA |NA |NA |- |HSALNT0289345 |HSALNG0140599 |LINC00893 |NA |NA |pathogenic process |hunter syndrome |- |HSALNT0290133 |HSALNG0142248 |PCBP3-OT1 |PCBP3-OT1,FLJ44028 |NA |NA |NA |- |HSALNT0289488 |HSALNG0141599 |BPESC1 |NCRNA00187 |NA |pathogenic process |blepharophimosis syndrome |- |HSALNT0289712 |HSALNG0141827 |COPG2IT1 |CIT1,NCRNA00170,COPG2AS |NA |NA |NA |- |HSALNT0265040 |HSALNG0128978 |LINC00652 |HSPC072 |NA |developmental process |NA |- |HSALNT0289282 |HSALNG0108689 |WASIR2 |NCRNA00286A |NA |NA |NA |- |HSALNT0246856 |HSALNG0119601 |LINC00470 |C18orf2 |NA |pathogenic process |age-related macular degeneration |- |HSALNT0289507 |HSALNG0141618 |LINC00588 |C8orf71,DKFZP434F122 |NA |NA |NA |- |HSALNT0276604 |HSALNG0134754 |TTC28-AS1 |TTC28AS,TTC28-AS,KIAA1648 |NA |NA |NA |- |HSALNT0237577 |HSALNG0114754 |CDRT7 |NCRNA00025,LINC00025 |NA |NA |NA |- |HSALNT0288912 |HSALNG0114755 |CDRT8 |NA |NA |NA |NA |- |HSALNT0275048 |HSALNG0133887 |CECR3 |NA |NA |pathogenic process |cat eye syndrome |- |HSALNT0288915 |HSALNG0133890 |CECR9 |NA |NA |pathogenic process |cat eye syndrome |- |HSALNT0288998 |HSALNG0133878 |HDHD5-AS1 |CECR4,CECR5-AS1,NCRNA00017 |NA |pathogenic process |cat eye syndrome |- |HSALNT0288914 |HSALNG0133878 |CECR5-AS1 |NCRNA00017 |NA |pathogenic process |cat eye syndrome |- |HSALNT0288919 |HSALNG0029809 |CLRN1-AS1 |CLRN1O,UCRP |NA |pathogenic process |usher syndrome type 3 |- |HSALNT0289271 |HSALNG0082585 |TMEM9B-AS1 |C11orf18 |NA |NA |NA |- |HSALNT0289324 |HSALNG0133586 |LINC01547 |C21orf69,C21orf67 |NA |pathogenic process |Down syndrome |- |HSALNT0270409 |HSALNG0131587 |LINC00029 |C20orf51,NCRNA00029,bA305P22.4 |NA |NA |NA |- |HSALNT0289336 |HSALNG0141634 |LINC00529 |C8orf8 |NA |pathogenic process |keratolytic winter erythema |- |HSALNT0288978 |HSALNG0010403 |FLVCR1-AS1 |FLVCR1-DT,LQK1 |NA |NA |NA |- |HSALNT0238050 |HSALNG0114969 |SMCR2 |NA |NA |pathogenic process |Smith-Magenis syndrome |- |HSALNT0289401 |HSALNG0114982 |SMCR5 |NCRNA00034 |NA |pathogenic process |Smith-Magenis syndrome |- |HSALNT0290246 |HSALNG0142361 |SMCR6 |NA |NA |pathogenic process |Smith-Magenis syndrome |- |HSALNT0274626 |HSALNG0133620 |LINC00205 |C21orf86,NCRNA00205, |NA |pathogenic process |NA |- |HSALNT0271512 |HSALNG0132117 |C21orf91-OT1 |NCRNA00285,D21S2089E |NA |NA |NA |- |HSALNT0272596 |HSALNG0132582 |LINC00307 |NCRNA00307,D21S2091E |NA |NA |NA |- |HSALNT0274502 |HSALNG0133549 |TSPEAR-AS2 |C21orf90 |NA |NA |NA |- |HSALNT0274807 |HSALNG0133721 |MCM3AP-AS1 |C21orf85,MCM3APAS,MCM3AP-AS,FLJ10508,NCRNA00031 |NA |NA |NA |- |HSALNT0288888 |HSALNG0133144 |B3GALT5-AS1 |C21orf88 |NA |NA |NA |- |HSALNT0288898 |HSALNG0133127 |BRWD1-AS2 |C21orf87,NCRNA00257,BRWD1-IT2 |NA |NA |NA |- |HSALNT0289031 |HSALNG0133621 |LINC00315 |C21orf93,NCRNA00315 |NA |NA |NA |- |HSALNT0289033 |HSALNG0133612 |LINC00334 |C21orf89,NCRNA00334 |NA |NA |NA |- |HSALNT0289322 |HSALNG0132477 |LINC00314 |C21orf94,NCRNA00314 |NA |NA |NA |- |HSALNT0271821 |HSALNG0132261 |LINC00308 |C21orf74,NCRNA00308,PRED16 |NA |pathogenic process |NA |- |HSALNT0289023 |HSALNG0132537 |LINC00189 |C21orf109,NCRNA00189 |NA |pathogenic process |NA |- |HSALNT0289375 |HSALNG0042788 |NCRUPAR |ncR-uPAR,ncRuPAR,NCRNA00193 |transcriptional regulation |developmental process |NA |- |HSALNT0273467 |HSALNG0133048 |DSCR10 |NA |NA |NA |NA |- |HSALNT0289480 |HSALNG0132984 |DSCR9 |NCRNA00038 |NA |NA |NA |- |HSALNT0290051 |HSALNG0142166 |MDS2 |NA |NA |pathogenic process |myelodysplastic syndrome |- |HSALNT0127810 |HSALNG0060777 |ST7-AS2 |ST7OT2,ST7AS2 |NA |pathogenic process |autism |- |HSALNT0127813 |HSALNG0060778 |ST7-OT3 |ST7OT3,NCRNA00026 |NA |pathogenic process |autism |- |HSALNT0290258 |HSALNG0142373 |ST7-OT4 |NA |NA |pathogenic process |autism |- |HSALNT0290257 |HSALNG0142372 |ST7OT |NONHSAT122926 |NA |NA |NA |- |HSALNT0289372 |HSALNG0074272 |MIR600HG |C9orf45,NCRNA00287,GL012,FLJ22161 |NA |NA |NA |- |HSALNT0013239 |HSALNG0006325 |ATP1A1-AS1 |C1orf203,ATP1A1OS,MGC16179 |NA |NA |NA |- |HSALNT0048563 |HSALNG0022910 |SPATA3-AS1 |NA |NA |NA |NA |- |HSALNT0050859 |HSALNG0024100 |LINC00852 |C3orf42,GHRLOS2,NAG73,GHRL-AS2 |NA |NA |NA |- |HSALNT0069395 |HSALNG0033002 |LINC01096 |NA |NA |NA |NA |- |HSALNT0072367 |HSALNG0034486 |LINC02260 |NA |NA |NA |NA |- |HSALNT0077259 |HSALNG0036896 |LINC01091 |NA |NA |NA |NA |- |HSALNT0096480 |HSALNG0046004 |SAP30L-AS1 |FLJ38109,GALNT10-AS1 |NA |NA |NA |- |HSALNT0098558 |HSALNG0046927 |PRR7-AS1 |NA |NA |NA |NA |- |HSALNT0099356 |HSALNG0047338 |LINC01622 |TCONS_00011202 |NA |NA |NA |- |HSALNT0113415 |HSALNG0053588 |LINC01312 |MGC34034 |NA |NA |NA |- |HSALNT0134652 |HSALNG0064240 |EXTL3-AS1 |C8orf50 |NA |NA |NA |- |HSALNT0138253 |HSALNG0065979 |C8orf34-AS1 |NA |NA |NA |NA |- |HSALNT0154876 |HSALNG0074139 |PSMD5-AS1 |NA |NA |NA |NA |- |HSALNT0163228 |HSALNG0078227 |LINC01553 |C10orf40,AC023904.2 |NA |NA |NA |- |HSALNT0175689 |HSALNG0084463 |LINC00301 |C11orf64,NCRNA00301,MGC39681 |NA |NA |NA |- |HSALNT0247235 |HSALNG0119722 |DLGAP1-AS3 |NA |NA |NA |NA |- |HSALNT0254200 |HSALNG0123001 |CIRBP-AS1 |C19orf23,MGC39338 |NA |NA |NA |- |HSALNT0257335 |HSALNG0124987 |LINC01785 |NA |NA |NA |NA |- |HSALNT0261582 |HSALNG0127139 |LINC01869 |MGC45922 |NA |NA |NA |- |HSALNT0269743 |HSALNG0131262 |LINC01711 |MGC4294 |NA |NA |NA |- |HSALNT0288468 |HSALNG0141311 |FAM41AY1 |FAM41AY |NA |NA |NA |- |HSALNT0288899 |HSALNG0045020 |C5orf66-AS2 |NA |NA |NA |NA |- |HSALNT0288922 |HSALNG0083517 |CSTF3-AS1 |CSTF3-DT |NA |NA |NA |- |HSALNT0288923 |HSALNG0014289 |CYP1B1-AS1 |C2orf58,MGC34824 |NA |NA |NA |- |HSALNT0288957 |HSALNG0025315 |ENTPD3-AS1 |FLJ36665 |NA |NA |NA |- |HSALNT0288970 |HSALNG0071511 |FAM27E3 |MGC42630 |NA |NA |NA |- |HSALNT0288972 |HSALNG0000046 |FAM41C |NA |NA |NA |NA |- |HSALNT0288977 |HSALNG0007223 |FLG-AS1 |NA |NA |NA |NA |- |HSALNT0288983 |HSALNG0105871 |GABPB1-IT1 |FLJ10038 |NA |NA |NA |- |HSALNT0289010 |HSALNG0123950 |ILF3-AS1 |ILF3-DT |NA |NA |NA |- |HSALNT0289034 |HSALNG0097943 |LINC00347 |NA |NA |NA |NA |- |HSALNT0289039 |HSALNG0004105 |LINC00466 |NA |NA |NA |NA |- |HSALNT0289040 |HSALNG0022951 |LINC00471 |C2orf52,MGC43122 |NA |NA |NA |- |HSALNT0289044 |HSALNG0119752 |LINC00526 |C18orf18,MGC17515,HsT959 |NA |NA |NA |- |HSALNT0289048 |HSALNG0106873 |LINC00593 |C15orf50,MGC42951 |NA |NA |NA |- |HSALNT0289050 |HSALNG0022320 |LINC00608 |NA |NA |NA |NA |- |HSALNT0289054 |HSALNG0104144 |LINC00638 |MGC23270 |NA |NA |NA |- |HSALNT0289056 |HSALNG0124410 |LINC00661 |NA |NA |NA |NA |- |HSALNT0289057 |HSALNG0125113 |LINC00662 |NA |NA |NA |NA |- |HSALNT0289062 |HSALNG0024755 |LINC00692 |NA |NA |NA |NA |- |HSALNT0289064 |HSALNG0075805 |LINC00705 |NA |NA |NA |NA |- |HSALNT0289067 |HSALNG0118878 |LINC00868 |C17orf52 |NA |NA |NA |- |HSALNT0130693 |HSALNG0062275 |LINC00996 |NA |NA |NA |NA |- |HSALNT0289101 |HSALNG0089327 |LINC01252 |NA |NA |NA |NA |- |HSALNT0289131 |HSALNG0113283 |LINC02135 |NA |NA |NA |NA |- |HSALNT0289193 |HSALNG0018445 |NIFK-AS1 |NA |NA |NA |NA |- |HSALNT0289244 |HSALNG0008972 |SMG7-AS1 |DKFZP564C196 |NA |NA |NA |- |HSALNT0235326 |HSALNG0113528 |SNAI3-AS1 |MGC23284 |NA |NA |NA |- |HSALNT0215205 |HSALNG0103442 |SNHG10 |C14orf62,FLJ40557,NCRNA00063,LINC00063 |NA |NA |NA |- |HSALNT0289290 |HSALNG0109122 |ZNF205-AS1 |MGC3771 |NA |NA |NA |- |HSALNT0289294 |HSALNG0009820 |LINC00260 |C1orf217,NCRNA00260,MGC5457 |NA |NA |NA |- |HSALNT0289295 |HSALNG0000511 |LINC00337 |C1orf211,NCRNA00337,MGC40168 |NA |NA |NA |- |HSALNT0289298 |HSALNG0076905 |WAC-AS1 |NA |NA |NA |NA |- |HSALNT0289299 |HSALNG0077486 |LINC00839 |NA |NA |NA |NA |- |HSALNT0289303 |HSALNG0089110 |LINC00612 |C12orf33,MGC40170,FLJ41814 |NA |NA |NA |- |HSALNT0289312 |HSALNG0124755 |LINC00663 |MGC39821 |NA |NA |NA |- |HSALNT0289320 |HSALNG0130611 |LINC00494 |NA |NA |NA |NA |- |HSALNT0289330 |HSALNG0039733 |LINC01019 |NA |NA |NA |NA |- |HSALNT0289333 |HSALNG0057380 |LINC00265 |NCRNA00265,NCRNA00265-1 |NA |NA |NA |- |HSALNT0289334 |HSALNG0062824 |LINC00689 |NA |NA |NA |NA |- |HSALNT0289337 |HSALNG0068847 |LINC01591 |NA |NA |NA |NA |- |HSALNT0289340 |HSALNG0072666 |LINC01501 |NA |NA |NA |NA |- |HSALNT0289346 |HSALNG0137712 |LINC01560 |CXorf24 |NA |NA |NA |- |HSALNT0289352 |HSALNG0045051 |LINC01959 |NA |NA |NA |NA |- |HSALNT0289353 |HSALNG0110333 |LINC02175 |NA |NA |NA |NA |- |HSALNT0289354 |HSALNG0064321 |LINC02209 |FAM183CP |NA |NA |NA |- |HSALNT0289359 |HSALNG0107406 |LINGO1-AS1 |NA |NA |NA |NA |- |HSALNT0289362 |HSALNG0119342 |MAFG-AS1 |MAFG-DT |NA |NA |NA |- |HSALNT0289373 |HSALNG0139326 |MORF4L2-AS1 |NA |NA |NA |NA |- |HSALNT0289381 |HSALNG0029035 |NPHP3-AS1 |NCRNA00119 |NA |NA |NA |- |HSALNT0289385 |HSALNG0062543 |PAXIP1-AS1 |NA |NA |NA |NA |- |HSALNT0289413 |HSALNG0082091 |TOLLIP-AS1 |NA |NA |NA |NA |- |HSALNT0289416 |HSALNG0113198 |LINC00311 |TMEM148,NCRNA00311,MGC22001 |NA |NA |NA |- |HSALNT0289422 |HSALNG0069500 |ZNF252P-AS1 |C8orf77 |NA |NA |NA |- |HSALNT0289423 |HSALNG0001624 |ZNF436-AS1 |C1orf213,FLJ90508 |NA |NA |NA |- |HSALNT0289429 |HSALNG0029047 |BFSP2-AS1 |MGC2848 |NA |NA |NA |- |HSALNT0289432 |HSALNG0032263 |CTBP1-AS1 |C4orf42,CTBP1-DT,CTBP1-DT,MGC21675 |NA |NA |NA |- |HSALNT0289436 |HSALNG0039444 |EXOC3-AS1 |C5orf55 |NA |NA |NA |- |HSALNT0289441 |HSALNG0049246 |HCG27 |bPG299F13.9,bCX101P6.9,bQB115I13.2,FLJ40123 |NA |NA |NA |- |HSALNT0289450 |HSALNG0067505 |BAALC-AS2 |C8orf56,BAALCOS,MGC39526 |NA |NA |NA |- |HSALNT0289453 |HSALNG0062877 |FAM87A |NA |NA |NA |NA |- |HSALNT0289459 |HSALNG0078365 |JMJD1C-AS1 |NA |NA |NA |NA |- |HSALNT0289465 |HSALNG0092957 |ATP2B1-AS1 |LINC00936 |NA |NA |NA |- |HSALNT0289466 |HSALNG0093183 |CEP83-AS1 |CEP83-DT |NA |NA |NA |- |HSALNT0289470 |HSALNG0107054 |HEXA-AS1 |C15orf34,FLJ13315 |NA |NA |NA |- |HSALNT0289487 |HSALNG0141598 |BIN3-IT1 |FLJ14107 |NA |NA |NA |- |HSALNT0289490 |HSALNG0141601 |CSNK1G2-AS1 |C19orf34,MGC39696 |NA |NA |NA |- |HSALNT0289508 |HSALNG0141619 |LINC00634 |NA |NA |NA |NA |- |HSALNT0289510 |HSALNG0141621 |LINC00685 |CXYorf10,NCRNA00107,PPP2R3B-AS1,OTTHUMT00000055574 |NA |NA |NA |- |HSALNT0289515 |HSALNG0141626 |SHANK2-AS3 |C11orf76 |NA |NA |NA |- |HSALNT0290073 |HSALNG0142188 |NCBP2-AS2 |NA |NA |NA |NA |- |HSALNT0289502 |HSALNG0141613 |KCNIP4-IT1 |NCRNA00099,UM9-5 |NA |NA |NA |- |HSALNT0289856 |HSALNG0141971 |GTSCR1 |NA |NA |pathogenic process |Gilles de la Tourette syndrome |- |HSALNT0289325 |HSALNG0008917 |LINC00272 |C1orf120,NCRNA00272,RP1-223H12.3 |NA |pathogenic process |prostate cancer |- |HSALNT0288512 |HSALNG0141348 |TTTY9B |NCRNA00132 |NA |NA |NA |- |HSALNT0290155 |HSALNG0142270 |Prion-associated RNAs |NA |NA |pathogenic process |prion disease |- |HSALNT0289444 |HSALNG0062567 |BLACE |NA |NA |pathogenic process |acute B lymphoblastic leukemias |- |HSALNT0060411 |HSALNG0028877 |H1FX-AS1 |C3orf47,FLJ34151 |NA |NA |NA |- |HSALNT0186668 |HSALNG0089868 |LINC00477 |C12orf67,FLJ32894,FAM191B |NA |NA |NA |- |HSALNT0275096 |HSALNG0133923 |LINC00528 |C22orf37,FLJ40542 |NA |NA |NA |- |HSALNT0287824 |HSALNG0140941 |ASMTL-AS1 |CXYorf2,NCRNA00105,ASMTLAS,ASMTL-AS,FLJ13330 |NA |NA |NA |- |HSALNT0288887 |HSALNG0106820 |ANP32A-IT1 |C15orf28,NCRNA00321,FLJ11722,HsT18971 |NA |NA |NA |- |HSALNT0289370 |HSALNG0010128 |MIR29B2CHG |C1orf132,FLJ35650 |NA |NA |NA |- |HSALNT0289396 |HSALNG0007497 |RUSC1-AS1 |C1orf104,FLJ35976 |NA |NA |NA |- |HSALNT0084628 |HSALNG0040236 |LINC01194 |CT49,TAG |NA |pathogenic process |melanoma |- |HSALNT0289468 |HSALNG0103838 |DIO3OS |C14orf134,NCRNA00041,DIO3-AS1,NONHSAT040032,NONHSAT040039,BC111049 |NA |NA |NA |- |HSALNT0121060 |HSALNG0057178 |NPSR1-AS1 |AAA1,IMAGE:4827585 |NA |NA |NA |- |HSALNT0074370 |HSALNG0035535 |LINC00575 |C4orf11 |NA |pathogenic process |NA |- |HSALNT0137345 |HSALNG0065537 |LINC01602 |T1560 |NA |pathogenic process |NA |- |HSALNT0289433 |HSALNG0035768 |FAM13A-AS1 |FAM13A1OS,FAM13AOS,NCRNA00039 |NA |NA |NA |- |HSALNT0289186 |HSALNG0072891 |MIRLET7DHG |NA |NA |NA |NA |- |HSALNT0155254 |HSALNG0074353 |MIR181A2HG |NA |NA |NA |NA |- |HSALNT0289283 |HSALNG0035624 |WDFY3-AS2 |C4orf12,NCRNA00247,FBI4 |NA |NA |NA |- |HSALNT0154555 |HSALNG0073990 |PAPPA-AS1 |PAPPAS,PAPPA-AS,DIPAS,TAF4B,TAF2C2,TAFII105,NCRNA00156 |NA |NA |NA |- |HSALNT0136307 |HSALNG0065020 |LINC00293 |BEYLA |NA |developmental process |NA |- |HSALNT0030983 |HSALNG0014614 |SIX3-AS1 |SIX3OS |NA |developmental process |NA |- |HSALNT0211503 |HSALNG0101546 |OTX2-AS1 |OTX2OS1 |NA |developmental process |NA |- |HSALNT0063422 |HSALNG0030360 |LINC01192 |CT64 |NA |NA |NA |- |HSALNT0217123 |HSALNG0104394 |LINC01193 |CT60,LOC348120 |NA |NA |NA |- |HSALNT0289664 |HSALNG0141779 |C1QTNF9B-AS1 |PCOTH |NA |pathogenic process |prostate cancer |- |HSALNT0289623 |HSALNG0141738 |ATP6V1G2-DDX39B |NA |NA |pathogenic process |dilated cardiomyopathy |- |HSALNT0289498 |HSALNG0141609 |FAM226B |CXorf50B,NCRNA00246B,LINC00246B |NA |NA |NA |- |HSALNT0289321 |HSALNG0133590 |LINC00163 |C21orf134,NCRNA00163,NLC1-A,NLC1A |NA |pathogenic process |narcolepsy |- |HSALNT0289505 |HSALNG0141616 |LINC00165 |C21orf135,NCRNA00165,NLC1-B |NA |NA |NA |- |HSALNT0290297 |HSALNG0142412 |TEA-ncRNAs |ENSG00000251002 |NA |NA |NA |- |HSALNT0274212 |HSALNG0133403 |LINC00322 |C21orf136,NCRNA00322,FLJ16545 |NA |NA |NA |- |HSALNT0289741 |HSALNG0141856 |DHFR upstream transcripts |DHFR minor transcript 5'-UTR,ENSG00000228716,NONHSAT102417 |transcriptional regulation |NA |NA |- |HSALNT0289527 |HSALNG0141642 |21A |ncRNA 21A,NONHSAT128494 |NA |NA |NA |- |HSALNT0289409 |HSALNG0080181 |TLX1NB |TD1,TDI,APT-B7 |NA |pathogenic process |leukemogenesis |- |HSALNT0289662 |HSALNG0141777 |C15orf2 |NA |NA |pathogenic process |Angelman syndrome |- |HSALNT0290097 |HSALNG0142212 |NPAP1 |NA |NA |pathogenic process |Angelman syndrome |- |HSALNT0217406 |HSALNG0104530 |PWRN2 |NCRNA00199 |NA |pathogenic process |Prader-Willi syndrome |- |HSALNT0289227 |HSALNG0104528 |PWRN1 |NCRNA00198 |NA |pathogenic process |Prader-Willi syndrome |- |HSALNT0262816 |HSALNG0127793 |MIMT1 |MIM1,NCRNA00067,LINC00067 |NA |NA |NA |- |HSALNT0289180 |HSALNG0000682 |MIR34AHG |NA |NA |NA |NA |- |HSALNT0289357 |HSALNG0049203 |LINC02570 |XXbac-BPG27H4.8 |NA |pathogenic process |MHC-associated diseases |- |HSALNT0290177 |HSALNG0142292 |RNY1 |NA |NA |pathogenic process |cervix cancer;prostate cancer;colorectal cancer;bladder cancer;kidney cancer;lung cancer |- |HSALNT0289378 |HSALNG0129114 |NKX2-2-AS1 |NKX2-2AS |transcriptional regulation |pathogenic process |NA |- |HSALNT0290151 |HSALNG0142266 |PR antisense transcripts |FJ515872.1,NONHSAT023851 |transcriptional regulation |NA |NA |- |HSALNT0180290 |HSALNG0086714 |PGR-AS1,PR antisense transcripts |AT1,AT2,AT3 |NA |NA |NA |- |HSALNT0289607 |HSALNG0141722 |anti-NOS2A |NA |NA |pathogenic process |meningioma;glioblastoma |- |HSALNT0289687 |HSALNG0141802 |CDKN1A-AS1 |p21NAT |transcriptional regulation |NA |NA |- |HSALNT0289166 |HSALNG0103805 |MEG9 |LINC00584 |NA |NA |NA |- |HSALNT0116668 |HSALNG0055114 |RPS6KA2-AS1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289384 |HSALNG0073983 |PAPPA-AS2 |AGU1 |NA |NA |NA |- |HSALNT0262802 |HSALNG0127785 |ZIM2-AS1 |ZIM2as |NA |NA |NA |- |HSALNT0289824 |HSALNG0141939 |Evf2 |Evf-2,Dlx6as1,Dlx6os1,ENSG00000231764, ENST00000430027.2,lnc-DLX5-3:1 |transcriptional regulation |NA |NA |- |HSALNT0289481 |HSALNG0134495 |ADORA2A-AS1 |C22orf45,FLJ34651 |NA |NA |NA |- |HSALNT0290146 |HSALNG0142261 |POU5F1P4 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290033 |HSALNG0142148 |LSINCT1 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290034 |HSALNG0142149 |LSINCT10 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290035 |HSALNG0142150 |LSINCT11 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290036 |HSALNG0142151 |LSINCT12 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290037 |HSALNG0142152 |LSINCT2 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290038 |HSALNG0142153 |LSINCT3 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290039 |HSALNG0142154 |LSINCT4 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290041 |HSALNG0142156 |LSINCT6 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290042 |HSALNG0142157 |LSINCT7 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290043 |HSALNG0142158 |LSINCT8 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0290044 |HSALNG0142159 |LSINCT9 |NA |NA |pathogenic process |lung cancer;breast cancer |- |HSALNT0289676 |HSALNG0141791 |CAR Intergenic 10 |FLJ31066,NONHSAT016928,lnc-FANK1-3:1 |transcriptional regulation |NA |NA |- |HSALNT0290032 |HSALNG0142147 |LRRC3DN |C21orf30,DKFZP434C128 |transcriptional regulation |NA |NA |- |HSALNT0266984 |HSALNG0129985 |SNHG11 |C20orf198,LINC00101,NCRNA00101 |NA |pathogenic process |obesity |- |HSALNT0289880 |HSALNG0141995 |KRASP1 |NONHSAT113225,ENSG00000220635 |ceRNA |NA |NA |- |HSALNT0006368 |HSALNG0003376 |CYP4A22-AS1 |ncRNA-a3 |transcriptional regulation |NA |NA |- |HSALNT0027470 |HSALNG0013045 |LINC00570 |ncRNA-a5 |transcriptional regulation |NA |NA |- |HSALNT0289066 |HSALNG0003381 |LINC00853 |PDZK1IP1-AS1,ncRNA-a4 |transcriptional regulation |NA |NA |- |HSALNT0289936 |HSALNG0142051 |lincRNA-ROR |ROR,lincRNA-ST8SIA3,ENSG00000258609,NONHSAT059436 |NA |NA |NA |- |HSALNT0289705 |HSALNG0141820 |CHL1-AS2 |NA |NA |pathogenic process |adolescent idiopathic scoliosis |- |HSALNT0076084 |HSALNG0036316 |SEC24B-AS1 |1/2-SBSRNA4 |siRNA |NA |NA |- |HSALNT0290137 |HSALNG0142252 |PDZRN3-AS1 |NA |NA |pathogenic process |type 2 diabetes |- |HSALNT0290237 |HSALNG0142352 |SCAANT1 |ATXN7-AS1 |transcriptional regulation |pathogenic process |spinocerebellar ataxia |- |HSALNT0289594 |HSALNG0141709 |AK123790 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289911 |HSALNG0142026 |LINC01451 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290401 |HSALNG0142516 |ZNF350-AS1 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289845 |HSALNG0141960 |GADD45G |NA |NA |pathogenic process |pituitary adenoma |- |HSALNT0289410 |HSALNG0043357 |TMEM161B-AS1 |AK082072,linc-POLR3G-8,ENSG00000247828 |NA |NA |NA |- |HSALNT0289736 |HSALNG0141851 |DAPK1 |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0290048 |HSALNG0142163 |MAP3K14 |MAP3K14 |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0290150 |HSALNG0142265 |PPP3CB |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0151531 |HSALNG0072477 |DAPK1-IT1 |NA |NA |pathogenic process |NA |- |HSALNT0288990 |HSALNG0041256 |GDNF-AS1 |GDNFOS |transcriptional regulation |pathogenic process |Alzheimer's disease |- |HSALNT0029702 |HSALNG0014093 |BIRC6-AS2 |megamind |NA |developmental process |NA |- |HSALNT0029692 |HSALNG0014085 |BIRC6-AS1 |NA |NA |NA |NA |- |HSALNT0289310 |HSALNG0116623 |LINC00854 |NA |NA |NA |NA |- |HSALNT0290332 |HSALNG0142447 |uc.73 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289841 |HSALNG0141956 |FR0257520 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290104 |HSALNG0142219 |NRG1 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289689 |HSALNG0141804 |CDKN2B-AS11 |NA |NA |pathogenic process;developmental process |stroke |- |HSALNT0289690 |HSALNG0141805 |CDKN2B-AS12 |NA |NA |pathogenic process |glioma |- |HSALNT0289691 |HSALNG0141806 |CDKN2B-AS13 |NA |NA |pathogenic process |plexiform neurofibroma |- |HSALNT0289697 |HSALNG0141812 |CDKN2B-AS7 |NA |NA |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0289826 |HSALNG0141941 |FADS1 |NA |NA |pathogenic process |lipid metabolism disorder |- |HSALNT0289698 |HSALNG0141813 |CDKN2B-AS8 |NA |NA |pathogenic process |melanoma |- |HSALNT0289696 |HSALNG0141811 |CDKN2B-AS6 |NA |NA |pathogenic process |neuroblastoma |- |HSALNT0289699 |HSALNG0141814 |CDKN2B-AS9 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0289688 |HSALNG0141803 |CDKN2B-AS10 |NA |NA |pathogenic process |stroke |- |HSALNT0288950 |HSALNG0031716 |ENST00000456816 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0290021 |HSALNG0142136 |LOC389332 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0290306 |HSALNG0142421 |TMEM72 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289641 |HSALNG0141756 |BC029135 |NA |NA |pathogenic process |renal clear cell cancer |- |HSALNT0290374 |HSALNG0142489 |X91348 |NA |NA |pathogenic process |renal clear cell cancer |- |HSALNT0289694 |HSALNG0141809 |CDKN2B-AS4 |NA |NA |pathogenic process |cancer |- |HSALNT0289692 |HSALNG0141807 |CDKN2B-AS2 |NA |NA |pathogenic process |coronary heart disease |- |HSALNT0289693 |HSALNG0141808 |CDKN2B-AS3 |NA |NA |pathogenic process |intracranial aneurysm |- |HSALNT0289695 |HSALNG0141810 |CDKN2B-AS5 |NA |NA |pathogenic process |type 2 diabetes |- |HSALNT0290319 |HSALNG0142434 |T-UCRs |NA |NA |pathogenic process |neuroblastoma |- |HSALNT0289530 |HSALNG0141645 |51A |NA |splicing regulation |pathogenic process |Alzheimer's disease |- |HSALNT0290163 |HSALNG0142278 |RAB4B-EGLN2 |NA |NA |pathogenic process |cancer |- |HSALNT0290167 |HSALNG0142282 |RERT |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0265263 |HSALNG0129088 |LINC00237 |NCRNA00237 |NA |pathogenic process |macrocephaly;obesity |- |HSALNT0267186 |HSALNG0130081 |LINC01370 |HI-LNC25,HILNC25 |NA |pathogenic process |type 2 diabetes |- |HSALNT0289114 |HSALNG0046884 |LINC01574 |HI-LNC12,TCONS_00009551 |NA |pathogenic process |type 2 diabetes |- |HSALNT0290159 |HSALNG0142274 |PTHLH |NA |NA |pathogenic process |brachydactyly |- |HSALNT0189394 |HSALNG0091306 |CISTR |CISTR-ACT,CISTRACT,re52431 |transcriptional regulation |pathogenic process |brachydactyly |- |HSALNT0289862 |HSALNG0141977 |HELLPAR |LINC-HELLP |NA |pathogenic process |HELLP syndrome |- |HSALNT0289904 |HSALNG0142019 |LINC01125 |NA |NA |pathogenic process |uremia |- |HSALNT0289544 |HSALNG0141659 |AC002511.1 |LINC01531 |NA |pathogenic process |enterovirus 71 infection |- |HSALNT0289609 |HSALNG0141724 |AP000688.29 |AP000688.2 |NA |pathogenic process |enterovirus 71 infection |- |HSALNT0289832 |HSALNG0141947 |FFAR2 |NA |NA |pathogenic process |enterovirus 71 infection |- |HSALNT0290222 |HSALNG0142337 |RP4-620F22.3 |AC099063.2 |NA |pathogenic process |enterovirus 71 infection |- |HSALNT0290227 |HSALNG0142342 |RP5-843L14.1 |LINC01716 |NA |pathogenic process |enterovirus 71 infection |- |HSALNT0287285 |HSALNG0140617 |MAGEA8-AS1 |RP5-869M20.2 |NA |NA |NA |- |HSALNT0289019 |HSALNG0094159 |LHX5-AS1 |locus4010 |NA |NA |NA |- |HSALNT0288902 |HSALNG0023597 |CAPN10-AS1 |CAPN10-DT,locus959 |NA |NA |NA |- |HSALNT0289404 |HSALNG0076463 |STAM-AS1 |locus3182 |NA |NA |NA |- |HSALNT0148276 |HSALNG0070806 |PTENP1-AS |PTENpg1-asRNA |transcriptional regulation |NA |NA |- |HSALNT0289562 |HSALNG0141677 |AF116616 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289589 |HSALNG0141704 |AK094838 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289620 |HSALNG0141735 |ASLNC00339 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289629 |HSALNG0141744 |BC002350 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289651 |HSALNG0141766 |BC091525 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289652 |HSALNG0141767 |BE503655 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289753 |HSALNG0141868 |ENO1 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289835 |HSALNG0141950 |FKBP10 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0290064 |HSALNG0142179 |MYHAS |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289985 |HSALNG0142100 |LncRNA-LALR1 |NA |transcriptional regulation |pathogenic process |liver cancer |- |HSALNT0289934 |HSALNG0142049 |lincRNA-LALR1 |NA |transcriptional regulation |pathogenic process |NA |- |HSALNT0091577 |HSALNG0043527 |NR2F1-AS1 |FLJ42709 |NA |NA |NA |- |HSALNT0289709 |HSALNG0141824 |CK19 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289943 |HSALNG0142058 |Llme23 |NA |NA |pathogenic process |melanoma |- |HSALNT0289553 |HSALNG0141668 |AC096655.1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289178 |HSALNG0137593 |MIR222HG |Lnc-Ang362 |NA |pathogenic process |Ang II-associated cardiovascular disease |- |HSALNT0289261 |HSALNG0032541 |STX18-AS1 |LOC100507266 |NA |pathogenic process |atrial septal defect |- |HSALNT0289849 |HSALNG0141964 |GHSR |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289850 |HSALNG0141965 |GHSROS |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289210 |HSALNG0072923 |PCAT7 |PCAN-R2 |NA |pathogenic process |prostate cancer |- |HSALNT0289702 |HSALNG0141817 |CES1P1 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289892 |HSALNG0142007 |LINC00210 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290006 |HSALNG0142121 |LOC100506974 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290219 |HSALNG0142334 |RP3-508I15.14 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290243 |HSALNG0142358 |SLC6A6 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290342 |HSALNG0142457 |uc003bgl.1 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289075 |HSALNG0008302 |LINC00970 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0211868 |HSALNG0101725 |SALRNA1 |SAL-RNA1,XLOC_023166 |NA |developmental process |NA |- |HSALNT0222267 |HSALNG0106957 |SALRNA3 |SAL-RNA3,XLOC_025918 |NA |developmental process |NA |- |HSALNT0222274 |HSALNG0106960 |SALRNA2 |SAL-RNA2,XLOC_025931 |NA |developmental process |NA |- |HSALNT0289428 |HSALNG0021790 |GPR1-AS |GPR1-AS1,GPR1AS |transcriptional regulation |NA |NA |- |HSALNT0226207 |HSALNG0108743 |LINC00235 |NA |NA |pathogenic process |anorexia nervosa |- |HSALNT0289526 |HSALNG0141641 |1B FGF-antisense transcripts |NA |NA |pathogenic process |endometriosis |- |HSALNT0290171 |HSALNG0142286 |RNA polymerase III-dependent lncRNAs |NA |NA |pathogenic process |diffuse cerebral hypomyelination |- |HSALNT0290168 |HSALNG0142283 |REST/CoREST-regulated lncRNAs |NA |NA |pathogenic process |Huntington disease |- |HSALNT0289606 |HSALNG0141721 |Alu lncRNAs |NA |NA |pathogenic process |macular degeneration |- |HSALNT0290358 |HSALNG0142473 |UCH1LAS |NA |NA |pathogenic process |Parkinson's disease |- |HSALNT0290244 |HSALNG0142359 |SLC7A2-IT1A/B |NA |NA |pathogenic process |progressive encephalopathy with severe infantile anorexia |- |HSALNT0289877 |HSALNG0141992 |Kcna2-AS |NA |NA |pathogenic process |neuropathic pain |- |HSALNT0289191 |HSALNG0053305 |NCOA7-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0290020 |HSALNG0142135 |LOC389023 |NA |transcriptional regulation |pathogenic process |psychiatric disease |- |HSALNT0175124 |HSALNG0084108 |PTPRJ-AS1 |NA |transcriptional regulation |NA |NA |- |HSALNT0289654 |HSALNG0141769 |BM742401 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289331 |HSALNG0049950 |LINC00951 |lincRNA-uc003opf.1,FLJ41649 |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0290130 |HSALNG0142245 |PAWR |NA |NA |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0290264 |HSALNG0142379 |T-ALL-R-LncR1 |NA |NA |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0289599 |HSALNG0141714 |AK130977 |NA |NA |pathogenic process |malignant pleural mesothelioma |- |HSALNT0289625 |HSALNG0141740 |AX746718 |NA |NA |pathogenic process |malignant pleural mesothelioma |- |HSALNT0289738 |HSALNG0141853 |DDR2 |NA |NA |pathogenic process |malignant pleural mesothelioma |- |HSALNT0290003 |HSALNG0142118 |LOC100131831 |NA |NA |pathogenic process |malignant pleural mesothelioma |- |HSALNT0290144 |HSALNG0142259 |POT1-AS1 |NA |NA |pathogenic process |malignant pleural mesothelioma |- |HSALNT0290253 |HSALNG0142368 |SNORA17B |NA |NA |pathogenic process |malignant pleural mesothelioma |- |HSALNT0207421 |HSALNG0099625 |GAS6-AS1 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289838 |HSALNG0141953 |FMR5 |NA |NA |pathogenic process |fragile X syndrome |- |HSALNT0208907 |HSALNG0100287 |FOXG1-AS1 |FOXG1-AS |NA |pathogenic process |autism spectrum disorder |- |HSALNT0290263 |HSALNG0142378 |SYNGAP1-AS1 |SYNGAP1-AS |NA |pathogenic process |autism spectrum disorder |- |HSALNT0290176 |HSALNG0142291 |RNase MRP |NA |NA |pathogenic process |cartilage hair hypoplaisia |- |HSALNT0289469 |HSALNG0105872 |GABPB1-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0289009 |HSALNG0075528 |IDI2-AS1 |C10orf110,IDI2-A,HT009,Em:AC022536.4 |NA |NA |NA |- |HSALNT0289093 |HSALNG0044716 |LINC01184 |FLJ33630 |NA |NA |NA |- |HSALNT0290108 |HSALNG0142223 |OGT |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290077 |HSALNG0142192 |ncNRFR |NA |transcriptional regulation |pathogenic process |colorectal cancer |- |HSALNT0290337 |HSALNG0142452 |uc001lsz |NA |NA |pathogenic process |gastric cancer;prostate cancer;liver cancer;lung cancer |- |HSALNT0289087 |HSALNG0021008 |LINC01090 |NA |NA |pathogenic process |post-traumatic stress disorder |- |HSALNT0289746 |HSALNG0141861 |DQ786227 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289981 |HSALNG0142096 |lncRNA-DQ786227 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289876 |HSALNG0141991 |JADRR |LINC00915,lncRNA-JADE |transcriptional regulation |pathogenic process |breast cancer |- |HSALNT0290254 |HSALNG0142369 |SOX2OT-S1 |NA |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0290404 |HSALNG0142519 |SOX2OT-S2 |NA |NA |pathogenic process |NA |- |HSALNT0289870 |HSALNG0141985 |HOXA13 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0078946 |HSALNG0037661 |SMAD1-AS1 |ENST00000513542 |NA |pathogenic process |ventricular septal defects |- |HSALNT0087329 |HSALNG0041545 |FGF10-AS1 |RP11-473L15.2 |transcriptional regulation |pathogenic process |ventricular septal defects |- |HSALNT0290318 |HSALNG0142433 |TUC339 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289819 |HSALNG0141934 |ERICD |LINC01130,TCONS_00014875,ERIC |transcriptional regulation |pathogenic process |retinoblastoma |- |HSALNT0289615 |HSALNG0141730 |ARA |NA |NA |pathogenic process |cancer |- |HSALNT0289822 |HSALNG0141937 |ESCCAL-5 |NA |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0290074 |HSALNG0142189 |ncC11orf49 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290076 |HSALNG0142191 |ncHDAC5 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290078 |HSALNG0142193 |ncRAB31 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290080 |HSALNG0142195 |ncSRPK1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0018253 |HSALNG0008819 |OVAAL |LINC01131,OVAL |NA |pathogenic process |ovarian cancer |- |HSALNT0289884 |HSALNG0141999 |LALR |NA |transcriptional regulation |pathogenic process |hepatocelluar cancer |- |HSALNT0289701 |HSALNG0141816 |CEACAMP8 |CEACAMP8 |NA |pathogenic process |pre-eclampsia |- |HSALNT0290018 |HSALNG0142133 |LOC284100 |NA |NA |pathogenic process |pre-eclampsia |- |HSALNT0290023 |HSALNG0142138 |LOC391533 |NA |NA |pathogenic process |pre-eclampsia |- |HSALNT0189558 |HSALNG0091365 |LINC01154 |NA |NA |NA |NA |- |HSALNT0196616 |HSALNG0094870 |THRIL |BRI3BP-AS1,BRI3BPAS1,Linc1992,TCONS_00020260 |transcriptional regulation |pathogenic process |Kawasaki disease |- |HSALNT0289235 |HSALNG0098080 |RNF219-AS1 |NA |NA |pathogenic process |blood pressure |- |HSALNT0289561 |HSALNG0141676 |AF086415 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0289583 |HSALNG0141698 |AK056098 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0289590 |HSALNG0141705 |AK095147 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0289600 |HSALNG0141715 |AK294004 |NA |transcriptional regulation |pathogenic process |nasopharyngeal cancer |- |HSALNT0289612 |HSALNG0141727 |AP5M1 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0290110 |HSALNG0142225 |ORAOV1 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0290210 |HSALNG0142325 |RP1-179N16.3 |Z95152.1 |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0037026 |HSALNG0017545 |LINC01159 |linc-Brn1b |NA |developmental process |NA |- |HSALNT0289014 |HSALNG0137988 |KANTR |KDM5C adjacent non-coding transcript |NA |developmental process |NA |- |HSALNT0289905 |HSALNG0142020 |LINC01157 |TCONS_00010378,linc-Enc1 |NA |developmental process |NA |- |HSALNT0289460 |HSALNG0087416 |APOA1-AS |NA |transcriptional regulation |NA |NA |- |HSALNT0290400 |HSALNG0142515 |ZNF300P1 |ZNF300P1 |NA |pathogenic process |ovarian cancer |- |HSALNT0289750 |HSALNG0141865 |EEF1A1P9 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289796 |HSALNG0141911 |ENST00000318333 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289797 |HSALNG0141912 |ENST00000374520 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289800 |HSALNG0141915 |ENST00000422362 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289808 |HSALNG0141923 |ENST00000455912 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289809 |HSALNG0141924 |ENST00000456007 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289810 |HSALNG0141925 |ENST00000456185 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289817 |HSALNG0141932 |EPOR |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289913 |HSALNG0142028 |LINC01550 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0290142 |HSALNG0142257 |PMS2P5 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0290269 |HSALNG0142384 |TCF7 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0290345 |HSALNG0142460 |uc003jfz.2 |NA |NA |pathogenic process |gastric cardia adenocarcinoma |- |HSALNT0289095 |HSALNG0018112 |LINC01191 |VIN,lnc-ACTR3 |transcriptional regulation |pathogenic process |influenza A virus |- |HSALNT0288976 |HSALNG0140165 |FIRRE |LINC01200 |transcriptional regulation |NA |NA |- |HSALNT0289097 |HSALNG0046284 |LINC01202 |NA |NA |NA |NA |- |HSALNT0290271 |HSALNG0142386 |TCONS_00014512 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290272 |HSALNG0142387 |TCONS_00014978 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290274 |HSALNG0142389 |TCONS_00024647 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290279 |HSALNG0142394 |TCONS_00090092_MEG3 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290280 |HSALNG0142395 |TCONS_l2_00000179 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290283 |HSALNG0142398 |TCONS_l2_00004424 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290284 |HSALNG0142399 |TCONS_l2_00006843 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290289 |HSALNG0142404 |TCONS_l2_00014091 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290291 |HSALNG0142406 |TCONS_l2_00018070 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290292 |HSALNG0142407 |TCONS_l2_00020565 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290293 |HSALNG0142408 |TCONS_l2_00021262 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0290296 |HSALNG0142411 |TCONS_l2_00030560 |NA |NA |pathogenic process |hepatoblastoma |- |HSALNT0289927 |HSALNG0142042 |lincRNA1611 |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0290149 |HSALNG0142264 |Ppp3ca |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0290265 |HSALNG0142380 |TC0100223 |NA |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0290267 |HSALNG0142382 |TC0101686 |NA |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0290268 |HSALNG0142383 |TC1500845 |NA |NA |pathogenic process |ovarian cancer |- |HSALNT0289318 |HSALNG0128589 |LAMP5-AS1 |NA |NA |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0234022 |HSALNG0112916 |LINC01228 |lincRNA-DYNLRB2-2 |NA |pathogenic process |NA |- |HSALNT0162654 |HSALNG0077963 |SGMS1-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0289206 |HSALNG0126202 |PCAT19 |LOC100505495,LINC01190 |NA |pathogenic process |prostate cancer |- |HSALNT0289521 |HSALNG0115583 |ABHD15-AS1 |linc-TP53I13,lnc-TP53I13 |NA |pathogenic process |cardiometabolic disease |- |HSALNT0289100 |HSALNG0069570 |LINC01230 |linc-DMRT2,lnc-DRMT2,TCONS_00015639 |NA |pathogenic process |cardiometabolic disease |- |HSALNT0249183 |HSALNG0120583 |PCAT18 |LINC01092 |NA |pathogenic process |prostate cancer |- |HSALNT0290029 |HSALNG0142144 |LOC728606 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0288956 |HSALNG0094171 |ENST00000547963.1 |NA |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0289802 |HSALNG0141917 |ENST00000435885 |NA |NA |pathogenic process |oesophageal squamous cell cancer |- |HSALNT0205898 |HSALNG0098920 |LINC01232 |FLJ41590,TCONS_00021520 |NA |pathogenic process |NA |- |HSALNT0257311 |HSALNG0124979 |LINC01233 |XLOC_013014 |NA |pathogenic process |NA |- |HSALNT0183247 |HSALNG0088110 |SENCR |FLI1-AS1 |NA |pathogenic process |vascular SMC phenotype |- |HSALNT0289296 |HSALNG0010286 |LINC00467 |C1orf97,MGC14801 |NA |pathogenic process |neuroblastoma |- |HSALNT0143586 |HSALNG0068435 |CASC21 |LINC01244,CARLo-2 |NA |pathogenic process |NA |- |HSALNT0288906 |HSALNG0068424 |CASC19 |LINC01245,CARLo-6 |NA |pathogenic process |NA |- |HSALNT0289754 |HSALNG0141869 |ENSG00000135253.9 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289755 |HSALNG0141870 |ENSG00000147753.5 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289756 |HSALNG0141871 |ENSG00000196096 |AC079610.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289757 |HSALNG0141872 |ENSG00000197251.3 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289758 |HSALNG0141873 |ENSG00000203325 |AL445248.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289759 |HSALNG0141874 |ENSG00000206129 |AC006305.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289760 |HSALNG0141875 |ENSG00000215231.3 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289761 |HSALNG0141876 |ENSG00000215374.4 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289762 |HSALNG0141877 |ENSG00000215808.2 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289763 |HSALNG0141878 |ENSG00000226496.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289764 |HSALNG0141879 |ENSG00000229563.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289765 |HSALNG0141880 |ENSG00000230133.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289766 |HSALNG0141881 |ENSG00000230544.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289767 |HSALNG0141882 |ENSG00000231133.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289768 |HSALNG0141883 |ENSG00000231185 |AC010317.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289769 |HSALNG0141884 |ENSG00000232021.2 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289770 |HSALNG0141885 |ENSG00000232046.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289771 |HSALNG0141886 |ENSG00000232956.3 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289772 |HSALNG0141887 |ENSG00000233154.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289773 |HSALNG0141888 |ENSG00000233251 |AC007743.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289774 |HSALNG0141889 |ENSG00000235285.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289775 |HSALNG0141890 |ENSG00000237036.3 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289776 |HSALNG0141891 |ENSG00000237548.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289777 |HSALNG0141892 |ENSG00000240453.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289778 |HSALNG0141893 |ENSG00000241269.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289779 |HSALNG0141894 |ENSG00000245910.3 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289780 |HSALNG0141895 |ENSG00000248176 |AC109349.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289781 |HSALNG0141896 |ENSG00000249364 |AC112206.2 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289782 |HSALNG0141897 |ENSG00000249772 |AC026427.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289783 |HSALNG0141898 |ENSG00000250195 |AC109927.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289784 |HSALNG0141899 |ENSG00000250608 |AC010210.1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289785 |HSALNG0141900 |ENSG00000254154 |AL359075.2 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289786 |HSALNG0141901 |ENSG00000255471 |AP001528.2 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289787 |HSALNG0141902 |ENSG00000256218 |AC007848.2 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289788 |HSALNG0141903 |ENSG00000259150.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289789 |HSALNG0141904 |ENSG00000259334.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289790 |HSALNG0141905 |ENSG00000259484.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289791 |HSALNG0141906 |ENSG00000259758.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289793 |HSALNG0141908 |ENSG00000263753.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289794 |HSALNG0141909 |ENSG00000264772 |AC016876.2 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289795 |HSALNG0141910 |ENSG00000266952.1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289828 |HSALNG0141943 |FAM66B |FAM66E |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289895 |HSALNG0142010 |LINC00336 |C6orf227,NCRNA00336 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289899 |HSALNG0142014 |LINC00929 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289906 |HSALNG0142021 |LINC01204 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289912 |HSALNG0142027 |LINC01538 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289915 |HSALNG0142030 |LINC01721 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289916 |HSALNG0142031 |LINC01762 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289917 |HSALNG0142032 |LINC01798 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0290247 |HSALNG0142362 |SMIM2-IT1 |C13orf44-IT1 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0290316 |HSALNG0142431 |TTTY7 |CLONE795723,LINC00129,NCRNA00129A,TTTY7B,TTY7,TTTY7 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289872 |HSALNG0141987 |HTTAS_v1 |NA |transcriptional regulation |pathogenic process |Huntington disease |- |HSALNT0290175 |HSALNG0142290 |RNA-a |NA |transcriptional regulation |pathogenic process |Opitz-Kaveggia syndrome |- |HSALNT0289525 |HSALNG0141640 |116HG |NA |transcriptional regulation |pathogenic process |Prader-Willi syndrome |- |HSALNT0290320 |HSALNG0142435 |U1 spliceosomal lncRNA |NA |NA |pathogenic process |Parkinson's disease |- |HSALNT0289102 |HSALNG0039360 |LINC01262 |TCONS_l2_00021807,RP11-462G22.1 |ceRNA |pathogenic process |Parkinson's disease |- |HSALNT0289681 |HSALNG0141796 |CCAT1-L |NA |transcriptional regulation |pathogenic process |colorectal cancer |- |HSALNT0290062 |HSALNG0142177 |MT-LIPCAR |uc022bqs.1,LIPCAR |NA |pathogenic process |heart disease |- |HSALNT0289941 |HSALNG0142056 |LIPCAR |NA |NA |pathogenic process |heart failure |- |HSALNT0200965 |HSALNG0096756 |TUSC8 |LINC01071,XLOC_010588 |NA |pathogenic process |cervical cancer |- |HSALNT0161787 |HSALNG0077519 |LINC01264 |RP11-124O11.2 |NA |pathogenic process |breast cancer |- |HSALNT0289733 |HSALNG0141848 |D4Z4 |NA |NA |pathogenic process;developmental process |facioscapulohumeral muscular dystrophy |- |HSALNT0289678 |HSALNG0141793 |CARL |NA |ceRNA |pathogenic process |myocardial infarction |- |HSALNT0289923 |HSALNG0142038 |linc-CBR1-2 |NA |NA |pathogenic process |lung cancer |- |HSALNT0243354 |HSALNG0117819 |WFDC21P |WAP four-disulfide core domain 21,pseudogene |transcriptional regulation |pathogenic process |DC dysfunction |- |HSALNT0290232 |HSALNG0142347 |RUNX1 |NA |NA |pathogenic process |acute myeloid leukemia |- |HSALNT0290234 |HSALNG0142349 |RUNXOR |NA |NA |pathogenic process |hematopoietic malignancies |- |HSALNT0289979 |HSALNG0142094 |lncRNA-CIR |NA |NA |pathogenic process |osteoarthritis |- |HSALNT0290368 |HSALNG0142483 |VIM2P |NA |NA |pathogenic process |osteoarthritis |- |HSALNT0289879 |HSALNG0141994 |KRAS1P |NA |NA |pathogenic process |cancer |- |HSALNT0290054 |HSALNG0142169 |MINA |NA |NA |pathogenic process |esophageal squamous cell cancer;gastric cancer;lung cancer;hepatocelluar cancer |- |HSALNT0289270 |HSALNG0117279 |TMEM92-AS1 |RP11-893F2.9,lncRNA-508851,TCONS_00025237 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0288900 |HSALNG0054937 |CAHM |LINC00468 |NA |pathogenic process |colorectal cancer |- |HSALNT0289593 |HSALNG0141708 |AK123657 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289659 |HSALNG0141774 |BX648207 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289660 |HSALNG0141775 |BX649059 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289846 |HSALNG0141961 |GAS2L3 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289633 |HSALNG0141748 |BC011663 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289867 |HSALNG0141982 |HIV1230 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290045 |HSALNG0142160 |M14574 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290245 |HSALNG0142360 |SLCO5A1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290326 |HSALNG0142441 |uc.341 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290344 |HSALNG0142459 |uc003iqu |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290346 |HSALNG0142461 |uc003tfx |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289950 |HSALNG0142065 |lnc-AL355149.1-1 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0290001 |HSALNG0142116 |lnc-ZNF674-1 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0286909 |HSALNG0140423 |LINC00632 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289105 |HSALNG0014134 |LINC01317 |NA |NA |NA |NA |- |HSALNT0234804 |HSALNG0113279 |LINC01081 |TCONS_00024764 |transcriptional regulation |pathogenic process |alveolar capillary dysplasia |- |HSALNT0289840 |HSALNG0141955 |FOSB |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289587 |HSALNG0141702 |AK093543 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289732 |HSALNG0141847 |D16366 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289814 |HSALNG0141929 |ENST00000501583 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290273 |HSALNG0142388 |TCONS_00018278 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289907 |HSALNG0142022 |LINC01374 |TCONS_00018278 |NA |pathogenic process |NA |- |HSALNT0231106 |HSALNG0111452 |CASC22 |LINC01373,TCONS_00024290,LincRNA-ENST00000515084 |NA |pathogenic process |breast cancer |- |HSALNT0058246 |HSALNG0027843 |LINC00882 |NA |ceRNA |pathogenic process |airway diseases |- |HSALNT0018288 |HSALNG0008840 |KIAA1614-AS1 |RP11-46A10.4 |ceRNA |pathogenic process |airway smooth muscle (ASM) disease |- |HSALNT0142310 |HSALNG0067913 |LINC00536 |NA |NA |pathogenic process |trichorhinophalangeal syndrome |- |HSALNT0034200 |HSALNG0016063 |LBX2-AS1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0149799 |HSALNG0071679 |ENST00000414223 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290012 |HSALNG0142127 |LOC105374631 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290305 |HSALNG0142420 |TMEM179 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290315 |HSALNG0142430 |TSPAN8 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290334 |HSALNG0142449 |uc001aka.2 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290339 |HSALNG0142454 |uc001vjj.1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290343 |HSALNG0142458 |uc003erl.1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290354 |HSALNG0142469 |uc009wkz.1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0027893 |HSALNG0013204 |MYCNUT |MYCNUN,lncUSMycN |NA |pathogenic process |neuroblastoma |- |HSALNT0273205 |HSALNG0132900 |LINC01436 |AP000688.8 |NA |pathogenic process |Down syndrome |- |HSALNT0266116 |HSALNG0129435 |MIR663AHG |RP3-410C9.1 |NA |pathogenic process |turner syndrome |- |HSALNT0289108 |HSALNG0080498 |LINC01435 |RP11-215N21.1,TCONS_00018040 |NA |pathogenic process |NA |- |HSALNT0289674 |HSALNG0141789 |CADM3-AS1 |NA |NA |pathogenic process |bladder cancer |- |HSALNT0289882 |HSALNG0141997 |KRT19P3 |NA |NA |pathogenic process |bladder cancer |- |HSALNT0290310 |HSALNG0142425 |TNXA |NA |NA |pathogenic process |bladder cancer |- |HSALNT0008750 |HSALNG0004412 |ZRANB2-AS2 |NA |NA |NA |NA |- |HSALNT0289745 |HSALNG0141860 |DMTF1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290059 |HSALNG0142174 |MRUL |NA |transcriptional regulation |pathogenic process |gastric cancer |- |HSALNT0185163 |HSALNG0089050 |FAM66C |NA |NA |NA |NA |- |HSALNT0289476 |HSALNG0132414 |CYYR1-AS1 |NA |NA |NA |NA |- |HSALNT0289535 |HSALNG0141650 |AA174084 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0266298 |HSALNG0129511 |ABALON |INXS |splicing regulation |pathogenic process |renal cell cancer |- |HSALNT0290370 |HSALNG0142485 |VTRNA2-1 |CBL-3,CBL3,MIR886,MIRN886,VTRNA2,hsa-mir-886,hvg-5,nc886,svtRNA2-1a |NA |pathogenic process |gastric cancer |- |HSALNT0289619 |HSALNG0141734 |ASK00420 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0289749 |HSALNG0141864 |EBIC |NA |transcriptional regulation |pathogenic process |cervical cancer |- |HSALNT0290299 |HSALNG0142414 |TI09485 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0290300 |HSALNG0142415 |TI10124 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0290301 |HSALNG0142416 |TI13831 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0290302 |HSALNG0142417 |TI18318 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0290303 |HSALNG0142418 |TI21327 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0290304 |HSALNG0142419 |TI22687 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0290307 |HSALNG0142422 |TMPOP2 |NA |transcriptional regulation |pathogenic process |cervical cancer |- |HSALNT0289570 |HSALNG0141685 |AK021444 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289601 |HSALNG0141716 |AK307796 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289801 |HSALNG0141916 |ENST00000425785 |SEC63P1 |NA |pathogenic process |colorectal cancer |- |HSALNT0289871 |HSALNG0141986 |HOXB-AS3 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290367 |HSALNG0142482 |URHC |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289085 |HSALNG0098166 |LINC01080 |TCONS_00021856 |NA |pathogenic process |Alzheimer's disease |- |HSALNT0289751 |HSALNG0141866 |EFNA3 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289798 |HSALNG0141913 |ENST00000395084 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289829 |HSALNG0141944 |FAM83A-AS1 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290164 |HSALNG0142279 |RAD1 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289585 |HSALNG0141700 |AK056988 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289638 |HSALNG0141753 |BC017743 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290156 |HSALNG0142271 |PRR26 |C10orf108 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290349 |HSALNG0142464 |uc003yqb.1 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289675 |HSALNG0141790 |CAI2 |NA |NA |pathogenic process |neuroblastoma |- |HSALNT0289673 |HSALNG0141788 |CADM1-AS1 |NA |transcriptional regulation |pathogenic process |renal clear cell cancer |- |HSALNT0290313 |HSALNG0142428 |TSLC1-AS1 |NA |NA |pathogenic process |glioma |- |HSALNT0013359 |HSALNG0006378 |LINC01525 |lnc-MAN1A2-1 |NA |pathogenic process |squamous cell cancer |- |HSALNT0109106 |HSALNG0051540 |LINC01526 |Lnc-FAM46A-1 |NA |pathogenic process |squamous cell cancer |- |HSALNT0162774 |HSALNG0078013 |LINC01468 |lnc-MBL2-4 |NA |pathogenic process |squamous cell cancer |- |HSALNT0289110 |HSALNG0074718 |LINC01503 |lnc-PPP2R4-5 |NA |pathogenic process |tongue squamous cell cancer |- |HSALNT0289968 |HSALNG0142083 |lnc-MBL2-4:3 |NA |NA |pathogenic process |tongue squamous cell cancer |- |HSALNT0289993 |HSALNG0142108 |lnc-STXBP5-1 |NA |NA |pathogenic process |tongue squamous cell cancer |- |HSALNT0289563 |HSALNG0141678 |AF118081 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289597 |HSALNG0141712 |AK124939 |NA |NA |pathogenic process |pulmonary adenocarcinoma |- |HSALNT0290153 |HSALNG0142268 |PRAS |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290249 |HSALNG0142364 |SNAR-A1 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289929 |HSALNG0142044 |lincRNA-BC2 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289930 |HSALNG0142045 |lincRNA-BC4 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289931 |HSALNG0142046 |lincRNA-BC5 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289932 |HSALNG0142047 |lincRNA-BC8 |NA |NA |pathogenic process |breast cancer |- |HSALNT0083190 |HSALNG0039551 |LINC01511 |RP11-325I22.2 |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290026 |HSALNG0142141 |LOC440905 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0083190 |HSALNG0039551 |LINC01511 |RP11-325I22.2 |NA |NA |NA |- |HSALNT0289552 |HSALNG0141667 |AC079776.2 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0289720 |HSALNG0141835 |CTA-363E6.2 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0289901 |HSALNG0142016 |LINC00987 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290185 |HSALNG0142300 |RP11-1C1.7 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290197 |HSALNG0142312 |RP11-445K13.2 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290199 |HSALNG0142314 |RP11-473M20.11 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290213 |HSALNG0142328 |RP11-893F2.6 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290217 |HSALNG0142332 |RP13-514E23.1 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290218 |HSALNG0142333 |RP1-90D4.3 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290220 |HSALNG0142335 |RP4-575N6.5 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290226 |HSALNG0142341 |RP5-826L7.1 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290378 |HSALNG0142493 |XLOC_003286 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290379 |HSALNG0142494 |XLOC_003405 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290389 |HSALNG0142504 |XLOC_012255 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290056 |HSALNG0142171 |MIR21 |NA |NA |pathogenic process |laryngeal squamous cell cancer |- |HSALNT0289621 |HSALNG0141736 |ASncmtRNAs |NA |transcriptional regulation |pathogenic process |cancer |- |HSALNT0289316 |HSALNG0022090 |LINC01614 |LCAL4,TCONS_00003105 |NA |pathogenic process |lung cancer |- |HSALNT0289982 |HSALNG0142097 |lncRNA-FER1L4 |NA |ceRNA |pathogenic process |gastric cancer |- |HSALNT0290016 |HSALNG0142131 |LOC283177 |NA |NA |pathogenic process |diffuse large B-cell lymphoma |- |HSALNT0289003 |HSALNG0134860 |HORMAD2-AS1 |MTMR3-AS1,NONHSAG033653 |NA |pathogenic process |type 1 diabetes;bowel disease |- |HSALNT0290372 |HSALNG0142487 |WNT4 |NA |NA |pathogenic process |endometriosis |- |HSALNT0289540 |HSALNG0141655 |AB074278 |NA |NA |pathogenic process |bladder cancer |- |HSALNT0290166 |HSALNG0142281 |RCCRT1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0289043 |HSALNG0043862 |LINC00491 |BC008363 |NA |pathogenic process |pancreatic ductal adenocarcinoma |- |HSALNT0289632 |HSALNG0141747 |BC008363 |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0289858 |HSALNG0141973 |H1.3 |NA |NA |pathogenic process |ovarian cancer |- |HSALNT0289896 |HSALNG0142011 |LINC00582 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0289301 |HSALNG0141635 |LINC01537 |RP11-169D4.1-001 |NA |pathogenic process |laryngeal squamous cell cancer |- |HSALNT0289551 |HSALNG0141666 |AC026166.2 |MTCO1P5 |NA |pathogenic process |laryngeal squamous cell cancer |- |HSALNT0290184 |HSALNG0142299 |RP11-169D4.1-001 |NA |NA |pathogenic process |laryngeal squamous cell cancer |- |HSALNT0289545 |HSALNG0141660 |AC006050.3 |NA |NA |pathogenic process |lung squamous cell cancer |- |HSALNT0289556 |HSALNG0141671 |AC138128.1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289818 |HSALNG0141933 |ERCC1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290061 |HSALNG0142176 |MT1DP |MT1DP |NA |pathogenic process |liver cancer |- |HSALNT0289578 |HSALNG0141693 |AK023096 |NA |NA |pathogenic process |Wilms’ tumor;uterine leiomyomas |- |HSALNT0289112 |HSALNG0003560 |LINC01562 |RP11-296A18.3 |transcriptional regulation |pathogenic process |intervertebral disc degeneration |- |HSALNT0289567 |HSALNG0141682 |AK000974 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289579 |HSALNG0141694 |AK024118 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289645 |HSALNG0141760 |BC040204 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290321 |HSALNG0142436 |U79277 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289869 |HSALNG0141984 |HOST2 |NA |ceRNA |pathogenic process |epithelial ovarian cancer |- |HSALNT0289368 |HSALNG0135509 |MGAT3-AS1 |TapSAKI |NA |pathogenic process |acute kidney injury |- |HSALNT0289624 |HSALNG0141739 |ATXN7L3B |NA |NA |pathogenic process |spinocerebellar ataxia |- |HSALNT0289990 |HSALNG0142105 |lnc-SCA7 |NA |ceRNA |pathogenic process |spinocerebellar ataxia |- |HSALNT0290004 |HSALNG0142119 |LOC100287482 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290383 |HSALNG0142498 |XLOC_007697 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290384 |HSALNG0142499 |XLOC_008559 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290385 |HSALNG0142500 |XLOC_009911 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0289813 |HSALNG0141928 |ENST00000480739 |RPL13AP23 |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0290111 |HSALNG0142226 |OS9 |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0290324 |HSALNG0142439 |uc.283-plus |NA |NA |pathogenic process |glioma |- |HSALNT0289117 |HSALNG0051652 |LINC01611 |RP1-90L14.1,TCONS_l2_00025430 |NA |pathogenic process |diabetic retinopathy |- |HSALNT0289529 |HSALNG0141644 |2900055J20Rik |2900055J20Rik |NA |pathogenic process |left ventricular hypertrophy |- |HSALNT0289792 |HSALNG0141907 |ENSG00000261777 |AC012184.3 |NA |pathogenic process |prostate cancer |- |HSALNT0289618 |HSALNG0141733 |Asb3 |NA |NA |pathogenic process |cardiovascular and renal disease |- |HSALNT0289703 |HSALNG0141818 |Chac2 |NA |NA |pathogenic process |cardiovascular and renal disease |- |HSALNT0290139 |HSALNG0142254 |Pex11b |NA |NA |pathogenic process |cardiovascular and renal disease |- |HSALNT0290255 |HSALNG0142370 |Sp5 |NA |NA |pathogenic process |cardiovascular and renal disease |- |HSALNT0211639 |HSALNG0101614 |PSMA3-AS1 |FLJ31306 |NA |pathogenic process |NA |- |HSALNT0289319 |HSALNG0141639 |LINC00493 |LOC388789 |NA |pathogenic process |NA |- |HSALNT0288903 |HSALNG0126842 |CARD8-AS1 |LOC100505812 |transcriptional regulation |pathogenic process |leukemia and neuroblastoma |- |HSALNT0064729 |HSALNG0030929 |KCNMB2-AS1 |RP11-385J1.2 |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289548 |HSALNG0141663 |AC013264.2 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289857 |HSALNG0141972 |GUCY1B2 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290190 |HSALNG0142305 |RP11-385J1.2 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290216 |HSALNG0142331 |RP1-317E23.3 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290317 |HSALNG0142432 |TUBA4B |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290375 |HSALNG0142490 |XLOC_000371 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290397 |HSALNG0142512 |Z82214.3 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289735 |HSALNG0141850 |DALIR |DALI |transcriptional regulation |NA |NA |- |HSALNT0290376 |HSALNG0142491 |XLOC_000620 |NA |NA |pathogenic process |H. pylori-related diseases |- |HSALNT0290380 |HSALNG0142495 |XLOC_004122 |NA |NA |pathogenic process |H. pylori-related diseases |- |HSALNT0290381 |HSALNG0142496 |XLOC_004562 |NA |NA |pathogenic process |H. pylori-related diseases |- |HSALNT0290382 |HSALNG0142497 |XLOC_005912 |NA |NA |pathogenic process |H. pylori-related diseases |- |HSALNT0290391 |HSALNG0142506 |XLOC_014388 |NA |NA |pathogenic process |H. pylori-related diseases |- |HSALNT0290028 |HSALNG0142143 |LOC652276 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290162 |HSALNG0142277 |R05532 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0098175 |HSALNG0046752 |LINC01411 |RP11-267A15.1 |NA |pathogenic process |prostate cancer |- |HSALNT0290025 |HSALNG0142140 |LOC401317 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0289726 |HSALNG0141841 |CTD-2574D22.4 |AC120114.2 |NA |pathogenic process |osteoarthritis |- |HSALNT0290141 |HSALNG0142256 |PMS2L2 |NA |NA |pathogenic process |osteoarthritis |- |HSALNT0289974 |HSALNG0142089 |lncRNA-422 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289520 |HSALNG0133454 |AATBC |NA |NA |pathogenic process |bladder cancer |- |HSALNT0289311 |HSALNG0141637 |LINC00974 |NA |ceRNA |pathogenic process |hepatocellular cancer |- |HSALNT0089943 |HSALNG0042820 |ZBED3-AS1 |NA |NA |developmental process |NA |- |HSALNT0289116 |HSALNG0135958 |LINC01589 |CTA-941F9.9,TCONS_00029353 |NA |pathogenic process |NA |- |HSALNT0289910 |HSALNG0142025 |LINC01426 |NA |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0290341 |HSALNG0142456 |uc002yug.2 |NA |splicing regulation |pathogenic process |esophageal squamous cell cancer |- |HSALNT0290250 |HSALNG0142365 |SNCG |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289949 |HSALNG0142064 |lnc-AF085935 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289996 |HSALNG0142111 |lnc-uc003wbd |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289559 |HSALNG0141674 |AF085935 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290347 |HSALNG0142462 |uc003wbd |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290098 |HSALNG0142213 |NR_001284 |TNXA |NA |pathogenic process |chronic thromboembolic pulmonary hypertension |- |HSALNT0290327 |HSALNG0142442 |uc.343 |NA |NA |pathogenic process |osteoarthritis |- |HSALNT0289196 |HSALNG0094525 |NRAV |DYNLL1-AS1 |transcriptional regulation |pathogenic process |influenza A virus |- |HSALNT0290140 |HSALNG0142255 |PLEC |NA |NA |pathogenic process |chronic obstructive pulmonary disease |- |HSALNT0290172 |HSALNG0142287 |RNA44121|UCSC-2000-3182 |NA |NA |pathogenic process |chronic obstructive pulmonary disease |- |HSALNT0290173 |HSALNG0142288 |RNA50010|UCSC-9199-1005 |NA |NA |pathogenic process |chronic obstructive pulmonary disease |- |HSALNT0290174 |HSALNG0142289 |RNA58351|CombinedLit_316_550 |NA |NA |pathogenic process |chronic obstructive pulmonary disease |- |HSALNT0289714 |HSALNG0141829 |CR613944 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289933 |HSALNG0142048 |lincRNA-CALCA |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290200 |HSALNG0142315 |RP11-501G6.1 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290208 |HSALNG0142323 |RP11-672F9.1 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290405 |HSALNG0142520 |C14orf132 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289937 |HSALNG0142052 |lincRNA-TSPAN8 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290225 |HSALNG0142340 |RP5-1014O16.1 |AC244098.1 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290275 |HSALNG0142390 |TCONS_00026102 |NA |NA |pathogenic process |atrial fibrillation |- |HSALNT0290277 |HSALNG0142392 |TCONS_00032546 |NA |NA |pathogenic process |atrial fibrillation |- |HSALNT0289037 |HSALNG0096978 |LINC00441 |RB1-DT,ncRNA-RB1 |NA |pathogenic process |NA |- |HSALNT0289661 |HSALNG0141776 |C1401f132 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289141 |HSALNG0039030 |LINC02365 |LVCAT8 |NA |pathogenic process |NA |- |HSALNT0288885 |HSALNG0095161 |ADGRD1-AS1 |LACAT8 |NA |NA |NA |- |HSALNT0289142 |HSALNG0034152 |LINC02475 |LVCAT1 |NA |NA |NA |- |HSALNT0289542 |HSALNG0141657 |Abhd11os |NA |NA |pathogenic process |neurodegenerative diseases |- |HSALNT0288895 |HSALNG0124521 |BISPR |NA |NA |pathogenic process |virus infection |- |HSALNT0233975 |HSALNG0112910 |MAFTRR |linc-MAF-4 |transcriptional regulation |NA |NA |- |HSALNT0290058 |HSALNG0142173 |MRAK052686 |NA |NA |pathogenic process |nonalcoholic fatty liver disease |- |HSALNT0290221 |HSALNG0142336 |RP4-583P15.10 |AL121845.1 |NA |pathogenic process |breast cancer |- |HSALNT0211341 |HSALNG0101470 |KTN1-AS1 |C14orf33,MYCLo-3 |NA |pathogenic process |colorectal cancer |- |HSALNT0266752 |HSALNG0129835 |DLGAP4-AS1 |CCAT7 |NA |pathogenic process |colorectal cancer |- |HSALNT0289682 |HSALNG0141797 |CCAT3 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289684 |HSALNG0141799 |CCAT8 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289898 |HSALNG0142013 |LINC00659 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289683 |HSALNG0141798 |CCAT7 |NA |NA |pathogenic process |NA |- |HSALNT0289627 |HSALNG0141742 |BALR-2 |NA |NA |pathogenic process |B cell acute lymphoblastic leukemia |- |HSALNT0289948 |HSALNG0142063 |lnc-ACACA-1 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289953 |HSALNG0142068 |lnc-BMP2-2 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289955 |HSALNG0142070 |lnc-CPN2-1 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289958 |HSALNG0142073 |lnc-FOXG1-2 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289960 |HSALNG0142075 |lnc-FZD1-2 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289962 |HSALNG0142077 |lnc-ITPR2-3 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289965 |HSALNG0142080 |lnc-LCP2-2 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289988 |HSALNG0142103 |lnc-RP3-368B9 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289991 |HSALNG0142106 |lnc-SLC30A4-1 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289992 |HSALNG0142107 |lnc-SPAM1-6 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289995 |HSALNG0142110 |lnc-TTC34-3 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0222064 |HSALNG0106856 |DRAIC |NA |NA |pathogenic process |prostate cancer;glioma;cancer;bladder cancer;renal clear cell cancer;skin melanoma;hepatocellular cancer;lung adenocarcinoma;stomach adenocarcinoma |- |HSALNT0005037 |HSALNG0002618 |LINC01137 |LOC728431 |NA |pathogenic process |NA |- |HSALNT0290390 |HSALNG0142505 |XLOC_014172 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290014 |HSALNG0142129 |LOC149086 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290183 |HSALNG0142298 |RP11-160H22.5 |AL121983.2 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289945 |HSALNG0142060 |LNC00964-3 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289616 |HSALNG0141731 |Arid2-IR |NA |NA |pathogenic process |renal inflammation |- |HSALNT0289716 |HSALNG0141831 |CR619813 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289739 |HSALNG0141854 |DDX6P1 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289938 |HSALNG0142053 |lincRNA-ZNF532 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0290011 |HSALNG0142126 |LOC105372753 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0290013 |HSALNG0142128 |LOC105377769 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0290205 |HSALNG0142320 |RP11-58D2.1 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0288946 |HSALNG0105101 |ENST00000434223 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0288947 |HSALNG0082178 |ENST00000442037 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0288953 |HSALNG0088449 |ENST00000540136 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290103 |HSALNG0142218 |NR_038125 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290136 |HSALNG0142251 |PDLIM3 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290335 |HSALNG0142450 |uc001gch.1 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290336 |HSALNG0142451 |uc001gzl.3 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290351 |HSALNG0142466 |uc004bbl.1 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290369 |HSALNG0142484 |VNN2 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0289577 |HSALNG0141692 |AK022798 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289663 |HSALNG0141778 |C1orf74 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289602 |HSALNG0141717 |AKR7L |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289711 |HSALNG0141826 |COL3A1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289878 |HSALNG0141993 |KCNE2 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289636 |HSALNG0141751 |BC015134 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289713 |HSALNG0141828 |CR594506 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289928 |HSALNG0142043 |lincRNA-BBOX1-2 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0271719 |HSALNG0132223 |LINC00320 |PRED14,FLJ37539 |NA |pathogenic process;developmental process |cortical white matter |- |HSALNT0289823 |HSALNG0141938 |EVADR |NA |NA |pathogenic process |pancreatic cancer;lung cancer;colorectal cancer;rectal cancer |- |HSALNT0289944 |HSALNG0142059 |Lnc_bc060912 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289952 |HSALNG0142067 |lnc-bc060912 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289613 |HSALNG0141728 |APF |NA |ceRNA |pathogenic process |myocardial infarction |- |HSALNT0289617 |HSALNG0141732 |AS Uchl1 |NA |NA |pathogenic process |Parkinson's disease |- |HSALNT0289104 |HSALNG0099739 |LINC01296 |FLJ39632 |NA |pathogenic process |colorectal cancer |- |HSALNT0290403 |HSALNG0142518 |ZXF2 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290113 |HSALNG0142228 |P14695 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290114 |HSALNG0142229 |P16984 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290115 |HSALNG0142230 |P19780 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290116 |HSALNG0142231 |P23099 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290117 |HSALNG0142232 |P24363 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290118 |HSALNG0142233 |P28210 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290120 |HSALNG0142235 |P33863 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290121 |HSALNG0142236 |P4091 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290122 |HSALNG0142237 |P6391 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290123 |HSALNG0142238 |P6488 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290124 |HSALNG0142239 |P700 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290125 |HSALNG0142240 |P8611 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290126 |HSALNG0142241 |P8725 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290127 |HSALNG0142242 |P8860 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290128 |HSALNG0142243 |P9745 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289269 |HSALNG0044864 |TH2LCRR |TH2-LCR |transcriptional regulation |pathogenic process |allergic asthma |- |HSALNT0289964 |HSALNG0142079 |lnc-LCE5A-1 |NA |NA |pathogenic process |laryngeal cancer;head and neck squamous cell cancer |- |HSALNT0055198 |HSALNG0026441 |FAM3D-AS1 |lnc-KCTD6-3 |NA |pathogenic process |tongue cancer;pharyngeal cancer;head and neck squamous cell cancer;laryngeal cancer |- |HSALNT0289843 |HSALNG0141958 |FRLnc1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0242005 |HSALNG0117109 |ENST00000575202 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0288952 |HSALNG0089220 |ENST00000539009 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0288954 |HSALNG0089242 |ENST00000544591 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289752 |HSALNG0141867 |EHHADH-AS1 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289812 |HSALNG0141927 |ENST00000468960 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290276 |HSALNG0142391 |TCONS_00026506 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0189952 |HSALNG0091595 |LRP1-AS |NA |transcriptional regulation |pathogenic process |Alzheimer's disease |- |HSALNT0032045 |HSALNG0015125 |LINC01122 |FLJ30838,AC007092.1 |NA |NA |NA |- |HSALNT0289565 |HSALNG0141680 |AI364715 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289921 |HSALNG0142036 |LINC0949 |NA |NA |pathogenic process |systemic lupus erythematosus |- |HSALNT0289680 |HSALNG0141795 |CCAL |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289079 |HSALNG0077354 |LINC00993 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289811 |HSALNG0141926 |ENST00000460164 |NA |NA |pathogenic process |triple-negative breast cancer |- |HSALNT0290282 |HSALNG0142397 |TCONS_l2_00003938 |NA |NA |pathogenic process |triple-negative breast cancer |- |HSALNT0289888 |HSALNG0142003 |LGALS3 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289963 |HSALNG0142078 |lnc-KCMF1-2:1 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289967 |HSALNG0142082 |lnc-LLPH-2:1 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289971 |HSALNG0142086 |lnc-PLA2R1-1:1 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289972 |HSALNG0142087 |lnc-PSD4-1:14 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290066 |HSALNG0142181 |n335550 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290070 |HSALNG0142185 |n340790 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290072 |HSALNG0142187 |n386477 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290286 |HSALNG0142401 |TCONS_l2_00010365 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0288944 |HSALNG0129184 |ENST00000422494 |NA |NA |NA |NA |- |HSALNT0289118 |HSALNG0038513 |LINC01612 |RP11-789C1.1,TCONS_00008319 |NA |pathogenic process |gastric cancer |- |HSALNT0289610 |HSALNG0141725 |AP001439.2 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289671 |HSALNG0141786 |CACNAICAS3 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289853 |HSALNG0141968 |GS1-5L10.1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289875 |HSALNG0141990 |INTS7 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290065 |HSALNG0142180 |MYLK-AS1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290157 |HSALNG0142272 |PRSS21 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290202 |HSALNG0142317 |RP11-528G1.2 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290207 |HSALNG0142322 |RP11-643M14.1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290209 |HSALNG0142324 |RP11-789C1.1 |LINC01612 |NA |pathogenic process |gastric cancer |- |HSALNT0290314 |HSALNG0142429 |TSNAX-DISC1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290386 |HSALNG0142501 |XLOC_010235 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289558 |HSALNG0141673 |AF075041 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289564 |HSALNG0141679 |AF339813 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289575 |HSALNG0141690 |AK022029 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289576 |HSALNG0141691 |AK022159 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289604 |HSALNG0141719 |AL389956 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0289640 |HSALNG0141755 |BC023629 |NA |NA |pathogenic process |pancreatic cancer |- |HSALNT0290096 |HSALNG0142211 |NONHSAT125629 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290393 |HSALNG0142508 |XR_250621.1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0288951 |HSALNG0033002 |ENST00000503938 |NA |NA |pathogenic process |triple-negative breast cancer |- |HSALNT0290085 |HSALNG0142200 |NONHSAT012762 |NA |NA |pathogenic process |triple-negative breast cancer |- |HSALNT0289151 |HSALNG0023952 |LMCD1-AS1 |NA |NA |pathogenic process |acute kidney injury |- |HSALNT0289926 |HSALNG0142041 |linc-PXN-1 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290281 |HSALNG0142396 |TCONS_l2_00001418 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290285 |HSALNG0142400 |TCONS_l2_00008237 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290287 |HSALNG0142402 |TCONS_l2_00011130 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290288 |HSALNG0142403 |TCONS_l2_00013175 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290294 |HSALNG0142409 |TCONS_l2_00022611 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290295 |HSALNG0142410 |TCONS_l2_00022670 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290352 |HSALNG0142467 |uc004bdv.3 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290363 |HSALNG0142478 |ULK4P2 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289942 |HSALNG0142057 |LK4P2 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289538 |HSALNG0141653 |AB019562 |NA |NA |pathogenic process |hypopharyngeal squamous cell cancer |- |HSALNT0091661 |HSALNG0043585 |ENST00000503710 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0289806 |HSALNG0141921 |ENST00000445734 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0289807 |HSALNG0141922 |ENST00000448093 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0289815 |HSALNG0141930 |ENST00000502941 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0290340 |HSALNG0142455 |uc002nbr.3 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0290348 |HSALNG0142463 |uc003xut. |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0290356 |HSALNG0142471 |uc021re1.1 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0289549 |HSALNG0141664 |AC016745.3 |AC016745.1 |NA |pathogenic process |glioma |- |HSALNT0290180 |HSALNG0142295 |RP11-128A17.1 |AC078909.1 |NA |pathogenic process |glioma |- |HSALNT0290377 |HSALNG0142492 |XLOC_001711 |NA |NA |pathogenic process |glioma |- |HSALNT0289975 |HSALNG0142090 |lncRNA-AK058003 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289061 |HSALNG0034072 |LINC00682 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289305 |HSALNG0089456 |LINC01559 |FLJ33810 |NA |pathogenic process |Huntington disease |- |HSALNT0289854 |HSALNG0141969 |GSTT1-AS1 |NA |transcriptional regulation |pathogenic process |mycobacterium tuberculosis infection |- |HSALNT0289978 |HSALNG0142093 |lncRNA-CD244 |NA |transcriptional regulation |pathogenic process |tuberculosis infection |- |HSALNT0289237 |HSALNG0068014 |SAMD12-AS1 |NA |NA |pathogenic process |neuroblastoma |- |HSALNT0290179 |HSALNG0142294 |RP11-119F7.4 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290278 |HSALNG0142393 |TCONS_00068220 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0285573 |HSALNG0139654 |DANT1 |NA |transcriptional regulation |NA |NA |- |HSALNT0288926 |HSALNG0139662 |DANT2 |NA |transcriptional regulation |NA |NA |- |HSALNT0290399 |HSALNG0142514 |ZMAT1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289554 |HSALNG0141669 |AC100865.1 |NA |NA |pathogenic process |coronary artery disease |- |HSALNT0289228 |HSALNG0105273 |RAD51-AS1 |TODRA |transcriptional regulation |pathogenic process |breast cancer |- |HSALNT0289743 |HSALNG0141858 |DKFZP434K028 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289630 |HSALNG0141745 |BC002811 |NA |NA |pathogenic process |astrocytoma |- |HSALNT0290387 |HSALNG0142502 |XLOC_010967 |NA |NA |pathogenic process |astrocytoma |- |HSALNT0288955 |HSALNG0084672 |ENST00000545440 |NA |NA |pathogenic process |pediatric acute myeloid leukemia |- |HSALNT0288981 |HSALNG0133391 |FRGCA |LncRNA-AP001631.9 |NA |pathogenic process |gastric cancer |- |HSALNT0289611 |HSALNG0141726 |AP001631.9 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289976 |HSALNG0142091 |LncRNA-AP001631.9 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289686 |HSALNG0141801 |CD99P1 |NA |ceRNA |pathogenic process |idiopathic pulmonary fibrosis |- |HSALNT0289119 |HSALNG0074097 |LINC01613 |n341773 |NA |pathogenic process |idiopathic pulmonary fibrosis |- |HSALNT0289844 |HSALNG0141959 |FTH1P3 |FTH1P3 |NA |pathogenic process |oral squamous cell cancer |- |HSALNT0289855 |HSALNG0141970 |GTF2IRD2P1 |GTF2IRD2P1 |NA |pathogenic process |oral squamous cell cancer |- |HSALNT0290135 |HSALNG0142250 |PDIA3F |NA |NA |pathogenic process |oral squamous cell cancer |- |HSALNT0289329 |HSALNG0026562 |LINC00994 |NA |NA |pathogenic process |inflammatory bowel disease |- |HSALNT0289208 |HSALNG0077290 |PCAT5 |LINC01452,TPCAT-10-36067 |NA |pathogenic process |prostate cancer |- |HSALNT0114870 |HSALNG0054158 |LUADT1 |NA |transcriptional regulation |pathogenic process |lung adenocarcinoma |- |HSALNT0289154 |HSALNG0107133 |LOXL1-AS1 |NA |NA |pathogenic process |exfoliation syndrome |- |HSALNT0289734 |HSALNG0141849 |DACOR1 |TCONS_00023265 |transcriptional regulation |pathogenic process |colorectal cancer |- |HSALNT0289060 |HSALNG0114548 |LINC00675 |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0288889 |HSALNG0070759 |B4GALT1-AS1 |NA |transcriptional regulation |pathogenic process |NA |- |HSALNT0289348 |HSALNG0083371 |LINC01616 |n341006 |NA |pathogenic process |Alzheimer's disease |- |HSALNT0290068 |HSALNG0142183 |n336934 |NA |NA |pathogenic process |Alzheimer's disease |- |HSALNT0290240 |HSALNG0142355 |SIRT1-AS |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290198 |HSALNG0142313 |RP11-457M11.2 |NA |ceRNA |pathogenic process |lung adenocarcinoma |- |HSALNT0150768 |HSALNG0072141 |LINC01507 |XLOC_000303 |NA |pathogenic process |colorectal cancer |- |HSALNT0289903 |HSALNG0142018 |LINC01057 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289914 |HSALNG0142029 |LINC01617 |C8orf23,NCRNA00249,XLOC_006844 |NA |pathogenic process |colorectal cancer |- |HSALNT0290015 |HSALNG0142130 |LOC152578 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0072252 |HSALNG0034426 |LINC01618 |LOC152578 |NA |pathogenic process |NA |- |HSALNT0156870 |HSALNG0075266 |NALT1 |MIR4674HG,LINC01573,TCONS_l2_00029132 |transcriptional regulation |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0289083 |HSALNG0045290 |MALINC1 |LINC01024,MA-linc1 |NA |pathogenic process |human breast and lung cancer |- |HSALNT0289902 |HSALNG0142017 |LINC01024 |MA-linc1 |NA |pathogenic process |osteosarcoma;lung cancer |- |HSALNT0289120 |HSALNG0071043 |LINC01627 |RP11-397D12.4 |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289121 |HSALNG0015617 |LINC01628 |AC007403.1 |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289820 |HSALNG0141935 |ERICH1-AS1 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290193 |HSALNG0142308 |RP11-397D12.4 |LINC01627 |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289122 |HSALNG0102605 |LINC01629 |linc-KIAA1737-2 |transcriptional regulation |pathogenic process |hypoxic and inflammatory renal epithelial injury |- |HSALNT0290161 |HSALNG0142276 |PTPRG-AS1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289980 |HSALNG0142095 |lncRNA-DLEU1 |NA |ceRNA |pathogenic process |breast cancer |- |HSALNT0289983 |HSALNG0142098 |lncRNA-Hh |NA |NA |pathogenic process |breast cancer |- |HSALNT0288986 |HSALNG0072437 |GAS1RR |LncRNA-Hh |NA |pathogenic process |breast cancer |- |HSALNT0288908 |HSALNG0005250 |CCDC18-AS1 |ENST00000440778.1 |NA |pathogenic process |adolescent idiopathic scoliosis |- |HSALNT0289055 |HSALNG0132813 |LINC00649 |TCONS_00028768 |NA |pathogenic process |adolescent idiopathic scoliosis |- |HSALNT0289219 |HSALNG0075966 |PRKCQ-AS1 |ENST00000414894.1 |NA |pathogenic process |adolescent idiopathic scoliosis |- |HSALNT0290203 |HSALNG0142318 |RP11-567G11.1 |LINC02041 |NA |pathogenic process |pancreatic cancer |- |HSALNT0289805 |HSALNG0141920 |ENST00000438550 |RPS24P1 |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0290083 |HSALNG0142198 |NONHSAG011351 |NA |NA |pathogenic process |type 1 diabetes |- |HSALNT0290049 |HSALNG0142164 |MCHR2-AS1 |NA |NA |pathogenic process |psychiatric disease |- |HSALNT0289799 |HSALNG0141914 |ENST00000414355 |NA |NA |pathogenic process |cadmium toxicology |- |HSALNT0290241 |HSALNG0142356 |SKP2 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289837 |HSALNG0141952 |FLJ90757 |NA |ceRNA |pathogenic process |hepatocellular cancer |- |HSALNT0290017 |HSALNG0142132 |LOC283663 |NA |ceRNA |pathogenic process |hepatocellular cancer |- |HSALNT0290019 |HSALNG0142134 |LOC338651 |NA |ceRNA |pathogenic process |hepatocellular cancer |- |HSALNT0290132 |HSALNG0142247 |PCATs |NA |NA |pathogenic process |prostate cancer |- |HSALNT0086786 |HSALNG0041277 |EGFLAM-AS1 |lncRNA-LOWEG |NA |pathogenic process |gastric cancer |- |HSALNT0290031 |HSALNG0142146 |LOWEG |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289635 |HSALNG0141750 |BC014579 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289721 |HSALNG0141836 |CTB-167B5.2 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289863 |HSALNG0141978 |HELLS |NA |NA |pathogenic process |leukemia |- |HSALNT0290195 |HSALNG0142310 |RP11-401P9.4 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0290252 |HSALNG0142367 |SNHG19 |NA |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0289557 |HSALNG0141672 |AF070632 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289569 |HSALNG0141684 |AK021443 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289728 |HSALNG0141843 |CTD-3080P12.3 |NA |ceRNA |pathogenic process |gastric cancer |- |HSALNT0289987 |HSALNG0142102 |lncRNA-n336928 |NA |NA |pathogenic process |bladder cancer |- |HSALNT0289723 |HSALNG0141838 |CTC-523E23.5 |AC008555.2 |NA |pathogenic process |intervertebral disc degeneration |- |HSALNT0289724 |HSALNG0141839 |CTD-2246P4.1 |NA |NA |pathogenic process |intervertebral disc degeneration |- |HSALNT0290055 |HSALNG0142170 |MIR132 |MIRN132,miRNA132,mir-132 |NA |pathogenic process |intervertebral disc degeneration |- |HSALNT0290189 |HSALNG0142304 |RP11-363G2.4 |NA |NA |pathogenic process |intervertebral disc degeneration |- |HSALNT0290191 |HSALNG0142306 |RP11-38F22.1 |LINC02424 |NA |pathogenic process |intervertebral disc degeneration |- |HSALNT0290223 |HSALNG0142338 |RP4-639J15.1 |AC006967.2 |NA |pathogenic process |intervertebral disc degeneration |- |HSALNT0290233 |HSALNG0142348 |RUNX1-IT1 |C21orf96 |NA |pathogenic process |gastric cancer |- |HSALNT0288943 |HSALNG0053446 |ENST00000415964 |NA |NA |pathogenic process |pediatric acute myeloid leukemia |- |HSALNT0290009 |HSALNG0142124 |LOC101927497 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289956 |HSALNG0142071 |lnc-CYP4A22-2/3 |NA |NA |pathogenic process |clear cell renal cell cancer |- |HSALNT0289999 |HSALNG0142114 |lnc-ZNF180-2 |NA |NA |pathogenic process |renal clear cell cancer |- |HSALNT0290086 |HSALNG0142201 |NONHSAT037832 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289658 |HSALNG0141773 |BX647187 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0288920 |HSALNG0017086 |CNNM3-DT |LOC100506036 |NA |NA |NA |- |HSALNT0289584 |HSALNG0141699 |AK056155 |NA |NA |pathogenic process |Loeys-Dietz syndrome |- |HSALNT0290057 |HSALNG0142172 |MR1 |NA |NA |pathogenic process |Loeys-Dietz syndrome |- |HSALNT0289543 |HSALNG0141658 |AC002454.1 |AC002454.1 |NA |pathogenic process |endometriosis |- |HSALNT0289909 |HSALNG0142024 |LINC01420 |NA |NA |pathogenic process |systemic lupus erythematosus |- |HSALNT0289531 |HSALNG0141646 |53BP1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290101 |HSALNG0142216 |NR_024118 |NA |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0290239 |HSALNG0142354 |SGO1-AS1 |SGOL1-AS1 |NA |pathogenic process |lung cancer |- |HSALNT0289293 |HSALNG0127764 |ZNF667-AS1 |MORT |NA |pathogenic process |breast cancer |- |HSALNT0289984 |HSALNG0142099 |lncRNA-HIF2PUT |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0288945 |HSALNG0018617 |ENST00000433673 |AC068282.1 |NA |pathogenic process |polycystic ovary syndrome |- |HSALNT0288948 |HSALNG0008353 |ENST00000454271 |AL021940.1 |NA |pathogenic process |polycystic ovary syndrome |- |HSALNT0289495 |HSALNG0141606 |ENST00000432431 |AC023128.1 |NA |pathogenic process |polycystic ovary syndrome |- |HSALNT0289918 |HSALNG0142033 |LINC01828 |NA |NA |pathogenic process |polycystic ovary syndrome |- |HSALNT0290388 |HSALNG0142503 |XLOC_011402 |NA |NA |pathogenic process |polycystic ovary syndrome |- |HSALNT0289873 |HSALNG0141988 |ICAM-1 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289668 |HSALNG0141783 |C5T1lncRNA |NA |transcriptional regulation |pathogenic process |rheumatoid arthritis |- |HSALNT0289667 |HSALNG0141782 |C5T1 |NA |NA |pathogenic process |NA |- |HSALNT0289666 |HSALNG0141781 |C5-OT1 |C5T1lncRNA |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0289626 |HSALNG0141741 |AX800134 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290338 |HSALNG0142453 |uc001ncr |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290330 |HSALNG0142445 |uc.48+ |NA |NA |pathogenic process |diabetic neuropathic pain |- |HSALNT0289098 |HSALNG0038313 |LINC01207 |NA |transcriptional regulation |pathogenic process |lung adenocarcinoma |- |HSALNT0289628 |HSALNG0141743 |BALR-6 |NA |transcriptional regulation |pathogenic process |B-lymphoblastic leukemia |- |HSALNT0290022 |HSALNG0142137 |LOC389641 |NA |NA |pathogenic process |Pancreatic ductal adenocarcinoma |- |HSALNT0289725 |HSALNG0141840 |CTD-2541M15 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289940 |HSALNG0142055 |LINK-A |NA |NA |pathogenic process |triple-negative breast cancer |- |HSALNT0290107 |HSALNG0142222 |NUTF2P3 |NUTF2P3 |NA |pathogenic process |pancreatic cancer |- |HSALNT0290095 |HSALNG0142210 |NONHSAT123350 |NA |NA |pathogenic process |renal clear cell cancer |- |HSALNT0290362 |HSALNG0142477 |UHRF1 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290366 |HSALNG0142481 |UPAT |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289307 |HSALNG0114404 |LINC00324 |FLJ34790,MGC104931 |NA |pathogenic process |NA |- |HSALNT0289969 |HSALNG0142084 |lnc-MX1-1 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0290024 |HSALNG0142139 |LOC400891 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0289883 |HSALNG0141998 |LA16c-313D11.11 |NA |ceRNA |pathogenic process |endometrial cancer |- |HSALNT0290192 |HSALNG0142307 |RP11-395G23.3 |AC027031.2 |NA |pathogenic process |endometrial cancer |- |HSALNT0289742 |HSALNG0141857 |DILC |NA |transcriptional regulation |pathogenic process |liver cancer |- |HSALNT0289957 |HSALNG0142072 |lnc-DILC |NA |transcriptional regulation |pathogenic process |liver cancer |- |HSALNT0289581 |HSALNG0141696 |AK027294 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290371 |HSALNG0142486 |WISP1 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0206117 |HSALNG0099020 |FGF14-AS2 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290131 |HSALNG0142246 |PCAT2 |CARLo-4,PCA2,TCONS_00015167 |NA |pathogenic process |prostate cancer |- |HSALNT0289528 |HSALNG0141643 |2700086A05Rik |2700086A05Rik |NA |pathogenic process |idiopathic pulmonary fibrosis |- |HSALNT0290251 |HSALNG0142366 |SNED1 |NA |NA |pathogenic process |Idiopathic pulmonary fibrosis |- |HSALNT0290333 |HSALNG0142448 |uc.77 |NA |NA |pathogenic process |idiopathic pulmonary fibrosis |- |HSALNT0289816 |HSALNG0141931 |ENST00000537266 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289860 |HSALNG0141975 |HAGLROS |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289881 |HSALNG0141996 |KRT18P55 |KRT18P55 |NA |pathogenic process |gastric cancer |- |HSALNT0229266 |HSALNG0110450 |IL21R-AS1 |NA |NA |pathogenic process |coronary artery disease |- |HSALNT0290112 |HSALNG0142227 |OTTHUMT00000387022 |NA |NA |pathogenic process |coronary artery disease |- |HSALNT0000551 |HSALNG0000226 |PRKCZ-AS1 |RP11-181G12.2 |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0030981 |HSALNG0014612 |LINC01833 |RP11-89,K21.1 |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0290214 |HSALNG0142329 |RP11-89K21 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0165271 |HSALNG0079188 |LINC00857 |NA |NA |pathogenic process |lung cancer |- |HSALNT0290109 |HSALNG0142224 |OR3A4 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290046 |HSALNG0142161 |MAGI1-IT1 |NA |ceRNA |pathogenic process |cardiac hypertrophy |- |HSALNT0290242 |HSALNG0142357 |SLC26A4-AS1 |NA |ceRNA |pathogenic process |cardiac hypertrophy |- |HSALNT0289302 |HSALNG0141636 |KRT7-AS |NA |NA |pathogenic process |gastric cancer |- |HSALNT0218672 |HSALNG0105101 |LINC01852 |ENST00000434223 |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290178 |HSALNG0142293 |RP11-1008C21.2 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289592 |HSALNG0141707 |AK123072 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289573 |HSALNG0141688 |AK021954 |NA |NA |pathogenic process |atherosclerosis |- |HSALNT0288916 |HSALNG0105961 |CERNA1 |LOC100129973 |ceRNA |pathogenic process |cardiovascular disease |- |HSALNT0018525 |HSALNG0008959 |LAMC1-AS1 |lnc-LAMC2-1:1 |NA |pathogenic process |colorectal cancer |- |HSALNT0290087 |HSALNG0142202 |NONHSAT040387 |NA |NA |pathogenic process |atrial fibrillation |- |HSALNT0290092 |HSALNG0142207 |NONHSAT098586 |NA |NA |pathogenic process |atrial fibrillation |- |HSALNT0289213 |HSALNG0108626 |PCSK6-AS1 |NA |NA |NA |NA |- |HSALNT0289637 |HSALNG0141752 |BC016831 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289874 |HSALNG0141989 |IGKV |NA |NA |pathogenic process |breast cancer |- |HSALNT0290196 |HSALNG0142311 |RP11-434D9.1 |AC112206.2 |NA |pathogenic process |breast cancer |- |HSALNT0289885 |HSALNG0142000 |LCAL6 |NA |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0289650 |HSALNG0141765 |BC088254 |NA |NA |pathogenic process |myocardial hypertrophy |- |HSALNT0289596 |HSALNG0141711 |AK124454 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289731 |HSALNG0141846 |CYP4B1-PS1 |NA |NA |pathogenic process |diabetic nephropathy |- |HSALNT0289106 |HSALNG0094020 |LINC01405 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290259 |HSALNG0142374 |ST8SIA6-AS1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289278 |HSALNG0047244 |TRIM52-AS1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0289634 |HSALNG0141749 |BC012900 |NA |NA |pathogenic process |ulcerative colitis |- |HSALNT0274011 |HSALNG0133283 |UMODL1-AS1 |FLJ33471 |NA |pathogenic process |breast cancer |- |HSALNT0289454 |HSALNG0075449 |ARRDC1-AS1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289456 |HSALNG0071200 |FAM74A3 |OTTHUMG00000067149 |NA |pathogenic process |breast cancer |- |HSALNT0289834 |HSALNG0141949 |FH |NA |NA |pathogenic process |Fumarase deficiency |- |HSALNT0289961 |HSALNG0142076 |lnc-HOXC4-3:1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289994 |HSALNG0142109 |lnc-TEAD4-1:1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290270 |HSALNG0142385 |TCONS_00003876 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289825 |HSALNG0141940 |EVI1 |NA |transcriptional regulation |pathogenic process |hepatocellular cancer |- |HSALNT0290235 |HSALNG0142350 |SARCC |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0290360 |HSALNG0142475 |ucoo2kmd.1 |NA |ceRNA |pathogenic process |colorectal cancer |- |HSALNT0289015 |HSALNG0001020 |KAZN-AS1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289722 |HSALNG0141837 |CTB-89H12.4 |AC021078.1 |ceRNA |pathogenic process |prostate cancer |- |HSALNT0289496 |HSALNG0141607 |EPB41L4A-AS2 |FLJ11235 |NA |pathogenic process |lung cancer;breast cancer;kidney cancer |- |HSALNT0289146 |HSALNG0004554 |LINC02567 |ENST00000427806 |NA |pathogenic process |attention deficit hyperactivity disorder |- |HSALNT0289833 |HSALNG0141948 |FGFR3-AS1 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289707 |HSALNG0141822 |CILinc01 |NA |NA |pathogenic process |osteoarthritis |- |HSALNT0289708 |HSALNG0141823 |CILinc02 |NA |NA |pathogenic process |osteoarthritis |- |HSALNT0286597 |HSALNG0140235 |LINC00629 |LINC00629AB,LINC00629C,LINC00629D,LINC00629 |NA |pathogenic process |choriocarcinoma |- |HSALNT0289665 |HSALNG0141780 |C2dat1 |NA |NA |pathogenic process |ischemic brain injury |- |HSALNT0289217 |HSALNG0057357 |POU6F2-AS2 |FLJ12971 |protein localization |pathogenic process |oesophageal squamous cell cancer |- |HSALNT0289946 |HSALNG0142061 |lnc13 |NA |NA |pathogenic process |celiac disease |- |HSALNT0289729 |HSALNG0141844 |CTD903 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290093 |HSALNG0142208 |NONHSAT104436 |NA |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0289550 |HSALNG0141665 |AC024560.2 |AC024560.1 |NA |pathogenic process |cervical cancer |- |HSALNT0289483 |HSALNG0134219 |ENST00000436681 |AP000552.1 |NA |pathogenic process |congenital heart defect |- |HSALNT0289536 |HSALNG0141651 |AA584040 |NA |NA |pathogenic process |congenital heart defect |- |HSALNT0289537 |HSALNG0141652 |AA709223 |NA |NA |pathogenic process |congenital heart defect |- |HSALNT0289657 |HSALNG0141772 |BX478947 |NA |NA |pathogenic process |congenital heart defect |- |HSALNT0247515 |HSALNG0119819 |LINC00668 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289719 |HSALNG0141834 |CRNDE-h |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0142879 |HSALNG0068121 |SMILR |NA |NA |pathogenic process |vascular pathologies |- |HSALNT0290396 |HSALNG0142511 |Z38 |NA |NA |pathogenic process |breast cancer |- |HSALNT0197213 |HSALNG0095037 |LINC00507 |NA |NA |developmental process |NA |- |HSALNT0289086 |HSALNG0113270 |LINC01082 |TCONSNA00024492 |NA |pathogenic process |alveolar capillary dysplasia with misalignment of pulmonary veins |- |HSALNT0289094 |HSALNG0015253 |LINC01185 |FLJ16341 |NA |pathogenic process |NA |- |HSALNT0290160 |HSALNG0142275 |PTPRD-AS1 |NA |NA |pathogenic process |ovarian cancer |- |HSALNT0290186 |HSALNG0142301 |RP11-254I22.1 |MIR583HG |NA |pathogenic process |ovarian cancer |- |HSALNT0290204 |HSALNG0142319 |RP11-57P19.1 |AC009432.1 |NA |pathogenic process |ovarian cancer |- |HSALNT0290211 |HSALNG0142326 |RP11-80H5.7 |AL157400.4 |NA |pathogenic process |ovarian cancer |- |HSALNT0290215 |HSALNG0142330 |RP1-223E5.4 |AL441883.1 |NA |pathogenic process |ovarian cancer |- |HSALNT0290224 |HSALNG0142339 |RP4-799P18.3 |AL122008.4 |NA |pathogenic process |ovarian cancer |- |HSALNT0289126 |HSALNG0045514 |LINC01844 |LOC101926975 |NA |pathogenic process |hirschsprung disease |- |HSALNT0289947 |HSALNG0142062 |Lnc34a |NA |transcriptional regulation |pathogenic process |colorectal cancer |- |HSALNT0289150 |HSALNG0075977 |LINP1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289951 |HSALNG0142066 |lncARSR |NA |ceRNA |pathogenic process |renal cell cancer |- |HSALNT0289392 |HSALNG0005967 |RBM15-AS1 |AS-RBM15 |translational control |pathogenic process |acute megakaryocytic leukemia |- |HSALNT0290089 |HSALNG0142204 |NONHSAT073641 |NA |NA |pathogenic process |vascular diseases |- |HSALNT0290027 |HSALNG0142142 |LOC572558 |NA |NA |pathogenic process |bladder cancer |- |HSALNT0289582 |HSALNG0141697 |AK033210 |NA |NA |pathogenic process;developmental process |bronchopulmonary dysplasia |- |HSALNT0289848 |HSALNG0141963 |GClnc1 |NA |transcriptional regulation |pathogenic process |gastric cancer |- |HSALNT0289572 |HSALNG0141687 |AK021630 |NA |NA |pathogenic process |Parkinson's disease |- |HSALNT0289603 |HSALNG0141718 |AL049437 |NA |NA |pathogenic process |Parkinson's disease |- |HSALNT0290007 |HSALNG0142122 |LOC100507661 |NA |NA |pathogenic process |thyroid cancer |- |HSALNT0289084 |HSALNG0122663 |LINC01029 |NA |NA |pathogenic process |cognitive functions and neuronal plasticity |- |HSALNT0290169 |HSALNG0142284 |RMEL3 |NA |NA |pathogenic process |melanoma |- |HSALNT0289959 |HSALNG0142074 |lnc-FRG2C-3 |NA |NA |pathogenic process |ankylosing spondylitis |- |HSALNT0289966 |HSALNG0142081 |lnc-LIN54-1 |NA |NA |pathogenic process |ankylosing spondylitis |- |HSALNT0289997 |HSALNG0142112 |lnc-USP50-2 |NA |NA |pathogenic process |ankylosing spondylitis |- |HSALNT0290000 |HSALNG0142115 |lnc-ZNF354A-1 |NA |NA |pathogenic process |ankylosing spondylitis |- |HSALNT0288949 |HSALNG0017887 |ENST00000455309 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0289920 |HSALNG0142035 |LINC02384 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0289998 |HSALNG0142113 |Lnc-UTS2D-1:1 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0290067 |HSALNG0142182 |n336161 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0290069 |HSALNG0142184 |n340599 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0290099 |HSALNG0142214 |NR_002712 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0290290 |HSALNG0142405 |TCONS_l2_00014794 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0290170 |HSALNG0142285 |RMRP |CHH,NME1R,RRP2,RMRP |ceRNA |pathogenic process |gastric cancer |- |HSALNT0289900 |HSALNG0142015 |LINC00961 |NA |NA |pathogenic process |ovarian cancer |- |HSALNT0289077 |HSALNG0068551 |LINC00977 |NA |NA |pathogenic process |primary spontaneous pneumothorax |- |HSALNT0289560 |HSALNG0141675 |AF085995 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289566 |HSALNG0141681 |AK000053 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289571 |HSALNG0141686 |AK021595 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289574 |HSALNG0141689 |AK022024 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289595 |HSALNG0141710 |AK124307 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289639 |HSALNG0141754 |BC020384 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289642 |HSALNG0141757 |BC030759 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289715 |HSALNG0141830 |CR615992 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289954 |HSALNG0142069 |lnc-CC3 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0289614 |HSALNG0141729 |APOC1P1-3 |NA |transcriptional regulation |pathogenic process |breast cancer |- |HSALNT0290365 |HSALNG0142480 |UNMIBC |NA |transcriptional regulation |pathogenic process |bladder cancer |- |HSALNT0290323 |HSALNG0142438 |uc.167 |NA |NA |pathogenic process |ventricular septal defects |- |HSALNT0290212 |HSALNG0142327 |RP11-838N2.4 |GAPLINC |ceRNA |pathogenic process |glioblastoma |- |HSALNT0289109 |HSALNG0121223 |LINC01478 |NA |NA |pathogenic process |blood pressure |- |HSALNT0289313 |HSALNG0016990 |LINC00342 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289677 |HSALNG0141792 |CAR10 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289365 |HSALNG0141638 |MAPT-AS1 |NA |transcriptional regulation |pathogenic process |Parkinson's disease |- |HSALNT0289679 |HSALNG0141794 |CAT104 |NA |ceRNA |pathogenic process |breast cancer |- |HSALNT0290260 |HSALNG0142375 |STXBP5-AS1 |NA |ceRNA |pathogenic process |breast cancer |- |HSALNT0289861 |HSALNG0141976 |HAR1 |NA |NA |pathogenic process |Huntington disease |- |HSALNT0290359 |HSALNG0142474 |UCHL1-AS1 |NA |translational control |pathogenic process |Parkinson's disease |- |HSALNT0290238 |HSALNG0142353 |SCAANT1-AS |NA |NA |pathogenic process |spinocerebellar ataxia |- |HSALNT0289648 |HSALNG0141763 |BC041488 |NA |transcriptional regulation |pathogenic process |bladder cancer |- |HSALNT0290188 |HSALNG0142303 |RP11-359E19.2 |AC022733.1 |transcriptional regulation |pathogenic process |bladder cancer |- |HSALNT0289669 |HSALNG0141784 |C6orf176-TV1 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289670 |HSALNG0141785 |C6orf176-TV2 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0289851 |HSALNG0141966 |GIHCG |NA |transcriptional regulation |pathogenic process |hepatocellular cancer |- |HSALNT0289649 |HSALNG0141764 |BC087858 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0290353 |HSALNG0142468 |uc004cov.4 |NA |NA |pathogenic process |hypertrophic cardiomyopathy |- |HSALNT0290357 |HSALNG0142472 |uc022bqu.1 |NA |NA |pathogenic process |hypertrophic cardiomyopathy |- |HSALNT0127837 |HSALNG0060796 |CFTR-AS1 |BGas |transcriptional regulation |pathogenic process |cystic fibrosis |- |HSALNT0046367 |HSALNG0021858 |MYOSLID |NA |NA |pathogenic process |vascular smooth muscle cell (VSMC) contractile phenotype |- |HSALNT0290331 |HSALNG0142446 |uc.63 |NA |NA |pathogenic process |breast cancer |- |HSALNT0290106 |HSALNG0142221 |numb |NA |NA |pathogenic process |uveal melanoma |- |HSALNT0289847 |HSALNG0141962 |GCASPC |TCONS_00011605,RP1-56L9.7-001,lnc-SOD2-1 |NA |pathogenic process |gallbladder cancer |- |HSALNT0289568 |HSALNG0141683 |AK001094 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289588 |HSALNG0141703 |AK093735 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289631 |HSALNG0141746 |BC003519 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0290100 |HSALNG0142215 |NR_003573 |ANXA2P2 |NA |pathogenic process |gastric cancer |- |HSALNT0290119 |HSALNG0142234 |P2RX7-V3 |NA |NA |pathogenic process |uveal melanoma |- |HSALNT0290308 |HSALNG0142423 |TMSB4 |NA |ceRNA |pathogenic process |osteoarthritis |- |HSALNT0288928 |HSALNG0090163 |DDX11-AS1 |CONCR |NA |pathogenic process |NA |- |HSALNT0290052 |HSALNG0142167 |MELOE |NA |NA |pathogenic process |melanoma |- |HSALNT0290231 |HSALNG0142346 |RSU1P2 |RSU1P2 |ceRNA |pathogenic process |cervical cancer |- |HSALNT0290165 |HSALNG0142280 |RBMY2FP |RBMY2FP |NA |NA |hepatocellular cancer |- |HSALNT0290071 |HSALNG0142186 |n375709 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0289748 |HSALNG0141863 |DUXAP8 |DUXAP8 |NA |NA |gastric cancer |- |HSALNT0290030 |HSALNG0142145 |LOC729966 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290143 |HSALNG0142258 |POIR |NA |ceRNA |pathogenic process |periodontitis |- |HSALNT0067481 |HSALNG0031988 |MELTF-AS1 |MFI2-AS1,AC068302.3 |NA |pathogenic process |osteosarcoma |- |HSALNT0290053 |HSALNG0142168 |MFI2 |NA |NA |pathogenic process |osteosarcoma |- |HSALNT0289922 |HSALNG0142037 |linc-223 |NA |ceRNA |pathogenic process |acute myeloid leukemia |- |HSALNT0014603 |HSALNG0006859 |LINC01138 |LINC00875,FLJ39739 |NA |pathogenic process |prostate cancer |- |HSALNT0290262 |HSALNG0142377 |SUZ12P1 |SUZ12P1 |NA |pathogenic process |prostate cancer |- |HSALNT0290005 |HSALNG0142120 |LOC100505976 |NA |NA |pathogenic process |laryngeal squamous cell cancer |- |HSALNT0290392 |HSALNG0142507 |XLOC_l2_010636 |NA |NA |pathogenic process |laryngeal squamous cell cancer |- |HSALNT0090295 |HSALNG0043014 |RASGRF2-AS1 |CTC-459I6.1 |NA |pathogenic process |sepsis-induced endothelial dysfunction |- |HSALNT0289852 |HSALNG0141967 |GPC3-AS1 |NA |transcriptional regulation |pathogenic process |hepatocellular cancer |- |HSALNT0189472 |HSALNG0091321 |HOXC-AS1 |NA |transcriptional regulation |pathogenic process |atherosclerosis |- |HSALNT0289157 |HSALNG0057557 |LUARIS |lncRNA#32 |transcriptional regulation |NA |NA |- |HSALNT0289371 |HSALNG0044828 |MIR3936HG |LOC553103,SLC22A5-AS1 |NA |pathogenic process |gastric cancer;nasopharyngeal cancer |- |HSALNT0290148 |HSALNG0142263 |Ppp1r1b |NA |transcriptional regulation |pathogenic process |congenital heart defect |- |HSALNT0289038 |HSALNG0099182 |LINC00460 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290194 |HSALNG0142309 |RP1-13P20.6 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0290364 |HSALNG0142479 |Unigene56159 |NA |ceRNA |pathogenic process |hepatocellular cancer |- |HSALNT0290355 |HSALNG0142470 |uc009yby.1 |NA |NA |pathogenic process |renal cell cancer |- |HSALNT0289406 |HSALNG0048011 |TFAP2A-AS2 |HIPSTR |NA |developmental process |NA |- |HSALNT0289704 |HSALNG0141819 |Chaer |NA |transcriptional regulation |pathogenic process |cardiac hypertrophy |- |HSALNT0289865 |HSALNG0141980 |HIF-2α |NA |NA |pathogenic process |NA |- |HSALNT0211378 |HSALNG0101489 |LINC00520 |C14orf34 |NA |pathogenic process |breast cancer |- |HSALNT0087374 |HSALNG0041561 |MRPS30-DT |BRCAT54 |NA |pathogenic process |breast cancer |- |HSALNT0289388 |HSALNG0092662 |PPP1R12A-AS1 |R12A-AS1 |translational control |NA |NA |- |HSALNT0289013 |HSALNG0088600 |ITFG2-AS1 |NA |NA |NA |NA |- |HSALNT0290088 |HSALNG0142203 |NONHSAT041499 |NA |NA |pathogenic process |schizophrenia |- |HSALNT0290091 |HSALNG0142206 |NONHSAT089447 |NA |NA |pathogenic process |schizophrenia |- |HSALNT0289970 |HSALNG0142085 |lnc-NKX2-3-1 |NA |transcriptional regulation |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0289989 |HSALNG0142104 |lnc-RTN4R-1 |NA |transcriptional regulation |pathogenic process |acute lymphoblastic leukemia |- |HSALNT0289821 |HSALNG0141936 |ERL |NA |NA |pathogenic process |Marek's disease |- |HSALNT0192459 |HSALNG0092867 |LINC02258 |RP11-248E9.5 |NA |pathogenic process |pneumonia |- |HSALNT0241871 |HSALNG0117085 |SKAP1-AS1 |RP11-456D7.1 |NA |pathogenic process |pneumonia |- |HSALNT0289439 |HSALNG0049760 |DINOL |DINO |NA |NA |NA |- |HSALNT0288901 |HSALNG0000547 |CAMTA1-DT |lncCAMTA1 |transcriptional regulation |pathogenic process |liver cancer |- |HSALNT0290328 |HSALNG0142443 |uc.345 |NA |transcriptional regulation |pathogenic process |pancreatic cancer |- |HSALNT0290060 |HSALNG0142175 |MSNP1AS |NA |translational control |pathogenic process |autism spectrum disorder |- |HSALNT0289376 |HSALNG0004596 |NEXN-AS1 |C1orf118,FLJ90637 |NA |pathogenic process |lung cancer |- |HSALNT0183194 |HSALNG0088083 |LINC02098 |RP11-702B10.1 |NA |pathogenic process |esophageal cancer |- |HSALNT0198055 |HSALNG0095473 |PSPC1-AS2 |RP11-523H24.3 |NA |pathogenic process |esophageal cancer |- |HSALNT0289155 |HSALNG0114857 |LRRC75A-AS1 |C17orf45,NCRNA00188,C17orf76-AS1,FAM211A-AS1,MGC40157 |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0289220 |HSALNG0077999 |PRKG1-AS1 |RP11-573I11.2 |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0289262 |HSALNG0076970 |SVIL-AS1 |RP11-534G20.3 |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0289281 |HSALNG0108169 |VPS33B-DT |NA |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0289804 |HSALNG0141919 |ENST00000438399 |NA |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0290228 |HSALNG0142343 |RPKG1-AS1 |NA |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0290350 |HSALNG0142465 |uc004afb.1 |NA |NA |pathogenic process |rheumatoid arthritis |- |HSALNT0289398 |HSALNG0135015 |SLC5A4-AS1 |RP1-90G24.10 |NA |pathogenic process |gastric cancer |- |HSALNT0289411 |HSALNG0063964 |TNFRSF10A-AS1 |RP11-1149O23.2 |NA |pathogenic process |gastric cancer |- |HSALNT0289727 |HSALNG0141842 |CTD-2616J11.14 |AC008750.7 |NA |pathogenic process |gastric cancer |- |HSALNT0290182 |HSALNG0142297 |RP11-150O12.3 |AC124067.4 |NA |pathogenic process |gastric cancer |- |HSALNT0289730 |HSALNG0141845 |CXCL1P1 |CXCL1P1 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289803 |HSALNG0141918 |ENST00000438347 |CCND3P1 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289897 |HSALNG0142012 |LINC00601 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289503 |HSALNG0141614 |KIAA0087 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0289827 |HSALNG0141942 |FAM212B-AS1 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0290010 |HSALNG0142125 |LOC102723552 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0290181 |HSALNG0142296 |RP11-140I24 |LINC01568 |NA |pathogenic process |endometrial cancer |- |HSALNT0290201 |HSALNG0142316 |RP11-501O2 |LINC02046 |NA |pathogenic process |endometrial cancer |- |HSALNT0290206 |HSALNG0142321 |RP11-600K151 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0290084 |HSALNG0142199 |NONHSAG051968 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290090 |HSALNG0142205 |NONHSAT076747 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0290094 |HSALNG0142209 |NONHSAT122730 |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0138768 |HSALNG0066240 |MIR2052HG |NA |transcriptional regulation |pathogenic process |breast cancer |- |HSALNT0289096 |HSALNG0096884 |LINC01198 |NA |NA |pathogenic process |glioma |- |HSALNT0289274 |HSALNG0096821 |TPT1-AS1 |NA |NA |pathogenic process |glioma |- |HSALNT0289924 |HSALNG0142039 |linc-cdh4-2 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0144641 |HSALNG0068878 |LINC02055 |RP1130-1 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289737 |HSALNG0141852 |DBCCR1 |NA |transcriptional regulation |pathogenic process |bladder cancer |- |HSALNT0289547 |HSALNG0141662 |AC012065.7 |NA |NA |pathogenic process |chronic lymphocytic leukemia |- |HSALNT0289229 |HSALNG0116565 |RAMP2-AS1 |NA |NA |pathogenic process |glioblastoma |- |HSALNT0289591 |HSALNG0141706 |AK098081 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289644 |HSALNG0141759 |BC037331 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289646 |HSALNG0141761 |BC040303 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289717 |HSALNG0141832 |CR749831 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289250 |HSALNG0040073 |SNHG18 |NA |NA |pathogenic process |glioma |- |HSALNT0106140 |HSALNG0050030 |FOXP4-AS1 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0026202 |HSALNG0012584 |RNASEH1-AS1 |LOC100506054 |NA |pathogenic process |colorectal cancer |- |HSALNT0288993 |HSALNG0088026 |GSEC |ST3GAL4-AS1,DCPS-AS1,FLJ39051 |NA |pathogenic process |colorectal cancer |- |HSALNT0060264 |HSALNG0028799 |DNAJB8-AS1 |NA |NA |NA |NA |- |HSALNT0248137 |HSALNG0120059 |CHMP1B-AS1 |NA |NA |NA |NA |- |HSALNT0021970 |HSALNG0010602 |TGFB2-AS1 |NR_046268 |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0078323 |HSALNG0037356 |SLC7A11-AS1 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0134663 |HSALNG0064248 |INTS9-AS1 |ENST00000520055 |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0231572 |HSALNG0111641 |MMP2-AS1 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0267869 |HSALNG0130456 |SLC12A5-AS1 |RP11-465L10.10 |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0288921 |HSALNG0002415 |CSMD2-AS1 |ENST00000434181 |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0288997 |HSALNG0052934 |HDAC2-AS2 |ENST00000421891 |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289012 |HSALNG0105327 |INO80-AS1 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289140 |HSALNG0075065 |LINC02247 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289161 |HSALNG0059170 |MAGI2-AS3 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289188 |HSALNG0062699 |MNX1-AS2 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289245 |HSALNG0140277 |SMIM10L2B-AS1 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289407 |HSALNG0102543 |TGFB3-AS1 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289457 |HSALNG0073036 |HSD17B3-AS1 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289919 |HSALNG0142034 |LINC02246 |NA |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289288 |HSALNG0100050 |ZNF710-AS1 |ENST00000558334 |NA |pathogenic process |early-onset preeclampsia |- |HSALNT0289266 |HSALNG0007188 |TDRKH-AS1 |RP11-98D18.9 |NA |pathogenic process |NA |- |HSALNT0289128 |HSALNG0057684 |LINC01952 |AC004854.4 |NA |pathogenic process |recurrent miscarriage |- |HSALNT0290075 |HSALNG0142190 |NCF4-AS1 |CTA-833B7.2 |NA |pathogenic process |recurrent miscarriage |- |HSALNT0289360 |HSALNG0029603 |LNCSRLR |lncRNA-SRLR |transcriptional regulation |pathogenic process |renal cell cancer |- |HSALNT0288918 |HSALNG0021529 |CFLAR-AS1 |ALS2CR10 |NA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0289710 |HSALNG0141825 |COL1A2-AS1 |TCONS_00013888,lncRNA8975-1 |transcriptional regulation |pathogenic process |hypertrophic scar |- |HSALNT0075075 |HSALNG0035847 |LNCPRESS2 |lncPRESS2 |transcriptional regulation |NA |NA |- |HSALNT0011289 |HSALNG0005432 |LINC01930 |EU358092 |NA |pathogenic process |schizophrenia |- |HSALNT0097120 |HSALNG0046325 |HMMR-AS1 |NA |NA |pathogenic process |basal-like breast cancer |- |HSALNT0184498 |HSALNG0088703 |CCND2-AS1 |CCND2-AS2 |NA |pathogenic process |glioma |- |HSALNT0289045 |HSALNG0030884 |LINC00578 |NA |NA |pathogenic process |major depression disorder |- |HSALNT0288884 |HSALNG0026576 |ADAMTS9-AS1 |NA |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0080041 |HSALNG0038152 |FAM198B-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0103007 |HSALNG0048820 |LINC00240 |C6orf41,NCRNA00240,bA373D17.1 |ceRNA |pathogenic process |esophageal squamous cell cancer |- |HSALNT0289071 |HSALNG0122453 |LINC00909 |NA |NA |NA |NA |- |HSALNT0289509 |HSALNG0141620 |LINC00680 |NA |NA |NA |NA |- |HSALNT0129070 |HSALNG0061394 |LINC00513 |AC016831.7 |NA |NA |NA |- |HSALNT0289129 |HSALNG0115960 |LINC02001 |RP11-1094M14.11 |NA |NA |NA |- |HSALNT0289215 |HSALNG0092950 |POC1B-AS1 |RP11-734K2.4 |NA |NA |NA |- |HSALNT0289241 |HSALNG0060049 |SLC12A9-AS1 |RP11-126L15.4 |NA |NA |NA |- |HSALNT0289275 |HSALNG0050617 |TRAM2-AS1 |NA |NA |NA |NA |- |HSALNT0002243 |HSALNG0001176 |LINC01772 |ENSG00000226029 |ceRNA |pathogenic process |oesophageal cancer |- |HSALNT0288941 |HSALNG0009693 |ELF3-AS1 |ENST00000415582 |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289134 |HSALNG0025450 |LINC02158 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289350 |HSALNG0133329 |LINC01671 |BC041455 |NA |pathogenic process |breast cancer |- |HSALNT0289124 |HSALNG0132343 |LINC01684 |lnc-JAM2-6 |NA |pathogenic process |nonalcoholic fatty liver disease |- |HSALNT0289036 |HSALNG0096092 |LINC00365 |NA |NA |pathogenic process |esophageal cancer |- |HSALNT0289111 |HSALNG0043625 |LINC01554 |C5orf27,FLJ38821,FIS |NA |pathogenic process |esophageal cancer |- |HSALNT0289132 |HSALNG0136701 |LINC02154 |GS1-600G8.5 |NA |pathogenic process |esophageal cancer |- |HSALNT0137721 |HSALNG0065704 |LINC02155 |RP11-705O24.1 |NA |pathogenic process |esophageal cancer |- |HSALNT0225363 |HSALNG0108398 |LINC02157 |RP11-327J17.1 |NA |pathogenic process |esophageal cancer |- |HSALNT0289133 |HSALNG0090758 |LINC02156 |RP1-90J4.1 |NA |pathogenic process |esophageal cancer |- |HSALNT0133924 |HSALNG0063832 |LINC02153 |NA |NA |pathogenic process |major depression disorder |- |HSALNT0181656 |HSALNG0087394 |LINC02151 |TCONS_00019174 |NA |pathogenic process |major depression disorder |- |HSALNT0227367 |HSALNG0109385 |LINC02152 |NA |NA |pathogenic process |major depression disorder |- |HSALNT0029246 |HSALNG0013844 |BRE-AS1 |NA |NA |NA |NA |- |HSALNT0289251 |HSALNG0056623 |SNHG26 |AC005682.5 |NA |pathogenic process |bladder urothelial cancer |- |HSALNT0252719 |HSALNG0122284 |LIVAR |lnc18q22.2 |NA |pathogenic process |nonalcoholic steatohepatiti |- |HSALNT0289074 |HSALNG0031832 |LINC00969 |ENST00000453324 |NA |pathogenic process |lung squamous cell cancer |- |HSALNT0289138 |HSALNG0140259 |LINC02243 |ENST00000441841 |NA |pathogenic process |lung squamous cell cancer |- |HSALNT0289399 |HSALNG0039449 |SLC9A3-AS1 |UC011CLY.2 |NA |pathogenic process |lung squamous cell cancer |- |HSALNT0288934 |HSALNG0126602 |DM1-AS |NA |NA |pathogenic process |myotonic dystrophy type 1 |- |HSALNT0009014 |HSALNG0004475 |LINC02238 |RP4-788P17.1 |NA |pathogenic process |B cell lymphoma |- |HSALNT0289163 |HSALNG0043374 |MEF2C-AS2 |CTC-467M3.1 |NA |pathogenic process |diffuse large B-cell lymphoma |- |HSALNT0289181 |HSALNG0003824 |MIR4422HG |RP11-101C11.1 |NA |pathogenic process |diffuse large B-cell lymphoma |- |HSALNT0289403 |HSALNG0082800 |SPON1-AS1 |RP11-21,L19.1 |NA |pathogenic process |diffuse large B-cell lymphoma |- |HSALNT0289461 |HSALNG0083610 |CD44-AS1 |RP1-68D18.4 |NA |pathogenic process |diffuse large B-cell lymphoma |- |HSALNT0262277 |HSALNG0127560 |LILRB1-AS1 |AC009892.10 |NA |pathogenic process |NA |- |HSALNT0289546 |HSALNG0141661 |AC009892.10 |LILRB1-AS1 |NA |NA |B cell lymphoma |- |HSALNT0282241 |HSALNG0137635 |LINC01186 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289168 |HSALNG0131657 |MHENCR |NA |ceRNA |pathogenic process |melanoma |- |HSALNT0072994 |HSALNG0034801 |LINC02232 |RP11-707A18.1 |NA |pathogenic process |NA |- |HSALNT0080161 |HSALNG0038220 |LINC02233 |RP11-6C14.1 |NA |pathogenic process |NA |- |HSALNT0084027 |HSALNG0039930 |LINC02236 |RP11-332J15.1 |NA |pathogenic process |NA |- |HSALNT0091870 |HSALNG0043678 |LINC02234 |RP11-455B3.1 |NA |pathogenic process |NA |- |HSALNT0139521 |HSALNG0066607 |LINC02235 |RP11-354A14.1 |NA |pathogenic process |NA |- |HSALNT0142040 |HSALNG0067779 |LINC02237 |RP11-1101K5.1 |NA |pathogenic process |NA |- |HSALNT0289135 |HSALNG0111295 |LINC02179 |RP11-189E14.4 |NA |pathogenic process |NA |- |HSALNT0289351 |HSALNG0132340 |LINC01689 |AP000469.2 |NA |pathogenic process |NA |- |HSALNT0289137 |HSALNG0091963 |LINC02231 |RP11-766N7.4 |NA |pathogenic process |Esophageal squamous cell cancer |- |HSALNT0220239 |HSALNG0105903 |MIR4713HG |RP11-108K3.1 |NA |pathogenic process |colorectal cancer |- |HSALNT0288967 |HSALNG0037858 |FAM160A1-DT |RP11-610P16.1 |NA |pathogenic process |colorectal cancer |- |HSALNT0289239 |HSALNG0021423 |SATB2-AS1 |NA |translational control |pathogenic process |osteosarcoma |- |HSALNT0289512 |HSALNG0141623 |LINC01826 |lnc-MKI67IP-3 |ceRNA |pathogenic process |atherosclerosis |- |HSALNT0289024 |HSALNG0104253 |LINC00226 |C14orf97,NCRNA00226 |NA |pathogenic process |pancreatic ductaladenocarcinoma |- |HSALNT0082192 |HSALNG0039173 |F11-AS1 |NA |NA |NA |NA |- |HSALNT0219108 |HSALNG0105295 |SPINT1-AS1 |RP11-532F12.5 |NA |pathogenic process |melanoma |- |HSALNT0289177 |HSALNG0088950 |MIR200CHG |U47924.27 |NA |pathogenic process |melanoma |- |HSALNT0289328 |HSALNG0031153 |LINC00888 |NA |NA |pathogenic process |melanoma |- |HSALNT0289309 |HSALNG0116205 |LINC00672 |NA |transcriptional regulation |pathogenic process |endometrial cancer |- |HSALNT0289198 |HSALNG0085691 |P4HA3-AS1 |NA |NA |pathogenic process |parkinson's disease |- |HSALNT0197312 |HSALNG0095075 |TMEM132D-AS1 |LOC283352 |NA |pathogenic process |human dermal fibroblasts |- |HSALNT0289472 |HSALNG0113128 |ATP2C2-AS1 |RP11-517C16.2-001 |NA |NA |NA |- |HSALNT0233849 |HSALNG0112863 |WWOX-AS1 |RP11-190D6.2 |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0128829 |HSALNG0061246 |FLNC-AS1 |NA |NA |pathogenic process |cervical squamous cancer |- |HSALNT0289889 |HSALNG0142004 |LIF-AS1 |Lnc-LIF-AS |NA |pathogenic process |cervical squamous cancer |- |HSALNT0011283 |HSALNG0005428 |DPYD-AS2 |NA |NA |pathogenic process |cervical squamous cancer |- |HSALNT0289836 |HSALNG0141951 |FLICR |NA |transcriptional regulation |pathogenic process |autoimmune diabete |- |HSALNT0289356 |HSALNG0090563 |LINC02402 |ENST00000550337.1 |NA |pathogenic process |diabetes |- |HSALNT0137118 |HSALNG0065453 |CERNA3 |CTA |ceRNA |pathogenic process |osteosarcoma |- |HSALNT0090838 |HSALNG0043312 |LINC02488 |CTD-2316B1 |NA |pathogenic process |NA |- |HSALNT0174947 |HSALNG0083979 |LINC02489 |CTD-2589M5 |NA |pathogenic process |NA |- |HSALNT0220441 |HSALNG0105991 |LINC02490 |RP11-209E8 |NA |pathogenic process |NA |- |HSALNT0289260 |HSALNG0045650 |STK32A-AS1 |CTC-255N20 |NA |pathogenic process |NA |- |HSALNT0289143 |HSALNG0055190 |LINC02487 |NA |NA |pathogenic process |squamous cell cancer |- |HSALNT0095585 |HSALNG0045503 |SPRY4-AS1 |THCAT68 |NA |pathogenic process |bladder cancer |- |HSALNT0288927 |HSALNG0090908 |DDN-AS1 |CAT1507 |NA |pathogenic process |bladder cancer |- |HSALNT0012862 |HSALNG0006150 |SLC16A1-AS1 |NA |NA |pathogenic process |acute myocardial infarction |- |HSALNT0289412 |HSALNG0000276 |TNFRSF14-AS1 |ENST00000416860.2 |NA |pathogenic process |acute myocardial infarction |- |HSALNT0259139 |HSALNG0125745 |LINC00665 |NA |NA |NA |NA |- |HSALNT0040268 |HSALNG0019085 |DARS-AS1 |NA |NA |pathogenic process |renal disease |- |HSALNT0288913 |HSALNG0125425 |CEBPA-AS1 |CEBPA-DT |NA |pathogenic process |gastric cancer |- |HSALNT0289011 |HSALNG0057479 |INHBA-AS1 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0288988 |HSALNG0067472 |GASAL1 |GASL1 |NA |pathogenic process |liver cancer |- |HSALNT0289127 |HSALNG0021881 |LINC01857 |AC079767.4 |NA |pathogenic process |tuberculosis |- |HSALNT0289091 |HSALNG0004949 |LINC01140 |FLJ41676 |NA |NA |NA |- |HSALNT0281957 |HSALNG0137521 |PINCR |NA |transcriptional regulation |pathogenic process |colorectal cancer |- |HSALNT0289344 |HSALNG0139543 |LINC00890 |NA |NA |pathogenic process |leiomyoma |- |HSALNT0019828 |HSALNG0009573 |LINC00862 |C1orf98,SMIM16 |NA |pathogenic process |cystic fibrosis |- |HSALNT0073790 |HSALNG0035237 |LINC02562 |RP11-44F21.5 |NA |pathogenic process |cystic fibrosis |- |HSALNT0263101 |HSALNG0127961 |LINC02560 |CTD-2619J13.13 |NA |pathogenic process |cystic fibrosis |- |HSALNT0289144 |HSALNG0088252 |LINC02551 |RP11-890B15.2 |NA |pathogenic process |cystic fibrosis |- |HSALNT0289458 |HSALNG0078773 |DDIT4-AS1 |RP11-442H21.2 |NA |pathogenic process |cystic Fibrosis |- |HSALNT0288992 |HSALNG0089423 |GPRC5D-AS1 |RP11-392P7.6 |NA |pathogenic process |colorectal cancer |- |HSALNT0289386 |HSALNG0015768 |PCBP1-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0289405 |HSALNG0044141 |STARD4-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0201547 |HSALNG0097004 |LINC00462 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0207103 |HSALNG0099453 |SOX1-OT |LINC00403 |NA |pathogenic process |NA |- |HSALNT0002131 |HSALNG0001107 |SLC25A34-AS1 |RP11-169K16.4 |NA |NA |NA |- |HSALNT0289218 |HSALNG0075163 |PPP1R26-AS1 |NA |NA |pathogenic process |breast cancer |- |HSALNT0289047 |HSALNG0064310 |LINC00589 |C8orf75,TSLNC8 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289516 |HSALNG0141627 |TPM1-AS |TPM1-AS1 |splicing regulation |pathogenic process |esophageal cancer |- |HSALNT0289314 |HSALNG0141631 |LINC01101 |FLJ14816 |NA |pathogenic process |HPV-induced cervical neoplasia |- |HSALNT0289147 |HSALNG0018748 |LINC02572 |AC079776.2 |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0096804 |HSALNG0046188 |LINC02202 |NA |NA |NA |NA |- |HSALNT0289076 |HSALNG0027511 |LINC00973 |CTD-2021J15.2 |NA |pathogenic process |colorectal cancer |- |HSALNT0288625 |HSALNG0141401 |TTTY10 |NCRNA00133 |NA |pathogenic process |colorectal cancer |- |HSALNT0289323 |HSALNG0133418 |LINC00319 |C21orf125,NCRNA00319,PRED49,FLJ38036 |ceRNA |pathogenic process |lung cancer |- |HSALNT0015533 |HSALNG0007394 |IL6R-AS1 |RP11-350G8.5 |NA |NA |NA |- |HSALNT0090330 |HSALNG0043020 |CKMT2-AS1 |NA |NA |NA |NA |- |HSALNT0012995 |HSALNG0006203 |HIPK1-AS1 |NA |NA |NA |NA |- |HSALNT0289216 |HSALNG0050214 |POLH-AS1 |RP3-337H4.8 |NA |NA |NA |- |HSALNT0289276 |HSALNG0053237 |TRDN-AS1 |HRAT13 |NA |NA |NA |- |HSALNT0289159 |HSALNG0069213 |LY6E-DT |LOC100133669 |NA |pathogenic process |ovarian cancer |- |HSALNT0289434 |HSALNG0040409 |BASP1-AS1 |LOC285696 |NA |pathogenic process |NA |- |HSALNT0288991 |HSALNG0069691 |GLIS3-AS1 |C9orf70,MGC16153 |NA |NA |NA |- |HSALNT0288896 |HSALNG0070213 |BNC2-AS1 |RP11-62F24.2 |NA |pathogenic process |gastric cancer |- |HSALNT0289292 |HSALNG0078947 |ZNF503-AS1 |NA |NA |pathogenic process |age-related macular degeneration |- |HSALNT0159506 |HSALNG0076434 |VIM-AS1 |NA |NA |pathogenic process |endometrial cancer |- |HSALNT0288882 |HSALNG0011058 |ACBD3-AS1 |RP11-275I14.4 |NA |pathogenic process |endometrial cancer |- |HSALNT0289156 |HSALNG0005074 |LRRC8C-DT |FLJ27354 |NA |pathogenic process |endometrial cancer |- |HSALNT0289447 |HSALNG0058889 |ELN-AS1 |CTB-51J22.1 |NA |pathogenic process |endometrial cancer |- |HSALNT0076712 |HSALNG0036645 |LINC02264 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0093666 |HSALNG0044495 |LINC02201 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0271685 |HSALNG0132198 |LINC02573 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0289125 |HSALNG0015785 |LINC01816 |LOC100133985 |NA |pathogenic process |gastric cancer |- |HSALNT0289355 |HSALNG0091335 |LINC02381 |LOC400043 |NA |pathogenic process |gastric cancer |- |HSALNT0289366 |HSALNG0029874 |MBNL1-AS1 |LOC401093 |NA |pathogenic process |gastric cancer |- |HSALNT0289513 |HSALNG0141624 |MIR4697HG |LINC00947,LOC283174 |NA |pathogenic process |gastric cancer |- |HSALNT0289073 |HSALNG0065480 |LINC00968 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0114453 |HSALNG0053963 |NMBR-AS1 |RP11-137J7.2 |NA |pathogenic process |non-melanoma skin cancer |- |HSALNT0289300 |HSALNG0077499 |LINC01518 |NA |NA |pathogenic process |non-melanoma skin cancer |- |HSALNT0003783 |HSALNG0002009 |LINC02574 |RP11-288L9.1 |transcriptional regulation |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0032721 |HSALNG0015486 |LINC02579 |AC007365.1 |NA |pathogenic process |NA |- |HSALNT0030828 |HSALNG0014519 |LINC02580 |AC093609.1 |NA |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0032808 |HSALNG0015519 |LINC02576 |NA |NA |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0127022 |HSALNG0060386 |LINC02577 |NA |NA |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0154722 |HSALNG0074062 |LINC02578 |RP11-127L21.1 |NA |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0288962 |HSALNG0084388 |FAM111A-DT |NA |NA |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0289148 |HSALNG0133545 |LINC02575 |AP001065.15 |transcriptional regulation |pathogenic process |UVB-irradiated KC & non-melanoma skin cancer |- |HSALNT0025249 |HSALNG0012143 |KIF26B-AS1 |RP11-62I21.1 |NA |NA |NA |- |HSALNT0177212 |HSALNG0085146 |RPS6KB2-AS1 |AP003419.16 |NA |pathogenic process |aging‑associated idiopathic pulmonary fibrosis |- |HSALNT0289072 |HSALNG0090150 |LINC00941 |lncRNA-MUF |ceRNA |pathogenic process |hepatocellular cancer |- |HSALNT0289338 |HSALNG0075045 |LINC00094 |FLJ35348,bA374P20.3 |NA |pathogenic process |lung squamous cell cancer |- |HSALNT0114192 |HSALNG0053894 |FILNC1 |NA |translational control |pathogenic process |renal tumor |- |HSALNT0289199 |HSALNG0128600 |PARAL1 |NA |ceRNA |pathogenic process |obesity |- |HSALNT0244832 |HSALNG0118528 |SOX9-AS1 |FLJ37644 |transcriptional regulation |NA |NA |- |HSALNT0289236 |HSALNG0118528 |ROCR |LINC02095 |transcriptional regulation |NA |NA |- |HSALNT0056667 |HSALNG0027060 |LINC02027 |LOC728290 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289424 |HSALNG0141124 |TTTY22 |NCRNA00147 |NA |NA |NA |- |HSALNT0289069 |HSALNG0030090 |LINC00880 |NA |NA |NA |NA |- |HSALNT0252974 |HSALNG0122396 |LINC02582 |CTD-2354A18.1 |NA |pathogenic process |colorectal cancer |- |HSALNT0289035 |HSALNG0097712 |LINC00364 |LncRNA00364 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0060981 |HSALNG0029189 |NCK1-DT |NCK1-AS1,SLC35G2-AS1 |ceRNA |pathogenic process |cervical cancer |- |HSALNT0288890 |HSALNG0067505 |BAALC-AS1 |lncFZD6,FZD6-DT |transcriptional regulation |pathogenic process |liver cancer |- |HSALNT0046602 |HSALNG0021972 |CPS1-IT1 |CPS1-IT,CPS1IT,CPS1IT1,PRO0132 |NA |pathogenic process |hepatocellular cancer;lung cancer;intrahepatic cholangiocarcinoma |- |HSALNT0289445 |HSALNG0059740 |DLX6-AS1 |DLX6-A, DLX6A, Evf-2,NCRNA00212,NCRNA00212,FLJ34048 |transcriptional regulation |pathogenic process |split hand/split foot malformation disorder;lung adenocarcinoma |- |HSALNT0289891 |HSALNG0142006 |LINC00114 |NA |NA |NA |NA |- |HSALNT0289415 |HSALNG0138601 |TSIX |LINC00013,NCRNA00013,XIST-A, XIST-AS1,XISTAS |transcriptional regulation |pathogenic process |systemic sclerosis |- |HSALNT0217334 |HSALNG0104503 |MKRN3-AS1 |ZNF127A, MKRN3A, MKRN3-A,FNZ127,NCRNA00009,ZNF127-AS |NA |pathogenic process |Prader-Willi syndrome |- |HSALNT0290256 |HSALNG0142371 |SRA |lnc-SRA1-1:1,SRA1,ENSG00000213523 |transcriptional regulation |pathogenic process |nonalcoholic fatty liver disease;polycystic ovary syndrome;ovarian cancer;dilated cardiomyopathy;cardiomyopathy;breast cancer;laryngeal squamous cell cancer;uterus cancer |- |HSALNT0289442 |HSALNG0049271 |HCP5 |6S2650E,D6S2650E,P5-1 |NA |pathogenic process |AIDS |- |HSALNT0289284 |HSALNG0083476 |WT1-AS |WIT1,WIT-1,WT1A, WT1-AS1 |transcriptional regulation |pathogenic process |gastric cancer;primary myelofibrosis;hepatocellular cancer;Wilms' tumor;acute myeloid leukemia |- |HSALNT0289421 |HSALNG0082235 |KCNQ1OT1 |KCNQ1-AS2,KCNQ10T1,Kncq1,KvDMR1,KvLQT1-A, LIT1,NCRNA00012 |transcriptional regulation |pathogenic process |prostate cancer;colorectal cancer;hepatocelluar cancer;acute myocardial infarction;kidney cancer;Beckwith-Wiedemann syndrome;breast cancer |- |HSALNT0263784 |HSALNG0128372 |PCNA-AS1 |PCNAA, PCNA-AS |transcriptional regulation |pathogenic process |gastric cancer;hepatocelluar cancer |- |HSALNT0289524 |HSALNG0049107 |HCG9 |PERB11,HCGIX,HCGIX4,HCGIX-4 |NA |NA |NA |- |HSALNT0289264 |HSALNG0103448 |TCL6 |TCL6e1,TNG2,TNG1 |NA |pathogenic process;developmental process |renal cell cancer;leukemia |- |HSALNT0289203 |HSALNG0072040 |PCA3 |DD3,NCRNA00019,PCAT3 |transcriptional regulation;ceRNA |pathogenic process |prostate cancer |- |HSALNT0289462 |HSALNG0082178 |H19 |ASM,ASM1,BW, D11S813E,LINC00008,NCRNA00008,WT2 |transcriptional regulation;ceRNA |developmental process;pathogenic process |prostate cancer;glioma;cancer;breast cancer;ovarian cancer;Marek's disease;gestational trophoblastic diseases;glioblastoma;non-small cell lung cancer;hyperhomocysteinemia;congenital heart defect;congenital hyperinsulinism;pancreatic cancer;Beckwith-Wiedemann syndrome;endometriosis;trophoblastic tumor;adrenocortical cancer;coronary artery disease;Wiedemann-Beckwith syndrome;bladder cancer;melanoma;myeloproliferative polycythaemia vera;hepatocelluar cancer;meningioma;breast adenocarcinoma;neuroblastoma;embryonal cancer;osteosarcoma;esophageal cancer;kidney cancer;malignant digestive cancer;chronic myeloid leukemia;mullerian aplasia;malignant hematopoiesis;gastric cardia adenocarcinoma;cervical cancer;gallbladder cancer;pheochromocytoma;germ cell tumor;colorectal cancer;hydatidiform mole;Pancreatic ductal adenocarcinoma;pre-eclampsia;atherosclerosis;esophageal squamous cell cancer;calcific aortic valve disease;gastric cancer;osteoarthritis;choriocarcinoma;chronic myeloproliferative disorders;neural tube defects;skin cancer;ulcerative colitis;type 2 diabetes;thyroid cancer;pneumoconiosis;infertility;liver cancer;heart failure;medulloblastoma;laryngeal squamous cell cancer;Silver-Russell syndrome;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;growth restriction;Prader-Willi syndrome;diabetic cardiomyopathy;obesity;lung cancer;Parkinson's disease;renal cell cancer;Wilms' tumor |- |HSALNT0288932 |HSALNG0097105 |DLEU1 |BCM, BCMS1,DLB1,LEU1,LEU2,LINC00021,NCRNA00021,XTP6 |transcriptional regulation;ceRNA |pathogenic process |lymphocytic leukemia;B-cell chronic lymphocytic leukemia;myeloma;multiple myeloma;hematopoietic and solid tumors;chronic lymphocytic leukemia;inherited bone marrow failure disorder;lymphoma;breast cancer;head and neck squamous cell cancer |- |HSALNT0289493 |HSALNG0141604 |DBH-AS1 |NCRNA00118,BPR |NA |pathogenic process |hepatocellular cancer |- |HSALNT0088415 |HSALNG0042101 |PART1 |DKFZP586D0823,NCRNA00206 |NA |pathogenic process |prostate cancer;glioblastoma |- |HSALNT0289463 |HSALNG0082197 |IGF2-AS |IGF2A,PEG8,IGF2-AS1 |transcriptional regulation |pathogenic process |liver cancer;type 1 diabetes;prostate cancer;Wilms' tumor;hepatocelluar cancer |- |HSALNT0269786 |HSALNG0131285 |GNAS-AS1 |GNASA, GNAS-A,SANG,NESP-A, NESPA, GNAS1A, NCRNA00075 |transcriptional regulation |pathogenic process |non-small cell lung cancer;pseudohypoparathyroidism type Ib |- |HSALNT0289252 |HSALNG0051709 |SNHG5 |C6orf160,MGC16362,bA33E24.2,U50HG,NCRNA00044,LINC00044 |NA |pathogenic process |gastric cancer;lymphoma;melanoma |- |HSALNT0023827 |HSALNG0011462 |DISC2 |DISC1-AS1,DISC1O, NCRNA00015 |transcriptional regulation |pathogenic process |bipolar disorder;affective disorder;major depressive affective disorder;schizophrenia;autism spectrum disorder;depression |- |HSALNT0203415 |HSALNG0097806 |ATXN8OS |SCA8,KLHL1A,NCRNA00003 |transcriptional regulation |pathogenic process |spinocerebellar ataxia;spinocerebellar ataxia |- |HSALNT0290312 |HSALNG0142427 |TRAF3IP2-AS1 |C6UA, C6orf3,NCRNA00248,TRAF3IP2-AS2 |transcriptional regulation |pathogenic process |schizophrenia;cocaine abuse |- |HSALNT0289008 |HSALNG0054049 |HYMAI |NCRNA00020 |NA |pathogenic process |transient neonatal diabetes |- |HSALNT0288968 |HSALNG0071146 |FAM201A |C9orf122 |NA |pathogenic process |leukemia |- |HSALNT0288969 |HSALNG0093910 |FAM222A-AS1 |NA |NA |pathogenic process |NA |- |HSALNT0289484 |HSALNG0138575 |FAM226A |CXorf50,NCRNA00246,NCRNA00246A,LINC00246A,MGC34827 |NA |pathogenic process |NA |- |HSALNT0289497 |HSALNG0141608 |FAM215A |C17orf88,APR-2,LINC00530 |NA |pathogenic process |ovarian cancer;leukemia |- |HSALNT0289230 |HSALNG0025991 |RBM5-AS1 |LUST |transcriptional regulation |pathogenic process |tumor |- |HSALNT0002923 |HSALNG0001554 |LINC00339 |NCRNA00339,HSPC157 |NA |pathogenic process;developmental process |Pancreatic ductal adenocarcinoma |- |HSALNT0144027 |HSALNG0068615 |ASAP1-IT1 |ASAP1-IT,ASAP1IT,ASAP1IT1,DDEF1IT1,HSPC054,NCRNA00050 |NA |pathogenic process |ovarian cancer |- |HSALNT0289212 |HSALNG0021208 |PCGEM1 |NCRNA00071,LINC00071,PCAT9 |transcriptional regulation;ceRNA |pathogenic process |osteoarthritis;prostate cancer;glioma |- |HSALNT0289016 |HSALNG0082243 |KCNQ1DN |BWRT,HSA404617 |NA |pathogenic process |aging;Wilms' tumor |- |HSALNT0288933 |HSALNG0097101 |DLEU2 |DLB2,BCMSUN,RFP2O,LEU2,TRIM13O, NCRNA00022,LINC00022,MIR15AHG |transcriptional regulation |pathogenic process |lymphocytic leukemia;B-cell chronic lymphocytic leukemia;myeloma;multiple myeloma;chronic lymphocytic leukemia;non-small cell lung cancer |- |HSALNT0217624 |HSALNG0104558 |PWAR4 |PAR4,PAR-4 |NA |pathogenic process |Prader-Willi syndrome and Angelman syndrome |- |HSALNT0289165 |HSALNG0103778 |MEG8 |SNHG23,SNHG24,NCRNA00024,Irm,Rian,Bsr,LINC00024,AL132709.8,lnc-MGC |NA |pathogenic process |Prader-Willi syndrome and Angelman syndrome;temple syndrome |- |HSALNT0289482 |HSALNG0133856 |CECR7 |SAHL1 |NA |pathogenic process |hepatocellular cancer;cat eye syndrome |- |HSALNT0074223 |HSALNG0035451 |PCAT4 |GDEP,PCAN1,PCA4 |NA |pathogenic process |prostate cancer |- |HSALNT0061175 |HSALNG0029318 |PISRT1 |NCRNA00195 |transcriptional regulation |developmental process;pathogenic process |blepharophimosis syndrome |- |HSALNT0190912 |HSALNG0092137 |IFNG-AS1 |Tmevpg1,LincR-Ifng-3'A, NEST |transcriptional regulation |pathogenic process |Hashimoto's thyroiditis;primary immune thrombocytopenia;multiple sclerosis;Sjögren syndrome |- |HSALNT0038178 |HSALNG0018067 |FAM138B |F379 |NA |NA |NA |- |HSALNT0145703 |HSALNG0069515 |FAM138C |F379 |NA |NA |NA |- |HSALNT0288963 |HSALNG0000006 |FAM138A |F379 |NA |NA |NA |- |HSALNT0183947 |HSALNG0088434 |FAM138D |F379 |NA |NA |NA |- |HSALNT0226092 |HSALNG0108677 |FAM138E |F379 |NA |NA |NA |- |HSALNT0253925 |HSALNG0122829 |FAM138F |F379 |NA |NA |NA |- |HSALNT0289326 |HSALNG0141632 |LINC00312 |LOH3CR2A,NCRNA00312,NAG7,NAG-7,ERR10,ERR-10,LMCD1DN |transcriptional regulation |pathogenic process |nasopharyngeal cancer;bladder cancer;non-small cell lung cancer |- |HSALNT0288886 |HSALNG0054798 |AIRN |AIR,NCRNA00088,IGF2RA, IGF2R-AS1 |transcriptional regulation |pathogenic process |NA |- |HSALNT0254857 |HSALNG0123415 |MIR7-3HG |C19orf30,NCRNA00306,LINC00306,PGSF1,PGSF1a,PGSF1b,Huh7,uc002mbe.2 |NA |pathogenic process |liver cancer;hepatocelluar cancer |- |HSALNT0185751 |HSALNG0089375 |LOH12CR2 |LOH2CR12 |NA |pathogenic process |pre-B acute lymphoblastic leukaemia |- |HSALNT0289479 |HSALNG0133055 |DSCR8 |C21orf65,MTAG2,CT25.1a,CT25.1b,MMA-1a,MMA-1b |NA |pathogenic process |Down syndrome;melanoma |- |HSALNT0289030 |HSALNG0133422 |LINC00313 |C21orf84,NCRNA00313, |NA |pathogenic process |lung cancer |- |HSALNT0289029 |HSALNG0132830 |LINC00310 |C21orf82,NCRNA00310 |NA |pathogenic process |NA |- |HSALNT0272435 |HSALNG0132500 |LINC00161 |C21orf100,NCRNA00161 |ceRNA |pathogenic process |osteosarcoma |- |HSALNT0289184 |HSALNG0132027 |MIR99AHG |C21orf35,FLJ38295,C21orf34,LINC00478,MONC |NA |pathogenic process |myeloid leukemia |- |HSALNT0289005 |HSALNG0056865 |HOXA11-AS |HOXA11A,HOXA11-AS1,HOXA11, HOXA-AS5,NCRNA00076 |ceRNA |pathogenic process |uterine cervix cancer;ovarian cancer;glioma;cervical cancer;gastric cancer |- |HSALNT0193654 |HSALNG0093342 |RMST |NCRM, NCRNA00054,LINC00054 |transcriptional regulation |developmental process;pathogenic process |breast cancer;rhabdomyosarcoma |- |HSALNT0290079 |HSALNG0142194 |ncR-PAR |NCRUPAR,ENSG00000225407 |transcriptional regulation |developmental process;pathogenic process |gastric cancer;colorectal cancer |- |HSALNT0289167 |HSALNG0061370 |MESTIT1 |MEST-AS1,MEST-IT,MEST-IT1,NCRNA00040,PEG1-AS |NA |pathogenic process |Silver-Russell syndrome |- |HSALNT0273791 |HSALNG0133168 |DSCAM-AS1 |M41 |NA |pathogenic process |adolescent idiopathic scoliosis;breast cancer |- |HSALNT0289391 |HSALNG0104546 |PWARSN |PAR-SN,PARSN |NA |pathogenic process |NA |- |HSALNT0127791 |HSALNG0060774 |ST7-AS1 |ST7OT1,ST7AS1 |NA |pathogenic process |glioma;autism |- |HSALNT0206298 |HSALNG0099122 |DAOA-AS1 |DAOAA, DAOA-A,G30 |NA |pathogenic process |panic disorder;schizophrenia;bipolar disorder |- |HSALNT0167060 |HSALNG0080104 |OLMALINC |C10orf75,NCRNA00263,LINC00263,bA34D15.5,FLJ12974,HI-LNC80 |NA |pathogenic process |type 2 diabetes |- |HSALNT0026878 |HSALNG0012802 |LINC00299 |C2orf46,NCRNA00299,FLJ45673 |NA |pathogenic process;developmental process |intellectual and developmental disability;neurodevelopmental disabilities |- |HSALNT0289081 |HSALNG0039816 |LINC01020 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0101186 |HSALNG0048016 |LINC00518 |C6orf218,MGC40222 |NA |pathogenic process |NA |- |HSALNT0083960 |HSALNG0039909 |LINC01018 |SRHC |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289361 |HSALNG0031463 |LPP-AS2 |MYCLo-5,MYCLo-6 |NA |NA |NA |- |HSALNT0143233 |HSALNG0068292 |LINC00964 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289364 |HSALNG0094063 |MAPKAPK5-AS1 |C12orf47,FLJ39616 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0289053 |HSALNG0027872 |LINC00635 |NA |NA |pathogenic process |lung cancer |- |HSALNT0289327 |HSALNG0141633 |LINC00636 |NA |NA |pathogenic process |breast cancer |- |HSALNT0262657 |HSALNG0127758 |ZNF582-AS1 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289020 |HSALNG0000022 |LINC00115 |NCRNA00115,FLJ22639 |ceRNA |pathogenic process |lung adenocarcinoma |- |HSALNT0289254 |HSALNG0075291 |SNHG7 |MGC16037,NCRNA00061 |NA |pathogenic process |lung cancer |- |HSALNT0289162 |HSALNG0020412 |MAP3K20-AS1 |MLK7-AS1 |NA |pathogenic process |gastric cancer |- |HSALNT0145357 |HSALNG0069280 |RHPN1-AS1 |C8orf51,MGC3113 |NA |NA |NA |- |HSALNT0289343 |HSALNG0138602 |XIST |DXS399E,NCRNA00001,DXS1089,swd66,LINC00001 |transcriptional regulation;ceRNA |pathogenic process |non-small cell lung cancer;B-cell acute lymphoblastic leukemia;bladder cancer;testicular germ cell tumor;colorectal cancer;cancer;ovarian cancer;female cancers;renal collecting duct cancer;membranous nephropathy;Trisomy 21;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;Klinefelter's syndrome;glioblastoma;breast cancer;cystic fibrosis |- |HSALNT0289389 |HSALNG0128330 |PRNT |M8 |NA |pathogenic process |NA |- |HSALNT0288942 |HSALNG0080912 |EMX2OS |NCRNA00045,EMX2-AS1 |transcriptional regulation |pathogenic process |NA |- |HSALNT0200443 |HSALNG0096546 |LINC00598 |TTL |NA |pathogenic process |NA |- |HSALNT0289517 |HSALNG0141628 |TTTY17A |NCRNA00140 |NA |NA |NA |- |HSALNT0027901 |HSALNG0013206 |MYCNOS |NCYM,N-CYM,MYCN-AS1 |transcriptional regulation |pathogenic process |neuroblastoma |- |HSALNT0047175 |HSALNG0022192 |DIRC3 |FLJ14199 |NA |pathogenic process |familial renal cell cancer;breast cancer |- |HSALNT0289363 |HSALNG0084905 |MALAT1 |PRO1073,MALAT-1,NCRNA00047,HCN,NEAT2,LINC00047,mascRNA |splicing regulation;;translational control;transcriptional regulation;protein localization;ceRNA |pathogenic process |prostate cancer;glioma;cancer;breast cancer;ovarian cancer;amyotrophic lateral sclerosis;proliferative vitreoretinopathy;glioblastoma;endometrial stromal sarcoma;oral squamous cell cancer;acute myocardial infarction;hemangioma;pancreatic cancer;endometrioid endometrial cancer;melanoma;tongue squamous cell cancer;HIV;hepatocelluar cancer;bladder cancer;neuroblastoma;lung cancer;nasopharyngeal cancer;osteosarcoma;esophageal cancer;kidney cancer;hepatic steatosis;urothelial cancer;diabetes;triple-negative breast cancer;liver fibrosis;cervical cancer;uterus cancer;gallbladder cancer;decreased myogenesis;esophageal squamous cell cancer;fibrosarcoma;colorectal cancer;Pancreatic ductal adenocarcinoma;pre-eclampsia;retinal neurodegeneration;small cell lung cancer;multiple myeloma;gastric cancer;lung adenocarcinoma;uveal melanoma;epithelial ovarian cancer;TDP-43-associated pathological states;thyroid cancer;congenital microtia;liver cancer;renal clear cell cancer;laryngeal squamous cell cancer;pituitary adenoma;hepatocellular cancer;non-small cell lung cancer;pulmonary arterial hypertension;diabetic cardiomyopathy;vulvar squamous cell cancer;hyperglycaemia;papillary thyroid cancer;Parkinson's disease;renal cell cancer;lung cancer brain metastasis |- |HSALNT0289744 |HSALNG0141859 |DLG2-AS1 |DLG2A, DLG2-A,PSZA11q14,SZ-1 |NA |pathogenic process |schizophrenia;myotonic dystrophy type 1;heart failure |- |HSALNT0289164 |HSALNG0103778 |MEG3 |FP504,GTL2,LINC00023,NCRNA00023,PRO0518,PRO2160,onco-lncRNA-83,prebp1 |translational control;transcriptional regulation;ceRNA |pathogenic process |oral squamous cell cancer;phaeochromocytoma;prostate cancer;testicular germ cell tumor;glioma;cancer;osteosarcoma;non-functioning pituitary adenoma;heroin abuse;stroke;non-small cell lung cancer;thrombocytopenic purpura;acute myeloid leukemia;pancreatic cancer;bladder cancer;tongue squamous cell cancer;hepatocelluar cancer;meningioma;drug abuse;liver fibrosis;pancreatic neuroendocrine tumor;esophageal squamous cell cancer;myelodysplastic syndrome;retinoblastoma;chronic myeloid leukemia;type 1 diabetes;breast cancer;cervical cancer;kidney cancer;gallbladder cancer;cholestatic liver injury;colorectal cancer;neuroblastoma;multiple myeloma;gastric cancer;osteoarthritis;lung adenocarcinoma;endometrial cancer;Huntington disease;diabetes;type 2 diabetes;lung cancer;epithelial ovarian cancer;primary myelofibrosis;metabolic syndrome;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;vulvar squamous cell cancer;papillary thyroid cancer;renal cell cancer;Wilms' tumor |- |HSALNT0290298 |HSALNG0142413 |TERC |DKCA1,PFBMFT2,SCARNA19,TR,TRC3,hTR |NA |pathogenic process |prostate cancer;dyskeratosis congenita;lung squamous cell cancer |- |HSALNT0288907 |HSALNG0080948 |CASC2 |NA |ceRNA |pathogenic process |colorectal cancer;gastric cancer;endometrial cancer;lung cancer;renal cell cancer;glioma |- |HSALNT0205332 |HSALNG0098601 |MIR17HG |C13orf25,MIRHG1,FLJ14178,MIRH1,MIHG1,NCRNA00048,miR-17-92,LINC00048 |NA |pathogenic process |diffuse large B-cell lymphoma;syndromic developmental defect;cancer |- |HSALNT0288716 |HSALNG0141456 |TTTY6 |TTY6,TTTY6A,LINC00127 |NA |NA |NA |- |HSALNT0288731 |HSALNG0141468 |TTTY4 |TTY4,TTTY4A,LINC00123 |NA |NA |NA |- |HSALNT0288815 |HSALNG0141548 |TTTY3 |TTY3,TTTY3A,LINC00121 |NA |NA |NA |- |HSALNT0288703 |HSALNG0141450 |TTTY5 |TTY5,LINC00126 |NA |NA |NA |- |HSALNT0289255 |HSALNG0036656 |SNHG8 |NCRNA00060,LINC00060 |NA |pathogenic process |gastric cancer;malignant pleural mesothelioma |- |HSALNT0289486 |HSALNG0141597 |BCYRN1 |BC200,BC200a,NCRNA00004,LINC00004 |splicing regulation;translational control |pathogenic process |aging;lung cancer;glioma;ovarian cancer;esophageal squamous cell cancer;non-small cell lung cancer;esophageal cancer;Alzheimer's disease;tongue cancer;parotid cancer;breast cancer;cervical cancer |- |HSALNT0144426 |HSALNG0068805 |ZFAT-AS1 |ZFATAS,ZFAT-AS,SAS-ZFAT,NCRNA00070 |NA |pathogenic process |autoimmune disease |- |HSALNT0289285 |HSALNG0077083 |ZEB1-AS1 |NA |NA |pathogenic process |esophageal squamous cell cancer;autoimmune thyroid disease;hepatocelluar cancer |- |HSALNT0289185 |HSALNG0135987 |MIRLET7BHG |linc-Ppara |NA |developmental process |NA |- |HSALNT0289374 |HSALNG0116616 |NBR2 |NCRNA00192 |transcriptional regulation |pathogenic process |gastric cancer;breast cancer;cancer |- |HSALNT0289417 |HSALNG0134930 |TUG1 |FLJ20618,NCRNA00080,LINC00080 |transcriptional regulation;ceRNA |pathogenic process |osteosarcoma;prostate cancer;glioma;ovarian cancer;glioblastoma;non-small cell lung cancer;B-cell neoplasms;chronic kidney disease;melanoma;bladder cancer;urothelial cancer of the bladder;esophageal squamous cell cancer;multiple sclerosis;breast cancer;hepatoblastoma;colorectal cancer;multiple myeloma;gastric cancer;Huntington disease;hepatocellular cancer;oesophageal squamous cell cancer;renal cell cancer |- |HSALNT0288973 |HSALNG0079552 |FAS-AS1 |FASA, FAS-A,SAF |transcriptional regulation |pathogenic process |ataxia telangiectasia |- |HSALNT0288996 |HSALNG0068110 |HAS2-AS1 |HAS2A, HAS2-A,HASNT,NCRNA00077 |transcriptional regulation |NA |NA |- |HSALNT0289390 |HSALNG0049245 |PSORS1C3 |NCRNA00196 |NA |pathogenic process |rheumatoid arthritis;psoriasis |- |HSALNT0289868 |HSALNG0141983 |HLA-AS1 |NA |NA |pathogenic process |psoriasis;liver injury;multiple sclerosis;AIDS |- |HSALNT0290154 |HSALNG0142269 |PRINS |NCRNA00074 |transcriptional regulation |pathogenic process |psoriasis;prostate cancer |- |HSALNT0262809 |HSALNG0127790 |PEG3-AS1 |PEG3AS,PEG3-AS,APEG3,NCRNA00155 |NA |NA |NA |- |HSALNT0289533 |HSALNG0141648 |7SL |7S RNA,SRP RNA,4.5S SRP RNA,4.5S RNA,RN7SL1 RNA,ENSG00000258486,lnc-LRR1-1:1 |protein localization |pathogenic process |AIDS;Leishmaniasis;dermatomyositis;polymyositis |- |HSALNT0290081 |HSALNG0142196 |NDM29 |29A,lnc-C11orf16-1:1 |NA |pathogenic process |neuroblastoma |- |HSALNT0289382 |HSALNG0074439 |NRON |NCRNA00194 |NA |pathogenic process |AIDS;Down syndrome;HIV |- |HSALNT0289253 |HSALNG0065926 |SNHG6 |U87HG,HBII-276HG,NCRNA00058 |translational control;ceRNA |pathogenic process |hepatocellular cancer;hereditary haemorrhagic telangiectasia |- |HSALNT0289653 |HSALNG0141768 |Beta-globin transcript |AY195961.1,NONHSAT017674,AY034469.1,NONHSAT017675,AY034470.1,NONHSAT017676 |NA |NA |NA |- |HSALNT0290398 |HSALNG0142513 |Zfhx2as |Zfh-5AS,ENSG00000157306,ENST00000554403.1 |NA |NA |NA |- |HSALNT0011306 |HSALNG0005433 |MIR137HG |NA |NA |pathogenic process |schizophrenia;lung cancer;malignant lymphoma |- |HSALNT0289449 |HSALNG0056858 |HOXA-AS3 |HOXA6as |NA |pathogenic process |glioma |- |HSALNT0289451 |HSALNG0068551 |CCDC26 |MGC27434,RAM |transcriptional regulation |pathogenic process |hematological malignancies;glioma;acute myeloid leukemia;leukemia;pancreatic cancer;breast cancer |- |HSALNT0289893 |HSALNG0142008 |LINC00271 |C6orf217,NCRNA00271 |NA |pathogenic process |type 2 diabetes;schizophrenia |- |HSALNT0288892 |HSALNG0109621 |BCAR4 |NA |transcriptional regulation |pathogenic process |osteosarcoma;breast cancer;colorectal cancer |- |HSALNT0289890 |HSALNG0142005 |LINC00032 |C9orf14,NCRNA00032 |NA |pathogenic process |narcolepsy;melanoma |- |HSALNT0274572 |HSALNG0133591 |PICSAR |C21orf113,LINC00162,NCRNA00162,NLC1-C,NLC1C,PRED74 |transcriptional regulation |pathogenic process |testicular embryonal cancer;narcolepsy;cutaneous squamous cell cancer |- |HSALNT0256354 |HSALNG0124398 |UCA1 |CUDR,LINC00178,NCRNA00178,UCAT1,onco-lncRNA-36 |transcriptional regulation;ceRNA |developmental process;pathogenic process |oral squamous cell cancer;osteosarcoma;prostate cancer;ovarian cancer;non-small cell lung cancer;acute myocardial infarction;pancreaticobiliary maljunction;pancreatic cancer;melanoma;tongue squamous cell cancer;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;esophageal squamous cell cancer;esophageal cancer;liver cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;urinary bladder;gastric cancer;endometrial cancer;breast cancer;hepatocellular cancer;squamous cell cancer;lung cancer;renal cell cancer |- |HSALNT0003871 |HSALNG0002066 |SNHG3 |NCRNA00014,RNU17C,RNU17D,U17HG,U17HG-A,U17HG-AB |NA |pathogenic process |ovarian cancer;hepatocellular cancer;colorectal cancer;Alzheimer's disease |- |HSALNT0289475 |HSALNG0131591 |HAR1A |HAR1F,NCRNA00064,LINC00064 |transcriptional regulation |pathogenic process |Huntington disease;Alzheimer's disease |- |HSALNT0288995 |HSALNG0131589 |HAR1B |HAR1R,NCRNA00065,LINC00065 |transcriptional regulation |pathogenic process |Huntington disease;hereditary haemorrhagic telangiectasia;Alzheimer's disease |- |HSALNT0288958 |HSALNG0044150 |EPB41L4A-AS1 |C5orf26,NCRNA00219,TIGA1 |NA |pathogenic process |lung cancer;cancer |- |HSALNT0289170 |HSALNG0134655 |MIAT |C22orf35,FLJ25967,Rncr2,gomafu,NCRNA00066,LINC00066,lncRNA-MIAT |splicing regulation;ceRNA |pathogenic process |prostate cancer;chronic lymphocytic leukemia;cancer;drug abuse;diabetes-induced microvascular dysfunction;schizophrenia;acute myocardial infarction;dilated cardiomyopathy;lung adenocarcinoma;diabetic retinopathy;myocardial infarction;Alzheimer's disease |- |HSALNT0289007 |HSALNG0047947 |HULC |NCRNA00078,LINC00078,HCCAT1 |transcriptional regulation;ceRNA |pathogenic process |prostate cancer;glioma;hepatocelluar cancer;osteosarcoma;atherosclerosis;gastric cancer;hepatocellular cancer;esophageal cancer;liver cirrhosis;diffuse large B-cell lymphoma;pancreatic cancer;papillary thyroid cancer;liver cancer;cervical cancer;colorectal cancer |- |HSALNT0288940 |HSALNG0023880 |EGOT |EGO,NCRNA00190 |NA |pathogenic process;developmental process |prostate cancer;breast cancer |- |HSALNT0289387 |HSALNG0001461 |PINK1-AS |PINK1-AS1,FLJ00387,PINK1A, naPINK1 |transcriptional regulation |pathogenic process |glucose metabolism disorder;Parkinson's disease;diabetes |- |HSALNT0289225 |HSALNG0068477 |PVT1 |NCRNA00079,LINC00079,onco-lncRNA-100,MIR1204HG,PVT |transcriptional regulation;translational control |pathogenic process |murine plasmacytomas;prostate cancer;cancer;ovarian cancer;renal cancer;B-cell lymphoma;non-small cell lung cancer;pancreatic cancer;Hodgkin's lymphoma;asthma;hepatocelluar cancer;bladder cancer;plasmacytoma;cleft lip;acute promyelocytic leukemia;diabetic nephropathy;esophageal cancer;kidney cancer;type 1 diabetes;breast cancer;cervical cancer;diabetic kidney disease;hematological malignancies;colorectal cancer;neuroblastoma;cardiac hypertrophy;multiple myeloma;gastric cancer;lymphoma;type 2 diabetes;thyroid cancer;pleural mesothelioma;lung squamous cell cancer;Burkitt lymphoma;hepatocellular cancer;renal cell cancer |- |HSALNT0289189 |HSALNG0073233 |NAMA |NA |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0246525 |HSALNG0119442 |NARF-AS1 |NA |NA |pathogenic process |hepatocellular cancer |- |HSALNT0147433 |HSALNG0070397 |CDKN2B-AS1 |CDKN2BA,ANRIL,RP11-145E5.4,NCRNA00089,p15A, CDKN2B-A, PCAT12 |siRNA;transcriptional regulation;ceRNA |pathogenic process |glaucoma;prostate cancer;glioma;cancer;osteosarcoma;neurofibromatosis;ischemic heart failure;stroke;non-small cell lung cancer;hypertension;intracranial aneurysm;aortic aneurysm;periodontitis;acute lymphoblastic leukemia;Alzheimer's disease;coronary artery disease;melanoma;bladder cancer;abdominal aortic aneurysm;ovarian cancer;esophageal cancer;basal cell cancer;breast cancer;cervical cancer;coronary heart disease;gallbladder cancer;acute myocardial infarction;colorectal cancer;neuroblastoma;peripheral artery disease;esophageal squamous cell cancer;atherosclerosis;leukemia;hereditary cutaneous malignant melanoma;gastric cancer;cardiovascular disease;coronary disease;frailty;diabetes;type 2 diabetes;thyroid cancer;primary open-angle glaucoma;ischemic stroke;plexiform neurofibroma;laryngeal squamous cell cancer;hepatocellular cancer;nasopharyngeal cancer;myocardial infarction;lung cancer;endometriosis;primary myelofibrosis |- |HSALNT0050854 |HSALNG0024099 |GHRLOS |NCRNA00068,GHRL-AS1 |transcriptional regulation |NA |NA |- |HSALNT0288959 |HSALNG0026279 |ESRG |HESRG |NA |pathogenic process |embryonal cancer |- |HSALNT0287173 |HSALNG0140560 |FMR1-AS1 |FMR1A, FMR1-A,ASFMR1,FMR4 |transcriptional regulation |pathogenic process |fragile X syndrome;neurological disorder |- |HSALNT0289499 |HSALNG0141610 |HCG4 |HCGIV-10,HCGIV.9 |NA |pathogenic process |NA |- |HSALNT0288994 |HSALNG0038609 |HAND2-AS1 |DEIN,NBLA00301,FLJ11539 |NA |pathogenic process |neuroblastoma |- |HSALNT0289286 |HSALNG0019362 |ZEB2-AS1 |ZEB2A, ZEB2-A,ZEB2NAT |splicing regulation |pathogenic process |bladder cancer;hepatocellular cancer |- |HSALNT0017702 |HSALNG0008545 |GAS5 |SNHG2,NCRNA00030 |transcriptional regulation;ceRNA |pathogenic process |varicose great saphenous veins;prostate cancer;glioma;cancer;ovarian cancer;non-small cell lung cancer;hypertension;pancreatic cancer;B-cell neoplasms;melanoma;head and neck cancer;hepatocelluar cancer;bladder cancer;autoimmune disease;liver fibrosis;kidney cancer;breast cancer;cervical cancer;colorectal cancer;multiple myeloma;gastric cancer;osteoarthritis;endometrial cancer;lymphoma;type 2 diabetes;pleural mesothelioma;hepatocellular cancer;lung adenocarcinoma;lung cancer;renal cell cancer |- |HSALNT0288891 |HSALNG0087449 |BACE1-AS |BACE1A,FJ573250,NCRNA00177,BACE1-AS1 |translational control;transcriptional regulation |pathogenic process |ovarian cancer;colorectal cancer;Alzheimer's disease |- |HSALNT0289414 |HSALNG0133533 |TRPM2-AS |TRPM2-AS1 |NA |pathogenic process |melanoma;prostate cancer |- |HSALNT0288935 |HSALNG0008462 |DNM3OS |DNM3-AS1,MIR199A2HG |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0288930 |HSALNG0133982 |DGCR5 |NCRNA00037,LINC00037 |transcriptional regulation |pathogenic process |Huntington disease;DiGeorge syndrome;velocardiofacial syndrome;clear cell renal cell cancer |- |HSALNT0288893 |HSALNG0083307 |BDNF-AS |BDNFO,BT2A,BT2B,BT2C,BT2D,NCRNA00049,BDNF-AS1,BDNFAS |siRNA;transcriptional regulation |developmental process;pathogenic process |Huntington disease;schizophrenia;psychiatric disease;obesity |- |HSALNT0120317 |HSALNG0056850 |HOTAIRM1 |HOXA-AS1,NCRNA00179,HOXA1-AS1 |transcriptional regulation |pathogenic process;developmental process |colorectal cancer;Pancreatic ductal adenocarcinoma;promyelocytic leukemia;acute myeloid leukemia;infiltrating ductal cancers ;acute promyelocytic leukemia;leukemia;glioma |- |HSALNT0290158 |HSALNG0142273 |PTCSC1 |PTCSC,AK023948,NCRNA00197 |NA |pathogenic process |papillary thyroid cancer |- |HSALNT0289004 |HSALNG0091318 |HOTAIR |HOXC-AS4,HOXC11-AS1,NCRNA00072 |siRNA;transcriptional regulation;ceRNA |pathogenic process |oral squamous cell cancer;prostate cancer;glioma;cancer;breast cancer;osteosarcoma;renal cancer;glioblastoma;non-small cell lung cancer;sarcoma;pancreatic cancer;large B-Cell lymphoma;bladder transitional cell cancer;B-cell neoplasms;melanoma;asthenozoospermia;hepatocelluar cancer;bladder cancer;acute myeloid leukemia;aortic valve calcification;infiltrating ductal cancers ;ovarian cancer;diffuse large B-cell lymphoma;gastrointestinal stromal tumor;atypical teratoid rhabdoid tumor;urothelial cancer;triple-negative breast cancer;gastric cardia adenocarcinoma;cervical cancer;temporomandibular joint osteoarthritis;gallbladder cancer;esophageal squamous cell cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;rheumatoid arthritis;gastric cancer ;pre-eclampsia;acute leukemia;small cell lung cancer;multiple myeloma;gastric cancer;osteoarthritis;LPS-induced sepsis;endometrial cancer;head and neck squamous cell cancer;gastric adenocarcinoma;lung cancer;liver cancer;ischemic stroke;ischemic heart failure;laryngeal squamous cell cancer;pituitary adenoma;hepatocellular cancer;nasopharyngeal cancer;lung adenocarcinoma;papillary thyroid cancer;Parkinson's disease;renal cell cancer;gastrointestinal cancer |- |HSALNT0289192 |HSALNG0084892 |NEAT1 |NCRNA00084,TncRNA,MENepsilon/beta,LINC00084,VINC |transcriptional regulation;ceRNA |pathogenic process |oral squamous cell cancer;glioma;ovarian cancer;amyotrophic lateral sclerosis;paraspeckle disintegration;nasopharyngeal cancer;AIDS;frontotemporal lobar degeneration;prostate cancer;systemic lupus erythematosus;renal syndrome;TDP-43-associated pathological states;HIV;Huntington disease;chronic lymphocytic leukemia;acute promyelocytic leukemia;esophageal squamous cell cancer;multiple sclerosis;breast cancer;intrauterine growth restriction;colorectal cancer;leukemia;gastric cancer;malignant pleural mesothelioma;endometrial cancer;gastric adenocarcinoma;papillary thyroid cancer;infertility;bladder cancer;hepatocellular cancer;non-small cell lung cancer;obesity;lung cancer;Parkinson's disease;laryngeal squamous cell cancer |- |HSALNT0095094 |HSALNG0045213 |SNHG4 |U19H,NCRNA00059 |NA |pathogenic process |myelodysplastic syndrome |- |HSALNT0245443 |HSALNG0118855 |SNHG16 |ncRAN,Nbla12061,Nbla10727 |NA |pathogenic process |bladder cancer;bladder cancer;colorectal cancer;neuroblastoma |- |HSALNT0288897 |HSALNG0023698 |BOK-AS1 |BOKA,NCRNA00151,NAToB |NA |pathogenic process |esophageal squamous cell cancer;testicular cancer;cancer |- |HSALNT0289532 |HSALNG0141647 |7SK |7-3 RNA,K-RNA,7SK-RNA,7SK snRNA,RN7SK,ENSG00000202198,NONHSAT113149 |transcriptional regulation |developmental process;pathogenic process |cancer;cardiac hypertrophy;gastric cancer;AIDS;multiple sclerosis;colorectal adenocarcinoma |- |HSALNT0289182 |HSALNG0017872 |MIR4435-2HG |MIR4435-1HG,LINC00978,AGD2,AK001796,lncRNA-AWPPH,MORRBID |NA |pathogenic process |lung cancer |- |HSALNT0289200 |HSALNG0016500 |PARTICL |PARTICLE |transcriptional regulation |pathogenic process |low-dose irradiation |- |HSALNT0289172 |HSALNG0069266 |MINCR |LINC01604,TCONS_00015189 |transcriptional regulation;ceRNA |pathogenic process |gallbladder cancer;Burkitt lymphoma |- |HSALNT0001792 |HSALNG0000905 |NPPA-AS1 |NPPAA, NPPA-AS |splicing regulation |pathogenic process |cardiovascular disease |- |HSALNT0290230 |HSALNG0142345 |RRP1B |NA |transcriptional regulation |pathogenic process |spinocerebellar ataxia;laryngeal squamous cell cancer;cancer |- |HSALNT0289467 |HSALNG0093062 |CLLU1 |NA |NA |NA |NA |- |HSALNT0289173 |HSALNG0087764 |MIR100HG |AGD1,lncRNA-N2,linc-NeD125 |NA |developmental process;pathogenic process |myeloid leukemia;myopia;cervical cancer;neuroblastoma |- |HSALNT0059175 |HSALNG0028235 |TUSC7 |LINC00902,LSAMP-AS1,LSAMP-AS3,LSAMPAS3,NCRNA00295 |transcriptional regulation;ceRNA |pathogenic process |glioma;Pancreatic ductal adenocarcinoma;osteosarcoma;esophageal squamous cell cancer;ischemic heart failure;gastric cancer;hepatocellular cancer;non-small cell lung cancer;acute myeloid leukemia;colorectal cancer |- |HSALNT0289647 |HSALNG0141762 |BC040587 |NA |NA |pathogenic process |osteosarcoma;breast cancer |- |HSALNT0059186 |HSALNG0028242 |LINC00901 |LSAMP-AS4,TCONS_00005428,BC040587 |NA |pathogenic process |osteosarcoma;gastric cancer;breast cancer |- |HSALNT0233366 |HSALNG0112604 |HCCAT5 |HTA,FJ222407 |NA |pathogenic process |hepatocellular cancer |- |HSALNT0290040 |HSALNG0142155 |LSINCT5 |NA |NA |pathogenic process |chronic heart failure;colorectal cancer;ovarian cancer;gastric cancer;lung cancer;breast cancer |- |HSALNT0179611 |HSALNG0086377 |DISC1FP1 |Boymaw |transcriptional regulation |pathogenic process |schizophrenia |- |HSALNT0217643 |HSALNG0104567 |SNHG14 |115HG,IC-SNURF-SNRPN,LNCAT,NCRNA00214,U-UBE3A-AT, UBE3A-A, UBE3A-AS1,UBE3AATS |ceRNA |pathogenic process |Angelman syndrome;cerebral infarction;Prader-Willi syndrome |- |HSALNT0289273 |HSALNG0000343 |TP73-AS1 |KIAA0495,PDAM |NA |pathogenic process |esophageal squamous cell cancer;oligodendroglial tumors;non-small cell lung cancer;glioblastoma;multiple myeloma |- |HSALNT0290311 |HSALNG0142426 |TP53COR1 |Trp53cor1 |transcriptional regulation |pathogenic process |prostate cancer;colorectal cancer;hepatocelluar cancer;atherosclerosis;Burkitt lymphoma;chronic lymphocytic leukemia;B cell lymphoma;lung cancer;cervical cancer |- |HSALNT0289221 |HSALNG0068414 |PRNCR1 |CARLo-3,PCAT8 |transcriptional regulation |pathogenic process |gastric cancer;prostate cancer;glioma;colorectal cancer |- |HSALNT0020131 |HSALNG0009743 |PCAT6 |KDM5B-AS1,ncRNA-a2,PCAN-R1,KDM5BAS1,onco-lncRNA-96 |transcriptional regulation |pathogenic process |prostate cancer;triple-negative breast cancer;lung cancer |- |HSALNT0289277 |HSALNG0130723 |TRERNA1 |LINC00651,ncRNA-a7,treRNA |transcriptional regulation |NA |NA |- |HSALNT0014972 |HSALNG0007045 |FALEC |LINC00568,ncRNA-a1,FAL1 |transcriptional regulation |pathogenic process |ovarian cancer;thyroid cancer |- |HSALNT0290008 |HSALNG0142123 |LOC100887755 |Noncoding RNA activating7: ncRNA-a7,ENST00000431460.1,ENSG00000231265,TRERNA1 |transcriptional regulation |pathogenic process |hepatocellular cancer |- |HSALNT0290248 |HSALNG0142363 |snaR |EU035784.1,lnc-BSPH1-1:1 |transcriptional regulation |NA |NA |- |HSALNT0289342 |HSALNG0138609 |JPX |NCRNA00183,ENOX,LINC00183,DCBALD06 |transcriptional regulation |pathogenic process |hepatocellular cancer |- |HSALNT0289231 |HSALNG0001716 |RCAN3AS |TCONS_00001428 |NA |NA |NA |- |HSALNT0289280 |HSALNG0069631 |VLDLR-AS1 |lincRNA-VLDLR |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0288982 |HSALNG0138614 |FTX |NCRNA00182,MIR374AHG,LINC00182,FLJ33139 |transcriptional regulation |pathogenic process |hepatocellular cancer;breast cancer;colorectal cancer;hepatocelluar cancer |- |HSALNT0091079 |HSALNG0043383 |MEF2C-AS1 |NA |NA |pathogenic process |gastric cancer;Prader-Willi syndrome and Angelman syndrome |- |HSALNT0189341 |HSALNG0091277 |PCBP2-OT1 |TUC338 |NA |pathogenic process |hepatocellular cancer;tongue squamous cell cancer |- |HSALNT0290373 |HSALNG0142488 |WRAP53 |NA |NA |pathogenic process |hepatocellular cancer;cancer;dyskeratosis congenita |- |HSALNT0289265 |HSALNG0049949 |TDRG1 |LINC00532,lincRNA-NRNA024015 |NA |pathogenic process |esophageal squamous cell cancer;gastric cancer;testicular cancer;aplastic anemia |- |HSALNT0289175 |HSALNG0132382 |MIR155HG |MIRHG2,BIC,NCRNA00172 |NA |pathogenic process |B-cell chronic lymphocytic leukemia;chronic lymphocytic leukemia;breast cancer;glioma |- |HSALNT0289051 |HSALNG0024293 |LINC00620 |NA |NA |pathogenic process |cervical cancer |- |HSALNT0120390 |HSALNG0056871 |HOTTIP |NCRNA00213,HOXA-AS6,RP1-170O19.3,HOXA13-AS1 |transcriptional regulation |pathogenic process |hirschsprung disease;colorectal cancer;prostate cancer;tongue squamous cell cancer;Pancreatic ductal adenocarcinoma;osteosarcoma;hepatocelluar cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;pancreatic cancer;lung cancer;glioma |- |HSALNT0289287 |HSALNG0130661 |ZFAS1 |C20orf199,NCRNA00275,ZNFX1-AS1,HSUP1,HSUP2 |transcriptional regulation;ceRNA |pathogenic process |gastric cancer;hepatocellular cancer;ductal cancer;colorectal cancer;breast cancer |- |HSALNT0289259 |HSALNG0045502 |SPRY4-IT1 |SPRIGHTLY |transcriptional regulation |pathogenic process |prostate cancer;melanoma;glioma;esophageal squamous cell cancer;pre-eclampsia;bladder cancer;renal clear cell cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;lung cancer;breast cancer;cervical cancer;colorectal cancer |- |HSALNT0105595 |HSALNG0049759 |PANDAR |PANDA |transcriptional regulation |pathogenic process |colorectal cancer;cancer;bladder cancer;gastric cancer;hepatocellular cancer;non-small cell lung cancer;p53-associated pathological states;breast cancer;renal cell cancer |- |HSALNT0068185 |HSALNG0032415 |HTT-AS |HTT-AS1,HTTAS |NA |pathogenic process |Huntington disease |- |HSALNT0099036 |HSALNG0047200 |HEIH |LINC-HEIH,lncRNA-HEIH,LINC00848,HCCAT2 |NA |pathogenic process |hepatocelluar cancer |- |HSALNT0222533 |HSALNG0107117 |NPTN-IT1 |lncRNA-LET |NA |pathogenic process |gallbladder cancer;colorectal cancer;hepatocelluar cancer;esophageal squamous cell cancer;lung squamous cell cancer;nasopharyngeal cancer;gastric cancer;hypoxia;squamous cell lung cancer;cervical cancer |- |HSALNT0289747 |HSALNG0141862 |DQ786243 |NA |transcriptional regulation |pathogenic process |crohn's disease;colorectal cancer;hepatocelluar cancer |- |HSALNT0289204 |HSALNG0068414 |PCAT1 |PCAT-1,PCA1 |transcriptional regulation;ceRNA |pathogenic process |prostate cancer;colorectal cancer;esophageal squamous cell cancer;bladder cancer;hepatocellular cancer;lung cancer |- |HSALNT0275894 |HSALNG0134403 |PCAT14 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0211999 |HSALNG0101780 |HIF1A-AS2 |3'aHIF-1A,aHIF |translational control |pathogenic process |bladder cancer;osteosarcoma;renal cancer;glioblastoma;gastric cancer;acute myocardial infarction;kidney cancer;breast cancer |- |HSALNT0288999 |HSALNG0101776 |HIF1A-AS1 |5'aHIF-1A,5'aHIF1alpha |NA |pathogenic process |acute myocardial infarction;non-small cell lung cancer;cardiovascular disease;aortic aneurysm;thoracoabdominal aorta aneurysm;kidney cancer |- |HSALNT0289258 |HSALNG0031034 |SOX2-OT |SOX2OT,DKFZp761J1324,NCRNA00043 |transcriptional regulation |pathogenic process |colorectal cancer;esophageal squamous cell cancer;lung squamous cell cancer;retinal neurodegeneration;neurodevelopmental syndromes associated with the SOX2 locus;hepatocellular cancer;lung cancer;breast cancer;Alzheimer's disease |- |HSALNT0289700 |HSALNG0141815 |CDR1-AS |CDR1NAT,ciRS-7,CDR1as |ceRNA |NA |NA |- |HSALNT0289149 |HSALNG0050599 |LINCMD1 |MIR133BHG,LINC-MD1 |ceRNA |developmental process;pathogenic process |Duchenne muscular dystrophy |- |HSALNT0288894 |HSALNG0082362 |BGLT3 |LINC01083,BGL3,lncRNA-BGL3 |ceRNA |pathogenic process |chronic myeloid leukemia |- |HSALNT0289042 |HSALNG0055058 |LINC00473 |C6orf176,bA142J11.1 |transcriptional regulation |pathogenic process |non-small cell lung cancer;renal cell cancer |- |HSALNT0101681 |HSALNG0048223 |LINC01108 |LncRNA-ES1 |NA |developmental process |NA |- |HSALNT0289418 |HSALNG0103465 |TUNAR |LINC00617,TUNA,HI-LNC78 |transcriptional regulation |developmental process;pathogenic process |breast cancer |- |HSALNT0289197 |HSALNG0105343 |OIP5-AS1 |cyrano,linc-OIP5 |NA |developmental process |NA |- |HSALNT0289046 |HSALNG0048515 |LINC00581 |NA |NA |pathogenic process |West Syndrome;West syndrome |- |HSALNT0289656 |HSALNG0141771 |BX118339 |NA |NA |pathogenic process |West syndrome |- |HSALNT0021726 |HSALNG0010465 |LINC00538 |Yiya,PROX1UT |NA |pathogenic process |colorectal cancer;cancer |- |HSALNT0273249 |HSALNG0132926 |CBR3-AS1 |PlncRNA-1,PlncRNA1 |ceRNA |pathogenic process |esophageal squamous cell cancer;hepatocellular cancer;prostate cancer |- |HSALNT0289179 |HSALNG0070363 |MIR31HG |LOC554202,hsa-lnc-31,LncHIFCAR |ceRNA |pathogenic process |bladder cancer;gastric cancer;breast cancer;colorectal cancer;Pancreatic ductal adenocarcinoma |- |HSALNT0288925 |HSALNG0034419 |DANCR |KIAA0114,SNHG13,ANCR,AGU2,lncRNA-ANCR |transcriptional regulation |developmental process;pathogenic process |prostate cancer;colorectal cancer;osteosarcoma;bone diseases;postmenopausal osteoporosis;hepatocellular cancer;breast cancer |- |HSALNT0290329 |HSALNG0142444 |uc.388 |NA |NA |pathogenic process |colorectal cancer |- |HSALNT0289842 |HSALNG0141957 |FR0348383 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0289279 |HSALNG0141211 |TTTY15 |DKFZP434I143,NCRNA00138 |NA |pathogenic process |NA |- |HSALNT0289718 |HSALNG0141833 |CRNDE |LOC643911,LINC00180,CRNDEP |transcriptional regulation;ceRNA |pathogenic process |gallbladder cancer;colorectal cancer;ovarian cancer;medulloblastoma;chronic lymphocytic leukemia;renal cell cancer;glioma |- |HSALNT0289685 |HSALNG0141800 |CCND1 |NA |NA |pathogenic process |tumor;cervical cancer |- |HSALNT0289935 |HSALNG0142050 |lincRNA-p21 |NA |transcriptional regulation |pathogenic process |lung cancer;cancer |- |HSALNT0290134 |HSALNG0142249 |PCNCR1 |NA |NA |pathogenic process |prostate cancer |- |HSALNT0289492 |HSALNG0141603 |DBET |DBE-T,DUX4L30 |transcriptional regulation |developmental process;pathogenic process |facioscapulohumeral muscular dystrophy |- |HSALNT0289455 |HSALNG0071734 |BANCR |LINC00586 |transcriptional regulation |pathogenic process |osteosarcoma ;lung cancer;melanoma;colorectal cancer;osteosarcoma;esophageal squamous cell cancer;bladder cancer;eosinophilic esophagitis;gastric cancer;hepatocellular cancer;non-small cell lung cancer;retinoblastoma;papillary thyroid cancer |- |HSALNT0209589 |HSALNG0100636 |PTCSC3 |NA |ceRNA |pathogenic process |papillary thyroid cancer;thyroid cancer |- |HSALNT0290063 |HSALNG0142178 |MVIH |NA |ceRNA |pathogenic process |hepatocellular cancer;non-small cell lung cancer;breast cancer;microvascular invasion in hepatocellular cancer;hepatocelluar cancer |- |HSALNT0289103 |HSALNG0052921 |LINC01268 |LOC285758 |NA |pathogenic process |NA |- |HSALNT0289070 |HSALNG0031716 |LINC00887 |linc-ATP13A4-8,HEIRCC |transcriptional regulation |pathogenic process |hypoxic and inflammatory renal epithelial injury;renal clear cell cancer |- |HSALNT0288931 |HSALNG0100075 |DHRS4-AS1 |C14orf167,PRO1488,AS1DHRS4 |transcriptional regulation |NA |NA |- |HSALNT0288974 |HSALNG0113304 |FENDRR |FOXF1-AS1,TCONS_00024240,lincFOXF1,onco-lncRNA-21 |transcriptional regulation |developmental process;pathogenic process |osteosarcoma;gastric cancer;non-small cell lung cancer;lung cancer |- |HSALNT0106473 |HSALNG0050235 |LINC01512 |LOC100132354,TCONS_00011120,HI-LNC77 |NA |pathogenic process |lung adenocarcinoma;type 2 diabetes |- |HSALNT0289059 |HSALNG0118547 |LINC00673 |HI-LNC75,HILNC75,LUCAIR1,SLNCR,SLNCR1 |transcriptional regulation |pathogenic process |pancreatic cancer;type 2 diabetes;non-small cell lung cancer;melanoma;Pancreatic ductal adenocarcinoma |- |HSALNT0289107 |HSALNG0128306 |LINC01433 |LOC728228 |NA |pathogenic process |lung cancer |- |HSALNT0143571 |HSALNG0068424 |CCAT1 |CARLo-5,onco-lncRNA-40 |ceRNA |pathogenic process |gallbladder cancer;glioma;hepatocelluar cancer;ovarian cancer;acute myeloid leukemia;gastric cancer;hepatocellular cancer;non-small cell lung cancer;lung adenocarcinoma;endometrial cancer;lung cancer;breast cancer;colorectal cancer |- |HSALNT0289408 |HSALNG0123467 |TINCR |ENST00000448587.1,FLJ90734,NCRNA00036,LINC00036,onco-lncRNA-16 |translational control |pathogenic process;developmental process |bladder cancer;colorectal cancer;esophageal squamous cell cancer;gastric cancer;skin desease;squamous cell cancer |- |HSALNT0289152 |HSALNG0060113 |LNCPRESS1 |lncPRESS1 |translational control |NA |NA |- |HSALNT0289145 |HSALNG0075843 |LINC02561 |RP11-445P17.8 |NA |pathogenic process |cystic fibrosis |- |HSALNT0289065 |HSALNG0140616 |LINC00850 |KUCG1 |NA |pathogenic process |Duchenne muscular dystrophy |- |HSALNT0289431 |HSALNG0032699 |AFAP1-AS1 |AFAP1A, AFAP1-A,MGC10981 |NA |pathogenic process |non-small cell lung cancer;colorectal cancer;Pancreatic ductal adenocarcinoma;esophageal squamous cell cancer;hepatocellular cancer;nasopharyngeal cancer;lung adenocarcinoma;pancreatic cancer;Barrett's Esophagus;lung cancer |- |HSALNT0289519 |HSALNG0141630 |XACT |NA |NA |NA |NA |- |HSALNT0248684 |HSALNG0120344 |GATA6-AS1 |locus5689,BM742401 |NA |pathogenic process |gastric cancer;chronic lymphocytic leukemia |- |HSALNT0289222 |HSALNG0073144 |PTCSC2 |NA |transcriptional regulation |pathogenic process |papillary thyroid cancer |- |HSALNT0289655 |HSALNG0141770 |BTG3-AS1 |ASBEL |translational control |pathogenic process |ovarian cancer;colorectal cancer |- |HSALNT0289224 |HSALNG0070801 |PTENP1 |NONHSAT130775,PTENpg1,PTEN2,ENSG00000237984 |transcriptional regulation;ceRNA |pathogenic process |gastric cancer;prostate cancer;renal cell cancer;cancer;hepatocelluar cancer |- |HSALNT0290129 |HSALNG0142244 |PAN |NA |transcriptional regulation |pathogenic process |Kaposi's sarcoma |- |HSALNT0289939 |HSALNG0142054 |LINC-ROR |lincRNA-RoR,lincRNA-ST8SIA3,ROR |transcriptional regulation;ceRNA |pathogenic process |gallbladder cancer;liver cancer;glioma;malignant melanoma;unveal melanoma;breast cancer;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;pancreatic cancer;endometrial cancer;triple-negative breast cancer;colorectal cancer |- |HSALNT0290322 |HSALNG0142437 |UBE3A-ATS |NA |NA |pathogenic process |Angelman syndrome |- |HSALNT0091004 |HSALNG0043367 |LINC00461 |EyeLinc1,Visc-1a,Visc-1b,Visc-2,LOC645323 |NA |pathogenic process;developmental process |retinal and visual function |- |HSALNT0289491 |HSALNG0141602 |CTBP1-AS |PCAT10 |transcriptional regulation |pathogenic process |chronic hepatitis C;prostate cancer;polycystic ovary syndrome |- |HSALNT0037401 |HSALNG0017694 |GACAT1 |LINC00876,AC096655.1-002 |NA |pathogenic process |gastric cancer |- |HSALNT0120344 |HSALNG0056854 |HOXA-AS2 |HOXA3as |transcriptional regulation |pathogenic process |promyelocytic leukemia;gastric cancer |- |HSALNT0091313 |HSALNG0043441 |LUCAT1 |SCAL1 |transcriptional regulation |pathogenic process |non-small cell lung cancer;lung cancer |- |HSALNT0289425 |HSALNG0009941 |BLACAT1 |linc-UBC1,LINC00912,onco-lncRNA-30 |transcriptional regulation |pathogenic process |bladder cancer;gastric cancer |- |HSALNT0149012 |HSALNG0071221 |GLIDR |LINC01172,MGC21881,TCONS_00015562 |NA |pathogenic process |glioblastoma |- |HSALNT0217561 |HSALNG0104548 |PWAR5 |PAR5,PAR-5 |NA |pathogenic process |glioblastoma;Prader-Willi syndrome and Angelman syndrome;Prader-Willi syndrome |- |HSALNT0289272 |HSALNG0059377 |TP53TG1 |TP53AP1,H_RG012D21.9,LINC00096 |NA |pathogenic process |non-small cell lung cancer;ataxia telangiectasia |- |HSALNT0289598 |HSALNG0141713 |AK126698 |NA |NA |pathogenic process |non-small cell lung cancer |- |HSALNT0217598 |HSALNG0104558 |IPW |NCRNA00002 |transcriptional regulation |pathogenic process |Prader-Willi syndrome |- |HSALNT0143633 |HSALNG0068443 |CCAT2 |NCCP1,LINC00873 |transcriptional regulation |pathogenic process |non-small cell lung cancer;oral squamous cell cancer;colorectal cancer;ovarian cancer;esophageal squamous cell cancer;bladder cancer;small cell lung cancer;gastric cancer;hepatocellular cancer;prostate cancer;cervical squamous cell cancer;lung cancer;breast cancer;cervical cancer |- |HSALNT0289026 |HSALNG0129180 |LINC00261 |C20orf56,NCRNA00261,bA216C10.1,HCCDR1,TCONS_00027846,ALIEN,DEANR1,onco-lncRNA-17 |NA |pathogenic process |pancreatic cancer;non-small cell lung cancer;gastric cancer |- |HSALNT0289078 |HSALNG0000303 |LINC00982 |FLJ42875 |NA |pathogenic process |gastric cancer |- |HSALNT0290082 |HSALNG0142197 |NEAT1_2 |NEAT1_2 |protein localization |pathogenic process |amyotrophic lateral sclerosis |- |HSALNT0288989 |HSALNG0076040 |GATA3-AS1 |NA |transcriptional regulation |pathogenic process |renal cell cancer |- |HSALNT0289427 |HSALNG0004297 |GNG12-AS1 |NA |transcriptional regulation |NA |NA |- |HSALNT0290395 |HSALNG0142510 |YAM1 |Yam-1 |transcriptional regulation |pathogenic process;developmental process |skeletal myogenesis |- |HSALNT0289202 |HSALNG0018036 |PAX8-AS1 |NA |NA |pathogenic process |malignant pleural mesothelioma;cervical cancer |- |HSALNT0054469 |HSALNG0026023 |RASSF1-AS1 |ANRASSF1 |transcriptional regulation |pathogenic process |breast cancer |- |HSALNT0290261 |HSALNG0142376 |SUMO1P3 |SUMO1P3 |NA |pathogenic process |bladder cancer;gastric cancer |- |HSALNT0289002 |HSALNG0094549 |HNF1A-AS1 |C12orf27,NCRNA00262,FLJ38690,HAS1 |ceRNA |pathogenic process |esophageal adenocarcinoma;osteosarcoma;esophageal squamous cell cancer;gastric cancer;hepatocellular cancer;nasopharyngeal cancer;adenocarcinoma;lung adenocarcinoma;pancreatic cancer |- |HSALNT0289377 |HSALNG0041218 |NIPBL-AS1 |NIPBL-DT,NIPBL-AS |NA |pathogenic process |autism spectrum disorder |- |HSALNT0289249 |HSALNG0057702 |SNHG15 |C7orf40,FLJ38860,MYO1GUT,Linc-Myo1g |NA |pathogenic process |gastric cancer;hepatocellular cancer;hereditary haemorrhagic telangiectasia |- |HSALNT0235898 |HSALNG0113835 |MIR22HG |C17orf91,MGC14376,DKFZp686O06159 |NA |pathogenic process |ovarian cancer |- |HSALNT0235898 |HSALNG0113835 |MIR22HG |C17orf91,MGC14376,DKFZp686O06159 |NA |NA |NA |- |HSALNT0288984 |HSALNG0119881 |GACAT2 |MTCL1-AS1,HMlincRNA717 |NA |pathogenic process |pancreatic cancer;non-small cell lung cancer;gastric cancer |- |HSALNT0289369 |HSALNG0134448 |MIF-AS1 |LOC284889,MIF-AS |transcriptional regulation |pathogenic process |malaria;nephrolithiasis |- |HSALNT0129086 |HSALNG0061385 |LINC-PINT |MKLN1-AS1,FLJ43663,PINT,LincRNA-Pint |transcriptional regulation |pathogenic process |colorectal cancer;heart failure |- |HSALNT0289240 |HSALNG0020769 |SCHLAP1 |LINC00913,SChLAP1,PCAT11 |transcriptional regulation |pathogenic process |bladder cancer;prostate cancer |- |HSALNT0193241 |HSALNG0093119 |SOCS2-AS1 |NA |transcriptional regulation |pathogenic process |prostate cancer |- |HSALNT0138824 |HSALNG0066261 |CASC9 |ESCCAL-1,ESSCAL1,LINC00981 |NA |pathogenic process |esophageal squamous cell cancer;esophageal cancer |- |HSALNT0267627 |HSALNG0130306 |HNF4A-AS1 |uc002xlx |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0289194 |HSALNG0131196 |NKILA |NA |NA |pathogenic process |nasopharyngeal cancer;breast cancer;tongue squamous cell cancer |- |HSALNT0289304 |HSALNG0088539 |LINC00942 |NA |NA |pathogenic process |ovarian cancer;autism spectrum disorder |- |HSALNT0289187 |HSALNG0062700 |MNX1-AS1 |CCAT5,LOC645249 |NA |pathogenic process |ovarian cancer;colorectal cancer |- |HSALNT0289518 |HSALNG0141629 |VPS9D1-AS1 |MYU |NA |pathogenic process |ovarian cancer;colorectal cancer |- |HSALNT0290266 |HSALNG0142381 |TC0101441 |NA |NA |pathogenic process |epithelial ovarian cancer |- |HSALNT0289426 |HSALNG0009856 |ERLNC1 |TC0101441,ElncRNA1 |NA |pathogenic process |ovarian cancer |- |HSALNT0290050 |HSALNG0142165 |Mdgt |NA |NA |NA |NA |- |HSALNT0043560 |HSALNG0020594 |HAGLR |HOXD-AS1,Mdgt |NA |pathogenic process |bladder cancer;neuroblastoma |- |HSALNT0289092 |HSALNG0017541 |LINC01158 |PANTR1,linc-Brn1a,linc-POU3F3 |transcriptional regulation |pathogenic process;developmental process |esophageal squamous cell cancer;gastric cancer;glioma |- |HSALNT0289448 |HSALNG0062110 |GHET1 |lncRNA-GHET1 |NA |pathogenic process |bladder cancer;gastric cancer;colorectal cancer |- |HSALNT0289514 |HSALNG0141625 |PEG13 |NA |transcriptional regulation |pathogenic process |intellectual disabilities |- |HSALNT0289183 |HSALNG0140233 |MIR503HG |MGC16121,H19X |NA |pathogenic process |choriocarcinoma |- |HSALNT0289201 |HSALNG0083445 |PAUPAR |NA |transcriptional regulation |pathogenic process;developmental process |uveal melanoma |- |HSALNT0288956 |HSALNG0094171 |LINC01234 |LCAL84,onco-lncRNA-32 |ceRNA |pathogenic process |oesophageal squamous cell cancer;breast cancer |- |HSALNT0289021 |HSALNG0016642 |CYTOR |C2orf59,NCRNA00152,MGC4677 |transcriptional regulation;ceRNA |pathogenic process |colorectal cancer;gastric cancer;hepatocellular cancer;pancreatic cancer;breast cancer;renal cell cancer |- |HSALNT0289706 |HSALNG0141821 |CHRF |NA |ceRNA |pathogenic process |cardiac hypertrophy;silicosis |- |HSALNT0143635 |HSALNG0068436 |CASC8 |LINC00860,CARLo-1 |NA |pathogenic process |lung cancer |- |HSALNT0143672 |HSALNG0068465 |CASC11 |TCONS_00014535,LINC00990,CARLo-7,ENST00000518376 |transcriptional regulation |pathogenic process |hepatocellular cancer;colorectal cancer |- |HSALNT0289032 |HSALNG0133191 |LINC00323 |PRED42,FLJ37173 |NA |pathogenic process |breast cancer;hereditary haemorrhagic telangiectasia |- |HSALNT0024655 |HSALNG0011845 |LINC01139 |LINK-A,TCONS_00000027 |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0289018 |HSALNG0036270 |LEF1-AS1 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia;colorectal cancer |- |HSALNT0247326 |HSALNG0119753 |LINC00667 |NA |NA |pathogenic process |hereditary haemorrhagic telangiectasia |- |HSALNT0290145 |HSALNG0142260 |POU3F3 |NA |transcriptional regulation |pathogenic process |esophageal squamous cell cancer;glioma |- |HSALNT0199349 |HSALNG0096112 |LINC00426 |NA |NA |pathogenic process |primary Sjögren's syndrome |- |HSALNT0155974 |HSALNG0074744 |LINC00963 |MetaLnc9 |NA |pathogenic process |prostate cancer;renal cell cancer |- |HSALNT0289211 |HSALNG0086124 |PCF11-AS1 |NA |NA |pathogenic process |hepatocellular cancer;adolescent idiopathic scoliosis |- |HSALNT0289534 |HSALNG0141649 |91H |NA |transcriptional regulation |pathogenic process |osteosarcoma;esophageal squamous cell cancer;breast cancer;colorectal cancer |- |HSALNT0289446 |HSALNG0055679 |ELFN1-AS1 |MYCLo-2 |transcriptional regulation |pathogenic process |colorectal cancer |- |HSALNT0288883 |HSALNG0079547 |ACTA2-AS1 |uc001kfo.1,ZXF1 |NA |pathogenic process |lung adenocarcinoma |- |HSALNT0289443 |HSALNG0059132 |APTR |RSBN1L-AS1 |transcriptional regulation |pathogenic process |liver fibrosis;glioblastoma |- |HSALNT0289986 |HSALNG0142101 |lncRNA-MVIH |NA |NA |pathogenic process |hepatocellular cancer;non-small cell lung cancer |- |HSALNT0289977 |HSALNG0142092 |lncRNA-ATB |NA |ceRNA |pathogenic process |colorectal cancer;hepatocelluar cancer;gastric cancer;pancreatic cancer;renal cell cancer;pneumoconiosis |- |HSALNT0289622 |HSALNG0141737 |ATB |NA |ceRNA |pathogenic process |prostate cancer;glioma;keloid;gastric cancer;hepatocellular cancer;pancreatic cancer;breast cancer;colorectal cancer |- |HSALNT0289586 |HSALNG0141701 |AK057054 |NA |NA |pathogenic process |gastric cancer |- |HSALNT0278370 |HSALNG0135702 |LINC01315 |lnc-C22orf32-1,C22orf32-1 |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0055601 |HSALNG0026583 |ADAMTS9-AS2 |NA |NA |pathogenic process |non-small cell lung cancer;glioma |- |HSALNT0289383 |HSALNG0009103 |PACERR |PACER,PTGS2-AS1 |transcriptional regulation |pathogenic process |osteosarcoma;osteoarthritis;inflammation and cancer |- |HSALNT0289268 |HSALNG0010604 |TGFB2-OT1 |FLJ11812 |ceRNA |NA |NA |- |HSALNT0288938 |HSALNG0027860 |DUBR |LINC00883 |ceRNA |pathogenic process |asthma and chronic obstructive pulmonary disease |- |HSALNT0290147 |HSALNG0142262 |POXCUT |TCONS_00011636 |NA |NA |NA |- |HSALNT0289440 |HSALNG0047407 |FOXCUT |LINC01379,TCONS_00011636 |transcriptional regulation |pathogenic process |esophageal squamous cell cancer;basal-like breast cancer;oral squamous cell cancer |- |HSALNT0288924 |HSALNG0059521 |CYP51A1-AS1 |ENST00000453068,LRRD1-AS1 |NA |pathogenic process |renal cell cancer |- |HSALNT0289395 |HSALNG0036288 |RPL34-AS1 |FLJ37673,RP11-462C24.1 |NA |pathogenic process |gastric cancer;colorectal cancer |- |HSALNT0289435 |HSALNG0045015 |C5orf66-AS1 |CTC-276P9.1,Epist |NA |pathogenic process |esophageal squamous cell cancer;bladder cancer |- |HSALNT0289052 |HSALNG0006924 |LINC00623 |NA |NA |pathogenic process |nasopharyngeal cancer |- |HSALNT0289831 |HSALNG0141946 |FER1L4 |FER1L4 |ceRNA |pathogenic process |gastric cancer;endometrial cancer;colorectal cancer |- |HSALNT0288985 |HSALNG0013215 |GACAT3 |LINC01458,lncRNA-AC130710 |NA |pathogenic process |ovarian cancer;gastric cancer |- |HSALNT0288881 |